Exploring Cancer's Fractured Genomic Landscape: Searching for Cancer Drivers and Vulnerabilities in Somatic Copy Number Alterations by Zack, Travis Ian
 
Exploring Cancer's Fractured Genomic Landscape: Searching for
Cancer Drivers and Vulnerabilities in Somatic Copy Number
Alterations
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 17, 2015 1:07:07 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13065031
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA	 ﾠsTitle 
 
Exploring cancer's fractured genomic landscape: Searching for cancer drivers 
and vulnerabilities in somatic copy number alterations 
 
A dissertation presented 
 by  
 
Travis Ian Zack 
 
to 
 
The committee on Higher Degrees in Biophysics 
 
in partial fulfillment of the requirements 
for the degree of 
 
Doctor of Philosophy 
 
in the subject of  
 
Biophysics 
 
 
 
 
 
 
Harvard University 
Cambridge, Massachusetts 
 
 
July 2014 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 Travis Zack 
All rights reserved. 
 
 
 
   iii 
 
Thesis  Advisor:  Rameen  Beroukhim      Travis  Zack 
Exploring cancer's fractured genomic landscape: Searching for cancer drivers 
and vulnerabilities in somatic copy number alterations 
Abstract 
 
Somatic copy number alterations (SCNAs) are a class of alterations that lead to 
deviations from diploidy in developing and established tumors. A feature that 
distinguishes SCNAs from other alterations is their genomic footprint. The large 
genomic footprint of SCNAs in a typical cancer’s genome presents both a challenge 
and an opportunity to find targetable vulnerabilities in cancer. Because a single event 
affects many genes, it is often challenging to identify the tumorigenic targets of 
SCNAs. Conversely, events that affect multiple genes may provide specific 
vulnerabilities through “bystander” genes, in addition to vulnerabilities directly 
associated with the targets. 
  We approached the goal of understanding how the structure of SCNAs may lead 
to dependency in two ways. To improve our understanding of how SCNAs promote 
tumor progression we analyzed the SCNAs in 4934 primary tumors in 11 common 
cancers collected by the Cancer Genome Atlas (TCGA). The scale of this dataset 
provided insights into the structure and patterns of SCNA, including purity and ploidy 
rates across disease, mechanistic forces shaping patterns of SCNA, regions 
undergoing significantly recurrent SCNAs, and correlations between SCNAs in regions 
implicated in cancer formation.  iv 
 
In a complementary approach, we integrating SCNA data and pooled RNAi 
screening data involving 11,000 genes across 86 cell lines to find non-driver genes 
whose partial loss led to increased sensitivity to RNAi suppression. We identified a 
new set of cancer specific vulnerabilities predicted by loss of non-driver genes, with 
the most significant gene being PSMC2, an obligate member of the 26S proteasome. 
Biochemically, we found that PSMC2 is in excess of cellular requirement in diploid 
cells, but becomes the stoichiometric limiting factor in proteasome formation after 
partial loss of this gene.   
In summary, my work improved our understanding of the structure and patterns 
of SCNA, both informing how cancers develop and predicting novel cancer 
vulnerabilities. Our characterization of the SCNAs present across 5000 tumors 
uncovered novel structure in SCNAs and significant regions likely to contain driver 
genes. Through integrating SCNA data with the results of a functional genetic screen, 
we also uncovered a new set of vulnerabilities caused by unintended loss of non-
driver genes.  
  v 
 
 
Table of Contents 
Title .................................................................................................................................. i	
Abstract  ......................................................................................................................... iii	
Front matter .................................................................................................................. vi	
Motivation ...................................................................................................................... 1	
Chapter 1: Introduction  ................................................................................................. 5	
1. The analysis of copy number change ............................................................................... 5	
2. Non-driver dependencies as a means of cancer therapy  .............................................. 27	
3. shRNA screens to discover cancer dependencies on non-driver SCNAs .................. 30	
Chapter 2: Structure of somatic copy number alterations ...................................... 36	
Section Goals ........................................................................................................................ 36	
Methods ................................................................................................................................. 36	
Results ................................................................................................................................... 43	
Discussion ............................................................................................................................. 54	
Chapter 3: Significance of recurrent, focal SCNAs across disease ....................... 58	
Section Goals ........................................................................................................................ 58	
Methods ................................................................................................................................. 59	
Results ................................................................................................................................... 64	
Discussion ............................................................................................................................. 88	
Chapter 4: The discovery of non-driver cancer dependencies using high-
throughput shRNA pooled screens. .......................................................................... 91	
Section goals  ......................................................................................................................... 91	
Methods ................................................................................................................................. 92	
Results ................................................................................................................................... 94	
Discussion ........................................................................................................................... 104	
Chapter 5: The proteasome and PSMC2 as a Cyclops target ............................... 106	
Section goals  ....................................................................................................................... 106	
Methods ............................................................................................................................... 108	
Results ................................................................................................................................. 118	
Discussion ........................................................................................................................... 141	
Perspectives and Future Directions ........................................................................ 146	
Conclusion .......................................................................................................................... 154	
Appendix 1: SNP6.0 array processing  ..................................................................... 156	
References ................................................................................................................. 162	
 
 
 
   
  vi 
Front matter	 ﾠ
There are a number of people who I would like to thank for their commitment to 
supporting me during the work discussed below.  
First my wife, Jenn. I do not think I could have ever gotten through this if she was 
different in any way. Besides providing emotional support every day, Jenn has helped 
me with everything from paper editing and tissue culture when work was running late, to 
discussing my projects and being my most vocal critic (in the best possible way). As a 
scientist herself, she understood how projects can be quite consuming and never 
faulted me for late nights or an inability to stop thinking about science after I left the lab.   
I’d like to thank my family for always supporting me in whatever I chose to do, 
especially my parents and grandparents, for believing in the importance of education. 
This includes my wife’s family, who welcomed me without hesitation and supported my 
career decisions, even as I moved Jenn three thousand miles away and continue my 
attempt to go through life without a real job. In terms of support, I’d like to thank the 
Ashford family for financial support and a big final thanks goes to Jim Hogle and 
Michelle Jakoulov, for running, (really creating) a truly unique program. The flexibility 
and support is really beyond parallel and more than a student could ever ask for. I 
especially thank them for being understanding with my shifting career interest and my 
tardy, and somewhat backwards, approach towards degree completion. 
On the science front, primary acknowledgement of course goes to Rameen, who 
has been a better mentor than I could have dreamed existed. From the start, he has let 
me jump into projects I had no business being a part of, and had the patience to give  
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me the time to learn so many different aspects of the science and techniques behind 
cancer discovery. I have learned so much from him about how to think productively 
about a scientific question, how to search for the best approach towards a solution, and 
how to efficiently tackle that solution. He also has been so patient with me. My 
communication skills were very under-developed (both in presentations and writing) 
when I entered his lab but he really took his mission as an educator seriously and gave 
me every opportunity to improve. Beyond his mentorship, he is a model scientist, both in 
his outlook towards the scientific pursuit and his ingenuity. Finally, his generosity is 
overwhelming, always making time to talk whenever I had questions or needed help and 
his passion for our work I think helped keep my energy for our projects going.  
I want to acknowledge two hands on mentors in particular for their willingness to 
teach me from the ground up. Deepak Nijhawan and I worked in together on so many 
aspects of our project. For almost all aspects of experimental biology, working on our 
project was my first introduction to the techniques, even for things as basic as PCR. 
This usually meant experimental results were accomplished in parallel to traversing a 
learning curve, but I always felt Deepak was happy to be patient and teach me skills 
often only learned through trial and error. As our conversations often helped drive the 
experimental biology, he was also very excited about learning bioinformatics and 
discussing better ways to ask our questions. I do not think our collaboration would have 
been nearly as successful in a traditional compartmentalization, and I know I would 
have a much narrower skill set with which to answer future biological questions.   
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Similarly, Steve Schumacher has been my constant source of knowledge about 
bioinformatics and problem solving in software development. I knew a very small 
amount of programming when I joined the lab, but from day one, Steve has been my 
crutch and I knew I could always turn to him if I was stuck on something for more than 
five minutes. Besides just material help, he was always willing to be a sounding board 
with a critical ear, taking the time to listen to all my crazy ideas and thoughts, even if 
most of them were presented in a stream-of-consciousness fashion. In addition, his 
tireless dedication to seeing projects through to a conclusion, combined with his 
attention to detail, was a perfect complement to my ADD and disorganization.  
Penultimately, though it is said a lot, it cannot be said enough: The unique and 
incredible atmosphere of support throughout the HMS and Broad community not just 
attracts great scientist, it breeds them.  The ability to walk down the hall and annoy THE 
world authority in a given field or technique is so underappreciated as a formative 
process, and I think a culture that encourages this kind of openness starts at the top. 
When people see legends like Dr. Altsuhler, Dr. Lander, or the people on this committee 
willing to take time to teach and listen, they realize how important sharing skills and 
knowledge can be, and that maybe they have more time for it than they otherwise would 
have acknowledged. Personally, I would like to thank Drs. Meyerson, Getz, Hahn, 
Carter, Goldberg, Besche, Cherniack, Zhang, Tsherniack, Tamayo, Weir, and 
Rosenbluh and countless others for taking the time to help, teach, or listen to me, 
whenever I asked.  Finally, a thanks to my committee for volunteering their time. 
   Motivation 
Over 100 years ago Hansemann, and subsequently Boveri, described abnormal 
numbers and shapes of chromosomes as a distinguishing feature of cells derived from 
cancerous neoplasms1,2. As our understanding of chromosomes and their role in 
genetics has grown, this observation on the fundamental relationship between DNA and 
cancer has only been strengthened. It was not until 1960, that the first specific genetic 
defect associated with cancer was discovered, a chromosomal translocation in chronic 
myelogenous leukemia (CML)3. In the next couple decades, several genes responsible 
for driving tumor formation were slowly elucidated
4-7. As genetic techniques became 
more refined, especially with the completion of the human genome project, the number 
of documented cancer genes and alterations has exploded8‐10.  
The idea of cancer as an evolutionary process originating from a single cell is 
well established and has changed little in 30 years11,12. As in other evolutionary 
processes within finite populations, cancerous (or precancerous) cells acquire random 
genetic or epigenetic alterations, which may have beneficial, detrimental, or neutral 
effects on cellular fitness.   Alterations that are strongly beneficial to cell survival and 
proliferation (driver alterations) may lead to expansion of the corresponding cell 
throughout the population (selective sweep). However, neutral or detrimental alterations 
present in the cell prior to these selective sweeps will also be present in the tumor 
(passenger alterations). Through this process, the genetic alterations observed at the 
time of diagnosis and/or tumor resection consist of some combination of driver and 
passenger alterations. 
1Early therapies postulated that known cytotoxic agents, such as mustard gas, 
would have similar effects on the unrestrained proliferation of cancer cells8‐11,13,14. While 
cytotoxic agents are still frequently applied in cancer treatment, recent advances in 
genetics have introduced the promise of “targeted therapies”: treatment designed to 
target vulnerabilities caused by specific alterations present in cancer cells, but not 
normal tissue. While the basic concept of exploiting phenotypic differences between 
cancer and normal cells directly related to a genotype is a very general aim, in practice 
these efforts have focused on driver alterations directly involved in tumorigenesis. 
Because driver alterations are directly responsible for facilitating malignancy 
progression, it is reasonable to assume many may be required for tumor maintenance, 
and thus would represent a cancer-specific dependency.  
Since the elucidation of the human genome, much of the research in cancer 
genetics can be broken down into three distinct pursuits: 
1.  Discovering driver alterations: Because we expect driver alterations to be 
preferentially maintained during the course of evolution, this often entails looking 
for alterations that recur in primary tumors more often than we would expect given 
our understanding of the background rate of the alteration. 
2.  Understanding how a driver alteration promotes or maintains cancer development: 
This step often involves experimental techniques to elucidate exactly how a 
genetic alteration alters cellular biology in a way that promotes tumorigenesis or 
tumor maintenance. Benchwork often represents both the backbone and a 
bottleneck of cancer discovery and has provided numerous insights not just into 
tumor formation, but basic cell biology and human physiology15,16.  
23.  Therapeutic development: Once the biology of a specific driver alteration is 
understood, therapies (often small molecule inhibitors) are developed to exploit 
predicted dependencies based on this alteration. While the initial phase of this 
step is often carried out at academic institutions, much of the time and cost of this 
step involves molecular optimization and toxicity profiling, often at pharmaceutical 
companies.   
Each patient’s cancer likely has a small handful of alterations driving tumor 
development
17,18, meaning each patient presents with a very limited set of opportunities 
for driver-directed targeted therapy. While research in the causes and progression of 
cancer has led to innumerable advances in the understanding of cellular biology writ 
large19‐22, targeted therapies based on certain classes of driver alterations (such as 
tumor suppressors or transcription factors) have not always been easy to design or to 
implement successfully23‐25. This leads to many patients in which we can identify the 
events that caused tumor formation, but cannot yet leverage this genomic information 
toward effective treatment. However, cancer dependencies predicted by driver 
alterations may only be a small subset of potential therapeutic targets. For example, 
driver alterations likely represent a small portion of all genetic differences between 
cancer and normal cells. By widening the search for cancer specific vulnerabilities 
beyond driver alterations, we may be able to open new therapeutic doors in targeted 
therapeutics.   
One of the many forms of genetic alterations in cancer cells is changes in DNA 
copy number, which are collectively termed Somatic Copy Number Alterations (SCNAs). 
While typical mammalian somatic tissue is diploid (two copies of each gene), many 
3cancers exhibit wide deviations from this norm, ranging from complete loss (zero 
copies) of some regions to amplifying other regions hundreds of times. SCNAs affect a 
larger fraction of the genome in cancers than do any other type of somatic genetic 
alteration26‐28. SCNAs can be caused by numerous distinct mechanisms, including 
multiple classes of errors in break repair and mitotic segregation29‐32.  SCNAs play 
critical roles in activating oncogenes and inactivating tumor suppressors28,33‐37 and 
understanding the biological and phenotypic effects of SCNAs has led to substantial 
advances in cancer diagnostics and therapeutics38‐41. 
The following research focuses on uncovering contributions of SCNAs to cancer 
development and novel cancer dependencies. We have employed two complementary 
techniques. In the first, we used a large collection of primary tumors to characterize the 
patterns of SCNA across cancer and implicate specific regions likely to contain driver 
genes. In the second, we used an in vitro screen of gene dependencies to find genes 
that directly lead to cancer vulnerability when lost through SCNAs, regardless of 
whether they are driver or passenger alterations.  
  
4Chapter 1: Introduction 
 
1. The analysis of copy number change 
Introduction: Patterns of genetic alterations as a window into cancer biology 
 
While a connection between certain behaviors and environmental conditions had 
been understood for centuries
42,43, it took until 1937 for scientist to prove a specific 
environmental toxin to be carcinogenic, with the exposure of mice to benzanthracenes, 
an element of coal tar. Concurrently, evidence arose of X-rays causing cancer
44 in 
addition to the (re-)discovery of cancer causing-viruses in the 1970s
45,46. Combined with 
growing evidence of causative nature of these agents in genetic alterations
47,48 and 
ingenious work to show that cancers were derived from clonal expansion of a single 
somatic cell
49, it became evident that cancer was a disease of somatic, genetic 
alterations.  
Therefore, a primary challenge in cancer biology is to distinguish the genetic 
alterations that allow clonal expansion and contribute to oncogenesis and cancer 
progression from the passenger events that are acquired during cancer evolution but do 
not contribute towards it50‐52.  The basic assumptions behind this pursuit are two-fold. 
The first element is that neoplasia is the result of a single-cell, evolutionary process that 
undergoes one or more clonal expansions. In such processes, genetic alterations that 
greatly improve fitness will be selected for and be enriched in subsequent 
measurements of the population (tumor biopsies, for example). The second assumption 
is that cancer biology remains relatively consistent across patients, meaning the same 
alteration may be selected for independently across multiple patients within a 
5population, and therefore would recur more frequently across biological samples than 
alterations with no selective advantage. These basic assumptions have, for the most 
part, proven fundamentally sound and have led to many breakthroughs in cancer, even 
before the introduction of high-throughput genetic techniques. 
Without modern genetic techniques, early studies relied on qualitative visual 
analysis of chromosomal number and shape in neoplastic cells arrested in metaphase 
with colchicine53,54. While crude by today’s standards, observation of static mitotic 
divisions allowed quantification and characterization of the chromosomal content, 
including “marker chromosomes” that were only observed neoplastic cells55‐57. The 
principle finding in these early studies is summarized succinctly by Wakonig-Vaartaja58 
 
“(a) neoplasia begins in a few or, more likely, in one cell, at least in certain types of 
neoplasia; (b) autonomous tendencies can be inherited from a cell to its descendants; 
(c) leukaemia, even with almost simultaneous symptoms in several tissues may 
originate at one site; from this it may spread through metastasis; (d) the majority of the 
cells in certain neoplasms are changed irreversibly, and not temporarily due to 
stimulation from other cells (physiological theories), otherwise the proportions of marked 
cells belonging to one clone would have been smaller; (e) the varying incidence of 
aneuploidy in the different sites, in spite of the same clonal origin of their cells, 
demonstrates genetic plasticity and random somatic evolution in neoplasms” 
 
  While less common, some “marker” chromosomes were observed repeatedly in 
patients of a particular disease, suggesting a role for these specific events in disease 
6formation56,59.  However, identification of recurrent genetic alterations was limited by an 
inability to reliably distinguish between different chromosomes. 
By 1970, experiments began to use quinacrine as a label for DNA regions for 
guanine-rich regions60‐62 and Giemsa staining for thymine-rich regions63‐66. This, and 
other advances in cytogenetics, precipitated a series of conferences on cytogenetic 
nomenclature, culminating in the Paris conference of 1971, which set in place the basic 
nomenclature we use today67, and led to a rapid increase in the discovery of DNA 
elements correlated with disease.  
Besides more accurately describing previously discovered malignancy-
associated alterations3,4,68,69, the ability to accurately distinguish chromosome regions 
led to associations between specific regions and malignancy in a wide variety of 
disease states, even if the functional cause was as yet undetermined70‐74.  
In parallel, the ability to laboriously sequence DNA75 and amino acids76, led to the 
discovery of many disease associated genes, with their genomic location often identified 
subsequently77‐80. By studying tumor-associated viruses, researchers were able to 
isolate endogenous protein associated with transformation through biochemical 
isolation81‐83 or isolation of human homologues of viral proteins through transformation 
assays7,83‐86. However, these discoveries were tethered to the relative simplicity of the 
viral genome, and the identification of human homologues, as well as their locations, 
was very tedious. Regardless, these first studies into the functional elements that lead 
to malignancy are responsible for discovery of many of the most well recognized tumor-
inducing agents, including tumor suppressor genes(RB1, TP53)22,87,88, oncogenes(Myc, 
EGFR)89,90, viral components (hepatitis B, human papillomavirus)91,92   and bacteria (H. 
7pylori)93. Again, in virtually all these cases, driver gene discovery was relatively 
opportunistic, discovering genetic elements through biochemical isolation or qualitative 
observation of highly recurrent genetic alteration.   
A complementary approach, originally termed “reverse genetics” or positional 
cloning, attempted to map the gene responsible for a disease trait to its genetic location 
prior to evaluation of gene product biochemistry or physiologic function94,95. While 
traditional approaches strove to first isolate and characterize proteins associated with a 
phenotype, subsequently identifying its amino-acid and DNA sequence, these 
approaches involved challenging isolation and biochemistry techniques and often 
required model systems that adequately recapitulated the phenotype of interest. As an 
alternative, early genomics pioneers attempted to associate DNA regions with 
inheritance of a specific disease phenotype, slowly narrowing the phenotype-associated 
region down to a single genetic element either through comparison of the affected 
region in diseased versus normal cells96‐99 or through amplification and segmentation of 
the region through the use of a library of recombinant DNA vectors100‐102. In this 
approach, only after a correlated genetic element is identified are experimental studies 
done to determine a mechanism behind its causal role. While also successful in 
mapping many human disease traits, the tedious nature of this approach precipitated 
the push for a complete mapping of the human genome94,103, as well as new techniques 
for precise characterization of genetic differences between samples. One of the most 
influential characterization techniques was the DNA microarray. 
 
History of DNA microarray analysis 
 
8The next big step towards large scale cancer genome characterization was the 
DNA microarray104,105. A microarray is the ordered, precision placement of many 
microscopic elements that allows segregation of signal or information in a very small 
system. For DNA microarrays, the segregated elements are DNA fragments (“target 
set”), covalently bonded to a solid support and then used to measure the amount of 
complementary DNA sequence that is fluorescently labeled in a small volume fluid 
sample (“probe set”). The advantage of this approach for interrogation of biological 
samples is multifaceted. A microscopic platform requires much less source material, 
while the high specificity of DNA to its complimentary sequence provides high signal to 
noise in a complicated sample, eliminating the need for step-wise sample simplification.  
The first described DNA microarrays were developed in the early 1990s105‐107, 
and can be separated into 3 approaches, based on the construction of the “target” 
library.  
In an early paper, cDNA was created from an Arabidopsis sp., and a small set of 
putative genes were independently PCR amplified105. Small volumes of these PCR 
products were spotted in an ordered fashion onto a poly-L-lysine coated microscope 
slide107.  After a chemical and heat treatment, the DNA probes were bonded to the slide 
surface and probed with fluorescently labeled mRNA samples.  More generally, this 
approach used cDNA to construct Expressed Sequence Tag (EST) target libraries. 
While it is easy to interpret the direct readout from these cDNA libraries, they suffered 
from tedious library construction and selection bias against low abundance mRNA.  
Regardless, this approach was successfully used to measure gene expression in many 
systems105,108,109. In cancer, the ability to monitor changes in gene expression across a 
9large portion of the genome allowed diagnosis and classification of disease state based 
on broad patterns of expression110,111. 
A separate approach created target libraries by spotting cosmid or Bacterial 
Artificial Chromosomes (BAC) libraries onto a microarray112. They improved on some 
spatial resolution and quantification issues of previous approaches and were able to 
quantitatively assess levels of human DNA spiked into a full human genome, as well as 
high resolution comparison of chromosome 20 in normal and breast tumor lines112.  
These libraries were also laborious to curate and maintain. 
Photolithographic synthesis of unique polymers in parallel directly on a solid state 
support113,114 solves these problems of library creation and maintenance, by “printing” 
an array of short synthetic nucleotides of any conceivable sequence without need for an 
initial biological sample isolations step. Often termed “in-situ” DNA microarrays, this 
principle was demonstrated early in DNA microarray development115, but the precise 
control over short target sequence made these arrays much better suited for sequence-
identity questions116‐118 or discovery of disease associated single nucleotide 
variation119,120. Nucleic acid quantification was demonstrated with synthetic arrays in 
1996121.  
While the utility of microarrays became obvious, the technical aspects and start-
up cost of individual investigator-based microarray creation severely limited the wide-
spread use of the technology initially. Because it was still impossible to characterize a 
whole genome on a single array, commercialization of microarray system led to 
individual development of target libraries, and microarray designs, which could be 
combined to answer specific biological questions (reviewed in Bowtell, 1999)106  
10 
Microarrays and copy number alterations. 
Though now nearly universally performed with microarrays, comparative genome 
hybridization (CGH) was originally developed as a cytogenetic technique122 in parallel to 
microarrays. Tumor DNA labeled with biotin was combined with normal genome 
reference DNA labeled with digoxigenin in equimolar amounts. This solution was then 
hybridized to metaphase spreads of normal cells, and the fluorescent signal intensities 
derived from each sample (tumor vs. normal) at each locus along the chromosome was 
used to determine relative copy number at these loci123. As signal was derived directly 
from condensed chromatin, resolution was limited124 and gene identification again 
required subsequent, more narrow genetic interrogation125,126. In addition, accessibility 
and hybridization efficiency vary widely across the genome during metaphase leading to 
interpretation difficulties. But the idea behind CGH transferred very well to discovering 
copy number abnormalities using microarrays. Initial array-based CGH112,127 were based 
on BAC (or similarly constructed) target libraries and improved the resolution of 
traditional CGH techniques enormously.  Subsequently, EST libraries were used to 
probe cancer copy number changes104 but in both cases, copy number analyses had 
difficulty replicating the success of EST-based mRNA expression studies, as copy 
number changes are typically more subtle, and thus harder to detect, than the changes 
frequent in expression patterns, which can often span orders of magnitude.  
The application of synthetic oligonucleotide technology to array CGH would only 
come after the human genome project128,129. Agilent Technologies used the consensus 
sequence to create an array of over 20,000 60-mer oligonucleotides that tiled 4 
11chromosomes130. While this platform still had a low signal to noise ratio, the high density 
of probes in each region allowed for signal intensity across adjacent probes to be 
averaged, improving resolution to the 50-100kb range and leading to more accurate 
interpretation of copy number changes.  
While homozygous loss is a common method of tumor suppressor inactivation, 
loss of heterozygosity (LOH) can also inactivate tumor suppressors131,132  if the 
remaining allele is rendered non-functional by some other means. While early aCGH 
techniques may not have been sensitive enough to accurately distinguish between one 
and two DNA copies, Mei et al133 and Lindblad-Toh et al
134 both realized one could take 
advantage of single heterozygous single nucleotide polymorphisms (SNPs) to increase 
the information from each oligonucleotide and more easily locate regions of the genome 
that had suffered LOH134,135. These methods improved as more germline SNPs were 
identified and added to microarray detection136,137, eventually allowing for quantitative 
models of copy number change detection138,139.  
 
Microarray information processing 
 
While powerful, microarrays are subject to a number of different sources of error, 
and the algorithms used to determine somatic copy number changes from microarray 
platforms have continued to improve. Systematic noise in microarray experiments is 
primary derived from two sources, the first relating to the target library and the second 
relating to the probe set140. DNA hybridization relies on the high specificity of 
complementary DNA sequences to bind one another, even in a complex solution. Each 
unique sequence represents a different chemical reaction, with different reaction rates, 
12specificities, and equilibria. As such, signal comparison across different targets on the 
microarray is very challenging. From the perspective of sample processing, most DNA 
samples require PCR amplification prior to genomic analysis. PCR amplification comes 
with the same set of chemical biases between reactions as the target sequences. 
However, because amplification is done over multiple cycles in series, errors and 
sequence biases are propagated and amplified with each reaction, leading to huge 
artifacts in analyses if not properly accounted for140. While gene expression arrays 
experience these sources of noise as well, the basic goal of gene expression analysis is 
to quantify the same molecule (mRNA species) across different samples. Differences in 
chemistry across different molecules are therefore only of secondary concern. In 
contrast, in DNA copy analysis, we wish to use signals from multiple target sequences, 
all derived from proximal areas of the genome, to inform the total copy level at that 
locus. This requires comparison of different chemical reactions, and therefore requires 
more sophisticated analyses.  
For a single target sequence, we would expect a linear relationship between the 
amount of complementary DNA in a sample and intensity of signal from that location on 
the microarray. This is indeed the case for moderate levels of copy level change (0-5) 
138,139, while fluorescence saturation is observed for very high levels of copy number 
amplification (>100)138.  
In the initial analysis of tumors, correlation between adjacent genomic markers 
within a given sample was low. In Bignell, 2004138, rather than providing relative 
genome-wide copy level, copy level determination was restricted to either small areas 
with multiple and concordant, unlikely intensities, or to very large areas with unlikely 
13average intensities. They found 24 regions with at least three consecutive SNPs with 
outlier intensity values when compared to a diploid sample, suggesting high level copy 
number change (putative regions of high level amplification or homozygous deletion). 
For more subtle copy number changes, averages of fluorescent intensity over large 
regions were able to predict whole chromosome changes to a limited degree.  
Around a similar time, Zhao, 2004139 developed more sophisticated data 
analyses of copy number change providing better opportunities to recognize CNA. They 
modeled the signal derived from the array as a Hidden Markov Model (HMM), with each 
target sequence informing the probability of a real copy level change in neighboring 
targets.  In brief, the proportion of the genome at a given copy level is initially based on 
heuristics (~90% diploid, with more extreme copy levels progressively less likely). The 
HMM then tried to determine where copy level changes occur (and hence the copy level 
at each locus), with transition probabilities based on both these proportions and the 
relative genomic spacing of target sequences. Finally, this process is repeated with new 
estimates for the proportion of the genome at each copy level to refine transition and 
copy level probabilities.  Using this more quantitative assessment of copy level 
changes, they were able to find smaller regions of subtle copy level change in many cell 
lines, as well as high level gains in many known oncogenes.  
These initial efforts at signal detection recognized that even if large portions of 
the genome are affected by copy number change, transitions between different copy 
levels are relatively rare. This means that signal from adjacent sequences reinforce 
each other, and utilizing this increases signal to noise. Going further, a systematic 
method for noise averaging that leads to an estimated copy number value at each 
14locus, as well as the most likely genomic position that signifies the start of copy number 
change (often referred to as copy number breakpoints) serves as a foundation for 
finding significant recurrence of copy number alterations. Circular binary segmentation 
(CBS) does this by taking each segment (starting with the whole chromosome) and 
recursively asking if there is likely to be a copy number breakpoint within that 
segment141,142. After finding the most likely breakpoints, it then averages intensity values 
across each segment to create segment-level data. 
To improve resolution, commercial arrays were developed to contain both 
common SNPs and additional synthetic oligonucleotides tiled across the genome (copy 
number probes) 143,144. The sequence of complementary sample DNA is (presumably) 
homogenous for these target sequences, therefore leading to different signal models.  
As projects moved to these platforms, decreasing cost and increasing reproducibility, 
algorithms were created and refined to integrate information from both SNP and copy 
number targets145  
Analyzing DNA derived from sampling a continuously evolving, heterogeneous 
population comes with its own complications. As primary solid tumor samples are 
traditionally derived from biopsies or resected tumors, DNA derived from all cells in 
these samples not only can mask tumor heterogeneity, because samples invariably 
have some mix of tumor and somatic tissue, normal cells can dampen tumor signal. 
Interpretation can also be complicated by large deviations from diploidy. Because cell 
number is not assessed prior to sample processing, a perfectly tetraploid cell would look 
identical to a diploid cell from a microarray’s perspective. These two confounders (tumor 
purity and ploidy) limited copy number determination to assessing relative changes 
15across loci, and complicated comparison across samples. Recently, several 
algorithms146,147 have attempted to use concordance in copy level across segments to 
infer tumor purity and ploidy and obtain the clonal number of DNA copies of each locus. 
ASCAT146 was the first method introduced for predicting purity and ploidy. It does so by 
looking for the best solution that explains the total copy ratio and relative ratio of the A/B 
allele outputs at each locus, using purity and allelic ploidy as parameters. Then, to find a 
solution for purity that minimizes these local solutions globally, they find the purity value 
that minimizes the overall distance between the copy number of each segment and its 
nearest, non-negative integer. The ABSOLUTE method used a similar underlying 
model, with improvements by allowing the flexibility of taking in other information, such 
as subclonality, somatic point mutations, and karyotypic probability based on previously 
characterized tumors147.  
 
SCNA structure in cancer 
 
Cancer genomes arise through a diverse set of permanent (or semi-permanent) 
alterations that can be separated into broad categories: sequence alterations, balanced 
structural rearrangements, copy number alterations, and epigenetic modifications. 
Sequence alterations are somatic changes in DNA sequence and include single base 
substitutions as well as small insertions and deletions that affect a few nucleotides. In 
contrast, epigenetic modifications, which encompass DNA methylation and histone 
modifications, are changes relative to the natural state of the cell of origin. As the 
precise cell of origin, much less its epigenetic state, can be difficult to determine, 
epigenetic modifications can be difficult to interpret148. Finally, structural rearrangements 
16and copy number alterations are reorganizations of the DNA content in a given cell, 
which can lead to changes in sequence (as disparate DNA elements are joined 
together) as well as changes total number of copies of affected regions33,149.  
 
Mitosis associated copy number alteration 
Whole chromosome instability (W-CIN) is generally thought to arise from either 
errors in the centrosome duplication cycle, leading to multiple centrosomes during 
mitosis150, or errors in spindle assembly checkpoint, which can allow progression of 
anaphase even without a full complement of kineticore attachment
151.  The centrosome 
is the organelle responsible for organizing and anchoring chromosomes involved in 
mitotic DNA segregation, and as such, its replication is intimately connected to the cell 
cycle and start of DNA replication152. Cell cycle components, particularly CDK2 and Rb, 
are important in the initiation of centrosome duplication and are also frequently 
dysregulated during cancer development. Errors in centrosome duplication can be a 
byproduct of driver gene activation or inactivation of these cell cycle components153‐155. 
Over-duplication of centrosomes may also occur after abortion of normal cell division, 
followed by aberrant re-entry into S-phase through inactivation of the p53-mediated 
checkpoint pathway156. Unlike the first mechanism, this route will lead to coinciding 
duplication in DNA for the cell and its progeny (tetraploidy). While there are 
mechanisms in the cell to prevent mis-segregation when microtubules from multiple 
centrosomes bind a single kineticore157, these mechanisms get overwhelmed in the 
case of over-duplication of centrosomes and can lead to subsequent aneuploidy158.  
17Whole chromosome instability is also frequently the result of errors in the spindle 
assembly checkpoint (SAC). While this checkpoint is active, a single unattached 
kineticore is enough to prevent initiation of anaphase159. Perhaps because loss of many 
of the genes in the complex directly responsible for this delay160 is embryonic lethal161‐
163, they are infrequently mutated in cancer164. However, dysregulation of this 
checkpoint through other means is fairly common, such as alterations in APC165 which 
can stabilize microtubules and REST166 and VHL167, which regulate components of the 
checkpoint complex. More recently, recurrent alterations have been observed in the 
Protein phosphatase 2 complex168, which regulates the attachment of the anaphase-
promoting complex to the mitotic spindle169.  
In addition to chromosomal mis-segregation, which has been well documented 
from the beginning of cancer cell biology170, breakage-fusion-bridge cycles (BFB) and 
chromothripsis represent processes that result in sub-chromosomal alterations that are 
believed to be associated with anaphase in mitosis30,171.  BFB cycles are thought to 
originate from an initial dsDNA break during anaphase, leading to loss of the telomeric 
region172.  After subsequent replication, the corresponding sister chromatids both lack 
telomeres, leading to fusion of the two strands and a “bridge” between them during 
anaphase. This bridge is only resolved when the centromeres of the sister chromatids 
are pulled to opposite ends of the dividing cell, leading to a mechanical break and again 
revealing chromosome ends uncovered by telomeres173.  This leads to a series of 
telomere bounded amplifications or deletions. Chromothripsis is a recently described 
phenomenon where a single chromosome undergoes dozens of genomic 
rearrangements, including the inversion or deletion of many regions of DNA, in a single 
18complicated event174,175. Though the mechanism of chromothripsis remains unclear, it 
has been postulated to occur while the chromosome is condensed during mitosis, either 
through temporary chromosomal isolation, mechanical stress during anaphase, or 
external mutagens, such as ionizing radiation30.  
 
Mechanisms of copy number alterations during DNA replication and break repair 
Common features of cancer cells include DNA damage and dysregulation of cell 
cycle processes17. As replicative stress can cause frequent dsDNA breaks during 
progressing replication forks, both of these processes lead to increased requirement for 
DNA break repair. Errors in the repair of these dsDNA breaks can lead to local changes 
in DNA copy number, through either homologous or non-homologous recombination176.  
Homologous Repair (HR) is the less error prone of the two repair pathways and requires 
long tracts of sequence homology near the breakpoint to be repaired177. The repair 
process involves invasion of the homologous sequence with a single strand of the 
broken DNA, and uses it as a template to extend beyond the break. Conversely, non-
homologous repair is relied upon when extensive sequence homology cannot be found 
as a template. This process relies on micro-homology, if available, or can continue with 
no homologous region at all and, theoretically, is much more likely to lead to copy 
number changes.  
As its name suggests, homologous recombination requires a template strand 
with significant local homology to the double stranded break. If both sides of the DSB 
are present (3’ and 5’), repair can pass through either a double Holliday junction 
intermediate, or through synthesis dependent strand annealing (SDSA). In the former, 
19template strand invasion is followed by resolution of a double Holliday junction, which 
can lead to allelic crossing over176. Even if alleles are correctly paired during HR 
through Holliday junctions, crossing over events can lead to loss of heterozygosity 
(LOH) if chromatids carrying the same allele segregate together during mitosis. 
Alternatively, while SDSA also involves template strand invasion, the ssDNA molecule 
from the DSB strand is separated from the template and re-ligated to a newly uncovered 
3’ overhang from its original DSB partner, preventing the possibility of a crossing over 
event178. If HR incorrectly pairs two regions of homology (not directly opposed alleles), 
crossing over can lead to inversion of duplication, depending on the orientation of the 
homologous regions. 
If a DSB occurs during replicative fork propagation, resulting in only a single 
DSB, repair proceeds through the Break-Induced Replication (BIR) pathway178. This 
pathway proceeds through a series of strand invasions, separations, and extensions 
until a high processivity replication is formed to continue DNA replication. While this 
process is immune to crossing over, LOH can occur if the DSB strand invades the 
homologous chromosome instead of the sister chromatid.   If HR takes place across two 
non-allelic homologous regions, it can lead to translocations179 and potentially other 
copy number changes.  
Non-homologous end-joining (NHEJ) and microhomology mediated end joining 
(MMEJ) are the two main repair pathways that do not require long sequences of sister-
strand homology. Without this strict template strand requirement, these can often lead 
to copy number alterations180,181. As its name implies NHEJ attempts to relegate two 
DSB; errors can often lead to micro-deletions or insertions. Alternatively, MMEJ tries to 
20find small regions of homology (5-25 nucleotides) near the DSB by resection to expose 
ssDNA until a region of microhomology between the two dsDNA elements are found, 
followed by ligation and synthesis. This process can lead to deletions of variable length, 
and potentially translocations if DSB are prevalent in the nucleus.  
  As many putative mechanisms for copy number alteration are known, there have 
been many efforts to identify mechanistic correlates of SCNA. One of the more 
important revelations from such studies has been the role genome architecture has in 
observed structural rearrangements and copy number changes182. Spatial organization 
during interphase seems to be related to frequent individual translocations183,184, though 
whether this is due to increased likelihood of cross-over errors after DSB or due to 
similar times in DNA replication remains unclear185,186.  
 
Significance analysis in somatic copy number change 
 
Having characterized many independent cancer genomes, an important goal is to 
discover recurrent alterations that lead to tumor formation, ideally taking into account 
what we know about the mechanism of their generation. The tools to do this are 
constantly evolving. In many of the first genetic abnormalities identified, an alteration is 
so ubiquitous across a particular disease, its significance can be determined 
qualitatively3,187,188. Unfortunately, in most solid tumor types, a ubiquitous alteration, 
pointing to a specific and unique cause for malignancy, is lacking. This, combined with 
the large portion of the genome altered in each sample, made a statistical approach 
towards the discovery of recurrent alterations a necessity to discover the vast majority 
of cancer genes.  
21In copy number analysis using DNA microarrays, initial methods for identification 
of significant regions were straightforward. One such approach involved finding the 
minimal common region of overlap between copy number changes in different samples, 
then refining the list of interesting regions through heuristics189. Unfortunately, the 
results of early methods designed to discover regions containing potential driver genes 
were very dissimilar, even in parallel datasets within the same disease50,137,189.   To 
address this, multiple groups undertook projects designed to improve our ability to 
identify regions likely to contain driver alterations50,190‐192 (reviewed in [Rueda 2010]193).  
The main advantage of these techniques over the initial attempts was 
propositioning a background rate of SCNA and using this proposed distribution to find 
regions with more alterations than expected. For example, the approach developed by 
our laboratory, Genomic Identification of Significant Targets In Cancer (GISTIC) creates 
a score for each locus by averaging the copy level at each locus across samples, then 
determines the probability of obtaining that score assuming a random distribution of 
copy levels within each sample50.  RAE190 applied a similar method, with the addition of 
a noise model of each individual tumor sample and boundaries.  
Building on its immediate predecessor50, GISTIC 2 recognized that most loci 
affected by copy number alterations are from chromosome-level changes and 
specifically looked to separate the significance of chromosome-level SCNAs from 
shorter “focal” SCNAs1,2,26. Unfortunately, the frequency and extent of chromosomal 
alterations often obscures recurrence of focal copy number alterations. To resolve this 
issue, GISTIC 2 introduced an algorithm that attempts to separate chromosome level 
events (“broad” events) from focal events, and assess the regions of significant 
22recurrence for each of these events separately3,194. Assigning significance between 
broad and focal events independently was a great leap forward in the discovery of driver 
SCNAs, leading to its broad implementation across the field.  
The biological complexity of primary tumor samples can complicate copy number 
analyses using DNA arrays. DNA microarrays measure the amount of DNA at a given 
locus, relative to the total amount of DNA extracted from the sample, providing 
information about “relative” copy number changes. For example, the microarray signal 
from a clonal population of diploid cells would be identical to one of tetraploid cells. This 
means there is potential for lost information, even in clonal populations. Moreover, the 
ideal case of an entire sample of clonal tumor cells is rare. Instead, tumor samples often 
contain large amounts of normal somatic tissue, such as infiltrating inflammatory cells or 
cells from the host organ. In addition, as a continuing evolutionary process, the cancer 
cell population is inherently heterogeneous. All these genetic backgrounds are 
homogenized and placed on the array simultaneously, which obscures the signal of 
clonal events.  Carter et al.147 designed a series of algorithms to address these issues 
by modeling the most likely values of tumor purity, ploidy and heterogeneity to lead to 
the observed data. 
 
Using genetic patterns to imply functionality  
 
Even once a region is determined to be significant for SCNA recurrence, the 
challenge of elucidating the functional unit responsible for this significance is often only 
partially complete. Unlike many other somatic alterations, the genetic footprints of 
SCNAs vary widely, from small regions of a single gene, up through whole 
chromosomes (100s to 1000s of genes). This means that even if we identify a specific 
23region as being recurrently affected, the genetic target of these alterations may remain 
ambiguous without additional information. There are many potential approaches 
towards removing this ambiguity.  
In traditional approaches, functional consequences of copy number change are 
assessed for each element within the region through molecular biology, such as in vitro 
or in vivo ORF and shRNA transformation or viability assays. While experimental 
approaches are, in some ways, the gold standard, the process can be very low 
throughput, with each gene having to be independently tested. In addition, each 
experimental system comes with its own caveats. Assays are designed to test for 
specific tumor-promoting properties, such as transformation195 or invasion196. Using the 
incorrect assay, could therefore lead to a false negative result for driver genes with an 
untested tumorigenic function. Even if the correct test is run, many tumor-promoting 
effects require a specific genetic context to lead to tumor promotion. These contexts can 
be difficult to predict and/or replicate in a laboratory setting197. Finally, some driver 
alterations, such as TP53 or BRCA1, will not transform cells in isolation because they 
disable growth checkpoints or increase the likelihood of other driver alterations, working 
indirectly to promote tumorigenesis198,199.  
For these reasons, using the genetic context of a driver alteration to both limit the 
number of hypothesis and refine the functional question can be very useful. For 
example, positive correlations with other genetic events may indicate functional 
synergies, where one is beneficial only in the context of the other. Alternatively, 
anticorrelations may indicate functional redundancies as redundant events would not be 
24required in the same primary tumor.  Several approaches have been developed to 
determine functional effects of genetic events based on anticorrelation patterns. 
In the past, using correlative structure in the genetic alterations of cancer could 
be separated into two distinct goals. In the first, the goal is to use biological pathway 
information, combined with genetic correlations, to improve our power to detect cancer-
driver genes. In the second, the goal is to leverage genetic correlations between known 
driver alterations to inform function.  
Examples of the first approach are exemplified by work form the Rafael lab200,201.  
In this approach, rather than identify significantly mutated genes, investigators identify 
significantly mutated subnetworks and the genes involved in them. In this way, they 
choose not just genes that are frequently mutated, but a set of genes that are both 
frequently altered AND that tend to be more mutually exclusive than expected by 
chance (and hence potentially explain more tumorigenesis).  
The second approach looks to inform functionality of known driver alterations by 
looking at their patterns of mutual exclusivity202. Standard tests of mutual exclusivity 
have proven inadequate for significance analysis in alteration datasets. Developing 
more sophisticated algorithms have led to interesting biological relationships203. 
  However, these techniques have not been systematically tested and 
implemented in the setting of SCNAs, where the structure and patterns of alterations 
may provide unique challenges. While permutation analyses are a standard approach 
for data that does not adhere to canonical distributions, SCNAs, unlike other alterations, 
often span large and overlapping regions, making a permutation analyses that 
maintains event structure challenging.  
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Cancer discovery as a collaborative goal 
 
Competition can be a great motivator of progress and discovery204 and the turn of 
this century saw multiple, parallel initiatives designed to collect and analyze collections 
of primary tumors from the same disease. It was recognized that, while these were very 
successful independently, collectivizing efforts and datasets would lead to more power 
in pattern detection and, ultimately, disease understanding205. In 1997, Vice President 
Albert Gore announced the Cancer Genome Anatomy Project (CGAP) website206,207, 
with the goal of making public 1. a large, standardized collection of genetic data derived 
from primary tumors and 2. state of the art technological tools to analyze this dataset. 
As the majority of this project took place prior to the completion of the human genome, 
early results focused on cytogenetics and gene expression profiling205,208, with whole 
genome structural information integrated subsequently209. Subsequently, The Cancer 
Genome Atlas (TCGA) was a collaborative effort instituted by the NIH to provide a 
comprehensive genomic characterization of 20 of the most common cancers in the 
United States, as well as smaller characterization projects in many, less common 
diseases. This initiative has been widely successful and already produced landmark 
papers in a number of common diseases5,6,210 9,10,211 11,12,168,212. Within the TCGA, the 
Pan-Cancer project was a collaboration to characterize and compare 11 of the most 
common diseases with the aim to identify patterns across all cancer subtypes, as well 
as distinguishing features of each disease.  
262. Non-driver dependencies as a means of cancer therapy 
While cancers arise from the accumulation of somatic genetic only a subset of 
these alterations (“driver events”) promote malignant transformation by activating 
oncogenes or inactivating tumor suppressor genes. Many somatic genetic alterations 
are the consequence of increased genomic instability that occurs in cancer but do not 
contribute to tumor development (“passenger events”). Even among events that 
promote tumor development, many of these alterations, specifically SCNAs, affect 
multiple genes simultaneously, with presumably a limited number of affected genes 
driving cancer (“driver genes”) while the rest are simply tolerated by the now more 
genetically fit cell (bystander genes). 
The demonstration that cancers are often dependent on specific driver 
oncogenes has stimulated efforts to find and exploit these targets therapeutically. By 
definition, driver events promoted cancer cell growth or development at some point 
during evolution, so expecting many of them to be specific cancer dependencies at the 
end stage of disease is a logical hypothesis that has proved successful therapeutically. 
For example, cancers that harbor translocations such as BCR-ABL or EML4-ALK, or 
mutations such as EGFR or BRAF, well proven transformative alterations, have been 
shown to depend on the activity of these gene products for tumor maintenance213‐215. 
Indeed these alterations have been successfully targeted in the development of novel 
targeted inhibitors in a number of cancers including leukemia, lung cancers and 
melanoma
216-218. Therefore, the presence of such an alteration often predicts response 
to drugs that inhibit the function of these proteins38,217‐219.  
27However, the focus on driver alterations as therapeutic targets presents some 
limitations. For one, many driver alterations belong to classes that have been very 
difficult to target with small molecule inhibitors, such as transcription factors or loss of 
function alterations in tumor suppressors220,221. As most primary tumors may be 
dependent on only a small handful of driver alterations222‐225, focusing solely on driver 
vulnerabilities leaves each patient with just a few opportunities for targeted therapy, 
even in the most ideal case.   
An alternative strategy to target cancers is to target genes that are not 
oncogenes, but which cancers require to withstand cancer-specific stress226,227. In 
comparison to normal cells, cancer cells rely inordinately on pathways that abrogate a 
variety of cancer related stressors, including DNA damage replication stress, 
proteotoxic stress, mitotic stress, metabolic stress, and oxidative stress228. Even though 
proteins within these pathways may be essential in all cells, pharmacologic inhibition 
may create a therapeutic window as a result of a cancer-specific stresses. 
While looking for pathways under increased cellular requirement in cancer is one 
approach at the discovery of non-driver dependencies, another is to look for 
dependencies caused by the large-scale rate of genetic alterations in cancer. For 
example, the majority of human cancers harbor copy-number alterations involving the 
loss or gain of broad chromosomal regions and these may be either driver or passenger 
events. As each chromosome arm can contain hundreds to thousands of functional 
elements, even driver chromosomal SCNAs affect a large number of bystander genes. 
In fact, the idea of chromosomal aberrations that drive cancer while affecting bystander 
28genes was recognized 100 years ago this year, in the original paper linking 
chromosomal aneuploidy to cancer1:  
 
“Another possibility is that there is a specific inhibitory mechanism in every normal cell 
that only permits cell division to take place when this mechanism is overcome by some 
special stimulus. It would accord with our basic concept if one assumed that there were 
specific chromosomes that inhibited cell division. If their inhibitory effect were transitorily 
overcome, then cell division would resume. A tumor cell that proliferated without 
restraint would be generated if these `inhibitory chromosomes' were eliminated. In this 
case, the tumor cell would also lose all the attributes that were located exclusively in the 
same chromosome as the inhibitory factors. 
However, the hypothesis that there are chromosomes that stimulate cell 
multiplication is also compatible with our proposal. In this view, cell division would take 
place when the operation of the stimulatory region of the chromatin, normally too weak, 
is enhanced by some active agent. The unrestrained proliferation of malignant tumour 
cells would then be due to a permanent excess of these stimulatory chromosomes.” 
  
A dependency induced by the loss of such passenger and bystander genes in 
primary tumors was postulated 20 years ago as potential indirect vulnerability in cancer 
cells229. The hypothesis postulated that random passenger alterations would lead to 
decreased abundance of certain essential proteins, which would render cancer cells 
highly vulnerable to further suppression or inhibition of those genes. 
In contrast to driver events, vulnerabilities associated with passenger or 
bystander alterations are much more difficult to detect through genetic enrichment 
29alone. As driver alterations promote tumorigenesis, they are likely to recur across 
multiple samples, and are more likely to predict dependency in samples in which they 
do occur. Incidental alterations, on the other hand, must be well tolerated, or at most, 
only slightly deleterious. However, in the absence of a positive selective pressure there 
would be very little evidence for dependency on bystander alterations in genetic data 
alone. An exception to this would be relative genomic integrity at a given locus, 
suggesting negative selection in cells harboring this alteration. Unfortunately, this would 
correspond to dependencies in a very small subset of patients (as the alteration is even 
rarer than the expected rate). Thus, ideally we are looking for passenger alterations that 
predict dependencies, yet do not lead to significant decreases in fitness at the time they 
are acquired.  
3. shRNA screens to discover cancer dependencies on non-driver SCNAs 
Expanding cancer genomics with functional screens 
 
While genetic analysis of primary tumors can elucidate a lot about a cancer’s 
evolutionary history, it has its limitations. For most datasets, primary tumors represent a 
window into the state of a tumor at one point in time. Although factors such as genetic 
context can provide clues as to the functional consequences of these alterations, these 
are best examined with direct experimentation.  
High-throughput screens of cancer cell lines can directly ascertain the functional 
consequences of genetic or environmental perturbations. These can complement 
genetic analysis as a hypothesis-generating tool for discovery of cancer dependencies. 
The most common screens involve small molecule perturbations, phenotypic 
perturbations, or genetic perturbations230‐232. One example, Project Achilles, was 
30developed to discover novel cancer dependencies by leveraging the full power of RNAi 
in a carefully constructed high-throughput system designed to assess relative gene 
dependency across a large panel of well-characterized cancer cell lines. In brief, this 
projected attempted to assess cell viability in 100 cell lines after suppression of over 
11,000 individual proteins using a pooled library of shRNA lentiviral vectors (with each 
clone harboring an identifying barcode)233. To generate the shRNA library, a set of rules 
curated from the literature were implemented to improve knock-down efficiency and 
avoid obvious off-target effects234. Cell culture techniques and data processing are also 
outlined in Cheung et al
233. 
The raw result of this large project is relative viability of cells infected with a 
specific shRNA, as compared to cells containing other shRNA in the lentiviral pool, as 
measured by relative abundance of a corresponding DNA barcode after a long period of 
cell growth. Given the efficacy and off-target concerns outlined below, interpretation of 
this data is challenging. In anticipation of these concerns, a level of redundancy was 
engineered in the screen, with each gene being targeted by at least three independent 
shRNA sequences, with a median number of five shRNAs per gene. This increases the 
chance that multiple shRNAs will effectively knock down the target allowing us to 
separate microRNA (miRNA) mediated off-target effects, which would likely be unique 
to each shRNA, from on-target responses, which would likely be shared across all 
effective shRNAs targeting a given gene [discussed below]. Separating these two 
effects has been accomplished a number of different ways and is a continually evolving 
problem.  
 
shRNA: power and cautions in high-throughput screens 
31 
Over the past 10 years, the use of short interference RNA (siRNA) to suppress 
translation of specific proteins has become a powerful tool in molecular biology. 
Originally discovered as an external modulator of gene regulation in Caenorhabditis 
elegans235, and subsequently extended to higher organisms236,237, this system uses 21-
23 nucleotides of double stranded RNA (siRNA) to target and eliminate longer strands 
of RNA (typically mRNA) containing the same base pair sequence238. In vitro RNAi can 
be utilized by either transfected double stranded RNA fragments, or transduced cells 
expressing an RNA hairpin which functions in the same manner (shRNA). In cells 
transduced with dsDNA, the mRNA product forms a looped secondary structure 
between complementary sequences that is cleaved by Dicer before being loaded onto 
the RNA-Induced Silencing Complex (RISC)239. Double stranded RNA is unwound into 
a passenger strand (which is degraded) and a guide strand, which is incorporated into 
RISC. RISC then uses the loaded guide strand to locate and target complementary 
mRNA for degradation, using its intrinsic Argonaute component237,240. 
The exogenous addition of siRNA/shRNA to suppress specific protein function is 
widely used, but its use is not without caveats. These can broadly be classified as 
shortcomings in either efficacy or precision.  Both the siRNA sequence and the location 
of that sequence in the target mRNA can greatly affect the efficiency of translational 
suppression. Most mRNAs are composed of hundreds of base pairs, offering a large 
number of potential siRNA designs. However, as this technique has progressed, it has 
become increasingly clear that a significant percentage of siRNAs designed to suppress 
a given protein will fail to do so to any appreciable degree241,242. A set of “guidelines” 
have been discovered that improve the chances of a designed siRNA having a 
32suppressive effect, but these methods do not guarantee functionality243‐245. With this in 
mind, validation of efficacy in each experimental system, by western blot or similar 
procedures, is a requirement for the use of siRNA. While this is straightforward during 
low-throughput experimentation, the variability in efficacy between different siRNA is a 
primary challenges in design and interpretation of hypothesis generating high-
throughput RNAi screens.     
In addition to issues with efficacy, siRNAs frequently generate many unintended 
cellular perturbations, or “off-target” effects246. The easiest off-target effect to 
understand, predict, and avoid is siRNA-mediated decay of mRNA sequentially similar 
to the target. This can be predicted based on BLAST alignment and avoided by careful 
selection of the target region, avoiding sequences that are shared with other functional 
elements of the genome. However, the siRNA pathway shares many elements with a 
similar, yet distinct, pathways of RNA-mediated translational regulation termed micro-
RNA (miRNA)247. Rather than recognizing an exact sequence, the miRNA pathway 
recognizes imperfect homology between the 3’UTR of an mRNA and a “seed region” on 
the dsRNA247. This allows a single endogenous miRNA to regulate multiple mRNA 
containing slightly different sequences, which is great for biological efficiency, but 
complicates interpretation for many carefully designed experiments. The target and 
strength of these off-target effects can be very challenging to predict246,248,249 or even 
determine experimentally241. In a low-throughput setting, a causative relationship 
between suppression of the target protein and an observed phenotype is verified using 
a series of well-established controls, including multiple target sequences, scrambled 
sequences, and rescue experiments. Unfortunately, as in efficacy issues, these simple 
33controls in a low throughput setting quickly become challenging in the setting of a high-
throughput screen. 
The high potential for false positives and low signal to noise means the design 
and execution of a high-throughput RNAi screen is only half the battle. Careful quality 
control, thoughtful data analysis, and experimental validation of individual results are 
just as important. 
 
Generating high-confidence gene-dependency scores from shRNA pooled 
screening data across a large panel of cell lines. 
 
Given a set of cell lines and data on relative viability for each cell line in response 
to numerous conditions, one standard hypothesis is that functional dependency can be 
predicted by a specific genetic alteration. In this case, by segregating cancer cell lines 
into two categories based on presence of the genetic alteration in question, you can 
look for functional perturbations, such as effect of gene suppression or drug tolerance, 
that best separate these two classes from one another.  
Besides allowing us to start with a testable hypothesis, pooling samples we 
expect to exhibit the same phenotype renders our hypothesis less susceptible to 
experimental and biological variation, allowing us to spot trends in viability that may 
point to underlying biology. Because most “normal” somatic tissue does not grow in 
vitro, susceptibilities found in this assay use a large panel of genetically diverse cancer 
cell lines as controls and allow us to immediately discount dependencies shared by all 
cells. 
  Finding gene dependencies using shRNA in the two-class comparison setting 
has been accomplished in a number of different ways. Most importantly, each method 
34must account for both the efficacy and the off-target effects described above, and does 
so by integrating information from all shRNA designed to target a gene. The most basic 
method frequently used is the “second best” shRNA approach250,251. In this approach, 
we score genes by the second most effective shRNA in differentially separating the two 
groups. This accounts for the possibility that the effect of the strongest shRNA may be 
miRNA mediated, while also realizing that the number of ineffective shRNA (#s 3-X) 
may vary across genes. However, this incorporates very little information about the 
distribution of all shRNA for a given gene. RNAi Gene Enrichment Ranking 
(RIGER)250,252 ranks each gene by enrichment of its shRNAs towards differential 
susceptibility between the altered and unaltered groups for each shRNA. While RIGER 
combines information from all shRNA in the screen, it systematically penalizes genes 
with multiple ineffective shRNA, even if they also have multiple effective shRNA 
providing good signal.   
  Shao et al.253 developed an algorithm to analyze pooled shRNA data that 
improves on the shortcomings of the previous two approaches. The basics of this 
approach are illustrated outlined in [Shao et al.]253. If the viability changes in response to 
two independent shRNA sequences are related to the same gene, we would expect 
these changes to track similarly across cell lines within our dataset. This idea of 
searching for similar patterns in shRNA targeting the same gene would theoretically 
ignore ineffective shRNA, while simultaneously removing shRNAs whose effects are 
dominated by the off-target miRNA pathway. This approach removes these shRNAs to 
create a “gene-dependency” score based on corroborating shRNA targeting a gene and 
removes genes that are not represented by multiple consistent shRNAs.  
35Chapter 2: Structure of somatic copy number alterations 
Section Goals 
Determining the patterns of somatic copy-number alterations (SCNAs) and how 
they promote cancer is important to understanding the disease. We characterized 
SCNA patterns among 4934 cancers from The Cancer Genome Atlas Pan-Cancer 
dataset and have integrated rigorous statistical approaches into these analyses, 
including absolute allelic copy-number profiling, as well as novel computational tools to 
determine individual SCNA events and their temporal ordering from these profiles. 
Whole-genome doubling, observed in 37% of cancers, was associated with higher rates 
of every other type of SCNA, with most of these events occurring subsequent to 
genome duplication.  SCNAs that were internal to chromosomes tended to be shorter 
than telomere-bounded SCNAs, suggesting different mechanisms of generation. Finally, 
we developed a method for predicting chromothripsis using SNP6.0 arrays alone and 
found that specific chromosomes and diseases, including chromosome 9 and 12 in 
glioblastoma multiforme, were significantly enriched for these events. We present this 
dataset and analyses as a foundation for further analyses.  
Methods 
 
1. Event Decomposition 
We deconstructed each chromosome individually in two sequential steps: 
1.  Find a set of the most parsimonious arrangements of copy levels on the two 
parental alleles (allelic partitioning). 
2.  Find the most likely set of SCNA events that would give rise to these copy-
number profile (allele deconstruction). 
36Allelic partitioning 
Our data consist of integer copy-numbers of each allele at each locus. The data 
are segmented, with infrequent changes in copy-number between adjacent markers on 
the array (fewer than one breakpoint per 1000 markers). We start with no information 
about which copy levels or breakpoints belong on the same allele. The purpose of this 
section is to find a set of the most parsimonious partitions of copy levels between the 
two alleles. 
There is some information inherent in the structure of the segmentation. Since 
breakpoints are rare, our model should minimize the number of breakpoints and remove 
those that are not necessary to explain our observation.  These breakpoints are 
common in situations where a deletion preceded amplification. The first step of our 
algorithm is to remove such unnecessary breakpoints. Once unnecessary breakpoints 
are removed, there remains ambiguity about the segmentation of each allele. 
There are two situations that lead to ambiguity in segment partitioning between 
the two alleles: 1) the two alleles are at the exact same copy level at a particular locus, 
or 2) both alleles have a breakpoint at the exact same SNP marker. The first situation is 
common, with the second being much rarer. However, in either case we lose the ability 
to say whether segments preceding that position occurred on the same or opposite 
allele as segments subsequent to this position. We call these loci “flex-points” as we are 
free to swap segments between the two alleles only in these regions. We label regions 
between adjacent flex-points “contigs”, as the partitioning of these segments relative to 
one another is fixed.  The total number of possible arrangements of a given 
chromosome is 2
f-1 where f is the number of flex-points on the chromosome.  
37If there are nine or fewer flex-points on a given chromosome, we enumerate all 
possible permutations of the contigs across the two alleles (256 different arrangements) 
and test each of them against each other in event deconstruction (below). This 
accounted for 98.8% of all chromosomes and removes the complication of allelic 
ambiguity by brute force. If there are nine or more flex-points, such enumeration is 
computationally prohibitive, and we focus on the most likely allelic partitions.  
To choose a set of partitions to test in deconstruction, we group segments by 
their copy level and chose a set of allelic phases based on assigning a priority to each 
set of copy level segments.  For each assignment of copy number priority, we took the 
copy level of highest priority and found the allelic structure that assigned as many 
segments of that copy level to the same allele. We then fixed these segments and 
applied the same technique to the copy level of the second priority, recognizing that 
optimization of the second copy level can be constructed on either allele. Of the 1.2% of 
chromosomes in which we could not enumerate all potential phasings, 77% had less 
than 7 unique copy levels (excluding the zero level) and in such cases, we permuted the 
priority structure of every copy level present on the chromosome. In cases where there 
were 7 or more unique copy levels, we assumed the most likely partitions would tend to 
assign unlikely copy-levels (which are rare across the set overall) to the same allele, so 
that they could be accounted for by a single event rather than requiring separate 
unlikely events on each allele. In this case, we ranked each copy level based on the log-
likelihood of all segments at that copy level across both alleles, assuming each segment 
is a different event.  This created a rank priority structure for each copy level. We then 
38only permuted the 7 copy levels with the highest priority structure in order to maintain 
reasonable potential deconstructions. 
 
Allele Deconstruction 
Once the segments have been fixed to each allele, SCNA determination is 
performed in similar fashion to methods described previously
1,75, which identify the 
combination of SCNAs that would result in the observed copy-number profile and have 
maximum likelihood of having occurred.  The likelihood of an SCNA occurring is 
estimated according to the observed frequencies of SCNAs with similar lengths and 
amplitudes of copy-number change across the entire dataset. In contrast to the previous 
implementation of this algorithm, we consider discrete copy-number values, whereas 
prior methods focused on continuous total copy ratios.  The simplified, discrete data 
allowed for added complexity when testing the for the MLE solution of chromosome 
deconstruction. Specifically, the added precision allows confidence about the euploid 
level (allelic copy level=1 for most samples) as well as loci that have been deleted 
(allelic copy level =0) and we take advantage of this to search for deconstructions with 
potentially higher log-likelihoods (LL). 
One improvement was directly testing for deletions followed by amplifications 
over the affected region. For each chromosome, we attempted a deconstruction (as 
done previously) as well as one where the deleted regions are assessed, then removed 
prior to chromosome deconstruction (simulating deletion followed by further 
aneuploidy). Secondly, a necessary heuristic in the previous algorithm created a 
maximum of two independent sections on the chromosome (a left and a right) and 
39deconstructing each of these independently. This may lead to an overabundance of 
telomere bounded events, as events that actually start internal to the chromosome may 
be end up in a solution that forces them to start on the telomere, followed by a SCNA 
that reverses the copy level change. To avoid these artifacts, we also tested 
deconstructions that started internal to the chromosome in the case of a euploid 
telomere, or if both telomeres are at the sample copy level. To more accurately 
distinguish SCNA likelihoods, we separated our dataset into two populations based on 
whether they had undergone whole genome doubling (called by absolute) and ran each 
set independently.  
2. SCNA timing relative to WGD and chromosome duplication 
We determined the temporal relations of individual SCNAs to WGD using 
different approaches for deletions and amplifications. 
We considered deletions that involved a change from two copies to zero copies 
of an allele in WGD samples to have likely occurred prior to WGD. Similarly, deletions 
that involved a change from two copies to one copy of an allele were considered to 
have occurred after WGD.  Other deletions were left uncalled because of ambiguities 
introduced by surrounding alterations. When determining timing of genome doubling, we 
did not include arm level or whole chromosome events, as the events of this size are 
too common to rule out two sequential events that appear to have the same 
breakpoints.  
Amplifications are more ambiguous than deletions because the extra copies of 
DNA may end up elsewhere in the genome and be affected by subsequent events in 
those regions. However, because WGD affects the whole genome simultaneously, we 
40expect estimates of WGD timing based on amplifications to be similar overall to 
estimates based on deletions. We called events with an even total copy change as 
occurring prior to WGD and events with odd copy change as occurring after WGD.  
The same metrics were used to determine events before or after chromosome 
duplication. Again, amplifications are more uncertain than deletions because they may 
involve disparate regions of the genome. 
 
3. Chromothripsis detection  
Chromothripsis results from different mechanisms to most focal events, and has 
a very different distribution across lineages
254. We identified chromothripsis events in 
diploid samples based on three features that are observable in copy-number profiles 
and which have been associated with chromothripsis previously
174:  
 
1. A single chromosome exhibits an unexpectedly large number of SCNAs given 
the observed frequency of SCNAs within the sample. 
2. SCNAs on this chromosome tend to be more  closely spaced than we would 
expect by chance. 
3.  The SCNAs are non-overlapping (because they occurred simultaneously) and 
lead to copy-number changes of +1 or -1.   
 
Prior estimates of rates of chromothripsis have been complicated by uncertainty 
as to the absolute numbers of copies of change. In our application of these criteria, we 
evaluated the absolute allelic copy-number data to identify chromosomes that contained 
41more non-overlapping SCNAs that involved a single-copy change than we would expect 
by chance, given the number of SCNAs within the sample and using the binomial 
distribution. From these chromosomes, we applied the additional criterion that these 
SCNAs should be more tightly distributed within the chromosome than we would expect 
given a random selection of non-overlapping SCNAs within our dataset. If this criterion 
was not met, we applied a recursive algorithm to remove the SCNA furthest from the 
centroid location of the SCNAs potentially derived from chromothripsis, and recomputed 
these two statistics. 
4.  Generation of relative copy-number profiles 
The pipeline used to generate relative copy-number estimates is attached as 
Appendix 1 (a more complete description is to be published separately; Tabak et al, in 
preparation). In brief, probe-level signal intensities from Affymetrix SNP6 .CEL files 
were normalized to a uniform brightness across arrays and merged to form intensity 
values for each probeset using SNPFileCreator, a Java implementation of dChip255,256.  
These intensities were mapped to copy-number levels using Birdseed145 in the case of 
SNP markers, and on the basis of experiments with cell lines with varying dosage of X 
in the case of copy-number markers
1.  Recurrent germline copy-number variations 
(CNVs) were identified across all DNA samples from normal tissue and markers within 
these regions (representing ~15% of all markers) were removed from further analysis 
(Appendix 1).  Noise was further reduced by application of Tangent normalization 
(Appendix 1) followed by Circular Binary Segmentation141,142. Quality control metrics 
were applied at various stages in the pipeline (Appendix 2), resulting in the removal of 
42data representing 23 cancers out of 4957 primary cancers that had been profiled by 
SNP6 arrays. 
HAPSEG257 and ABSOLUTE147, running on FireHose258, were applied to data 
from 4870 of these cancers, including both the SNP6 data and, when available, whole-
exome sequencing data from the same cancers (1069 samples). Of these, purity and 
ploidy estimates and genome-wide absolute allelic copy-numbers were called in 3847 
cancers (Table 1). The 200 acute myeloid leukemia samples were not called by 
ABSOLUTE because they exhibited copy-number alterations across small fractions of 
their genomes, resulting in insufficient data for accurate calls by the algorithm. 
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Results 
Cancer purities, ploidies, and rates of copy-number alteration within and across 
cancer types 
We analyzed the copy-number profiles of 4934 primary cancer specimens across 
11 cancer types (minimum 136 for bladder cancer; maximum 880 samples for breast 
43cancer; colon and rectal adenocarcinomas were combined; Table 1). In each cancer, 
we determined copy-numbers at each of 1,559,049 loci relative to the median copy-
number genome-wide, using Affymetrix SNP6 arrays and previously described 
algorithms20,22,192. For 3847 cancers, we also determined the purity, ploidy, and absolute 
allelic copy-number profiles23‐25,147 of the malignant cells using SNP6 array data and, in 
1069 cases, matched whole-exome sequencing data (Table 1). In the other 1087 
cases, purity and ploidy estimates were ambiguous and left uncalled. This included all 
cases of acute myeloid leukemias [AMLs], which exhibit very few SCNAs. 
We then inferred the sequence of somatic copy-alteration (SCNA) events that led 
to each copy-number profile, using the most parsimonious set of SCNAs that could 
generate the observed absolute allelic copy-numbers. Using a maximum likelihood 
approach, we reported the most likely series of SCNAs that led to the copy-number 
profiles generated by ABSOLUTE for each homologous chromosome (henceforth, 
“allele”). Each SCNA was characterized by its length, amplitude, genomic position, and, 
when determinable, allele and the timing of its generation relative to neighboring 
segments (Methods, Fig. 1a,b). We identified a total of 202,244 SCNAs, a median of 39 
per cancer sample, comprising six categories: focal SCNAs that were shorter than one 
chromosome arm (a median of 11 amplifications and 12 deletions per sample); arm-
level SCNAs that were chromosome-arm length or longer (a median of three 
amplifications and five deletions per sample); copy-neutral loss-of-heterozygosity events 
(cnLOHs), in which one allele had been deleted and the other amplified coextensively (a 
median of one per sample); and whole-genome duplications (WGDs, in 37% of 
44T
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46Figure 1: 
(a) Schematic indicating procedure to determine SCNAs.  Absolute allelic copy-numbers 
generated by ABSOLUTE (left panel) are partitioned with the lowest copy-numbers on one allele 
(blue) and the higher copy-numbers on the other (red).  We repartition the copy-numbers between 
alleles to test all possibilities if computationally efficient, or the most likely possibilities if not 
(middle panel).  The most likely set of SCNAs generating each copy-number profile is then 
determined (right panel).  Regions in red are amplifications; regions in blue are deletions.  The 
black lines in allele 2 indicate deletions that preceded an amplification, so that segments that 
appear discontinuous on the reference genome were amplified in a single event. (b) Schematic 
indicating temporal order of SCNAs determined in (a). In this example, deletions followed by a 
chromosome level amplification can account for the copy-number profiles in (a).  For the same 
profile to be generated by amplifications followed by deletions, either the deletions would have to 
remove two copy-levels, requiring sequential deletions with identical boundaries, or multiple 
neighboring, non-contiguous amplifications would be required in addition to multiple, non-
contiguous deletions.  We assume both of these possibilities are unlikely. (c) Sample purities (top 
panel) and ploidies (bottom panel) across lineages (see Supplementary Table 1 for a list of 
lineage abbreviations).  Near-diploid samples are designated in purple; cancers that have 
undergone one or more than one WGD event are designated by green and red, respectively.  
Summarized data across all lineages are indicated on the right. 
	 ﾠ
47cancers). By amplifications and deletions, we refer to copy-number gains and losses, 
respectively, of any length and amplitude. 
Estimated purities and ploidies per cancer varied substantially within and across 
diseases (Fig. 1c). The purity estimates correlated with estimates derived from 
measurements of leukocyte and lymphocyte contamination using DNA methylation data 
from the same cancers (Fig. 2a) (Shen et al, unpublished data), but tended to indicate 
lower purity, consistent with the presence of non-hematopoietic contaminating normal 
cells.  
Average ploidies within diseases mirrored their frequencies of WGD (Fig. 1c). 
The average estimated ploidy within samples that had undergone a single WGD was 
3.31 (not four), suggesting that WGD events are associated with large amounts of 
genome loss. By contrast, samples that had not undergone WGD had an average 
estimated ploidy of 1.99.  
Compared to the near-diploid cancers within each disease, cancers with WGD 
had higher rates of every other type of SCNA (Fig. 2b) and twice the rate of SCNAs 
overall. Across diseases, overall SCNA rates largely reflected rates of WGD (2c).  
In cancers with WGD, most other SCNAs occurred after WGD (Fig. 2d, see 
Methods). The fractions of amplifications and deletions that were estimated to occur 
prior to WGD were highly correlated across diseases (R=0.64, Fig. 2d), indicating a 
consistent estimate for the timing of WGD with respect to other SCNAs. WGD was 
inferred to occur earliest relative to focal SCNAs among diseases where WGD was 
common (ovarian, bladder, and colorectal cancers), and after most focal SCNAs in 
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Figure 2 
(a) Estimates of purity according to ABSOLUTE (y-axis) against estimates of 
purity according to a lymphocyte/leukocyte DNA methylation signature (x-axis) 
across 3735 cancers. The estimate from the lymphocyte/leukocyte DNA 
methylation signature tended to provide higher purity estimates, suggesting 
other types of normal cells may contribute to impurities detected by 
ABSOLUTE.  (b) Numbers of arm-level (top) and focal (bottom) amplifications 
(left) and deletions (right) across lineages.  For each lineage, near-diploid and 
WGD samples are indicated by bars on the left and right, respectively; events 
among WGD samples are resolved according to their timing relative to WGD. 
(c) Number of SCNA events in samples with WGD (y-axis) against number of 
SCNAs in near-diploid samples (x-axis) across diseases. Most diseases show 
a greater than 2:1 ratio (red line) between the average number of events 
observed in WGD samples versus their near-diploid counterparts. (d) Fraction 
of focal amplifications (red) and deletions (blue) occurring prior to WGD by 
disease. The fractions of amplifications and deletions that occur prior to WGD 
within each disease are highly correlated and vary across diseases. The 
amplifications estimate carries greater ambiguity because amplifications 
involve DNA being placed in disparate regions of the genome.  SCNAs whose 
timing relative to WGD are ambiguous were omitted. 
49diseases in which WGD was least common (glioblastoma and kidney clear cell 
carcinoma). 
 
SCNA lengths suggest varied mechanisms of generation 
Focal SCNAs for which one boundary is the telomere (telomere-bounded) tend to 
be longer than SCNAs in which both boundaries are internal to a chromosome (median 
SCNA length: amplifications 19.6 Mb versus 0.9 Mb; deletions: 22.7 Mb versus 0.7 Mb, 
for telomere-bounded and internal events respectively). These differences reflect 
differences across the entire length distributions of internal and telomere-bounded 
events. Focal internal SCNAs were observed at frequencies inversely proportional to 
their lengths (Fig. 3a-b), as noted previously
26. However, telomere-bounded SCNAs 
tend to follow a superposition of 1/length and uniform length distributions. These 
distributions are the same whether measuring distance by kb, number of array markers, 
or number of genes, indicating that they do not result from variations in array resolution 
or gene density genome-wide (data not shown). Focal, telomere-bounded SCNAs also 
accounted for more SCNAs (12% and 26% of focal amplifications and deletions, 
respectively) than expected assuming random SCNA locations (p<0.0001). Both 
telomere-bounded and internal SCNAs are more likely to end within the centromere 
than expected given the centromere’s length (Fig. 3c), but the differences in their length 
distributions remain when centromere-bounded events are excluded. Differences 
between telomere-bounded and internal SCNAs are even more marked for cnLOH 
events (Fig. 3d). 
We detected chromothripsis in 5% of samples, ranging from none of head and 
neck squamous cell carcinomas to 16% of glioblastomas (Fig. 4a; see Methods). The 
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51Figure 3: SCNA length distribution 
(a) Frequencies of all amplifications (green) and amplifications that begin at the telomere (blue) or 
are internal to the chromosome (red) against amplification length.  We used a fixed number of 
events per bin as opposed to a fixed bin size to compute our least squared fit because there were 
many fewer long events. The frequencies of amplifications that are greater than 400 kb and less 
than a chromosome arm in length follow a power law f(L) = 1/L
β , where for all events, β = 1.05 
and r
2=0.99; for telomeric events β = 0.45 and r
2=0.90; and for internal events, β = 1.12 and 
r
2=0.97 (b) The distribution of lengths of SCNAs originating at telomeres (black line) compared to 
SCNAs that are internal to the chromosome. (c) Number of amplification (red, top) and deletion 
(blue, bottom) endpoints in chromosome arms (colored regions) and centromeres in metacentric 
chromosomes (black regions) for telomere-bounded SCNAs (left panels) and internal SCNAs 
(right panels).  SCNAs are more likely to end within the centromere than expected given the 
centromere’s length for both telomeric and internal SCNAs (p<0.0001 in both cases).  In the case 
of telomeric events, this tendency results in a propensity for SCNAs to be arm-level events 
involving precisely one chromosome arm and suggests that focal telomeric SCNAs are generated 
by similar mechanisms to such arm-level events. Note that centromeres often span large regions 
without SNP array markers, preventing detection of many SCNA endpoints in these regions. The 
width of each region reflects the size of its genomic locus. (d) Rates of cnLOH events that were 
internal to chromosomes (y-axis) against rates of cnLOH events that were telomere-bounded (x-
axis) across diseases. Only 2% of focal SCNAs were cnLOH, and these events had more 
pronounced differences between telomeric and internal events than did amplifications and 
deletions. Most cnLOHs (58%) involved either whole chromosomes or exactly one chromosome 
arm, compared to an 18% rate of arm- and chromosome-level events for other SCNAs (p < 
0.0001). Internal cnLOHs were typically much smaller than other focal internal SCNAs (median 
0.2 Mb vs 0.8 Mb, Mann-Whitney (MW) p < 0.0001), whereas telomeric cnLOHs were much 
larger than other telomeric SCNAs (median 82Mb vs 27.2Mb, p<0.0001). Rates of telomeric and 
internal cnLOH show no correlation across diseases, suggesting the processes that lead to these 
events may be distinct. 
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Figure 4-Chromothripsis across cancer 
(a) Rates of chromothripsis across lineages. (b) Rates of chromothripsis across 
chromosomes.  Chromothripsis events that involved peak regions of amplification 
and deletion (see below) are indicated in blue (dark blue: amplifications >4.4 
copies or deletions<-1; light blue: low-level events involving smaller changes); 
events that do not involve peak regions are indicated in grey. 
53rate of chromothripsis was not related to overall rates of SCNA (r=0.13, p=0.3). As 
previously reported
259, samples with chromothripsis were more likely to have 
chromothripsis on more than one chromosome (14/122 samples with chromothripsis 
had two to three such events, p=0.003). Many chromothripsis events were concentrated 
in a few genomic regions, often associated with known driver events (Fig. 4b). In 
glioblastomas, chromothripsis events were concentrated in chromosomes 9 and 12 and 
corresponded respectively to homozygous loss of CDKN2A (20/22 samples) and 
coamplification of discontinuous regions containing CDK4 and MDM2 (9/12 samples). 
Across all cancers, 72% of chromothripsis events included a GISTIC peak region (see 
below). 
 
Discussion 
Comprehensive analysis of SCNA across human tumors 
This study represents the largest analysis to date of high-resolution copy-number 
profiles generated using a single platform, and the largest analysis of absolute allelic 
copy-number data across cancer types. The TCGA Pancancer project was designed to 
combine the efforts of many individuals and institutions and comprehensively 
characterize a large, well annotated collection of primary tumors. Cataloging and 
analyzing the SCNAs in this set is an integral part of this endeavor and will be a 
foundation for future studies such as those described in Chapter 3.   
Assessing sample purity and its importance on primary tumor analysis 
As current genetic analysis techniques involve interpretation of bulk tumor 
samples, purity of the tumor within the biopsy, and overall ploidy of the cancer cells can 
confound both detection of SCNAs and significance analyses. Even worse, driver 
54alterations, such as BRAF-V600E260 status or TP53 inactivation261 may correlate with 
purity or ploidy, biasing the significance we assign to important steps in cancer 
development. Besides allowing us to reject impure samples, we can build models that 
correct for these confounders both in current and future significance studies. We found 
that purity and ploidy varied greatly both within and across disease, with lung and head 
and neck cancers being the most impure tumors, and GBM and ovarian being relatively 
pure. Outside of SCNA analysis, these purity values should be utilized in other analyses 
of TCGA data, including expression, DNA methylation, and mutational analyses. 
Selective pressures. 
A primary challenge in the analysis of somatic genetic data is distinguishing 
between patterns of alteration that reflect the mechanism by which those alterations are 
generated, from those that represent selection, specifically positive selection.  An 
underlying assumption of our current analyses is that patterns of alteration that are 
observed across all chromosomes are likely to reflect mechanistic biases, whereas 
deviations from these patterns at individual loci are likely to reflect selective pressures. 
However, cancer is a complicated evolutionary process and improving our 
understanding of the background rate of alteration will improve current and future 
significance models.  
We identified common patterns of SCNA across cancer types, including a 
tendency for telomeric events to be longer and more frequent than SCNAs within 
chromosomes. The differences between telomere-bounded and internal SCNAs across 
all chromosomes suggest different mechanisms underlie their generation. Internal 
SCNAs have been proposed to occur as a result of apposition of their two breakpoints 
55in three-dimensional space. Chromatin is arranged as a “fractal globule” during 
interphase262,263, during which time the likelihood that two breakpoints would be 
apposed decreases proportionally to the linear distance between them, implying a 
1/length distribution. Conversely, SCNAs that start on the telomere may be related to 
telomere shortening and telomere crisis, and associated with a single double-strand 
break that could occur anywhere within the chromosome264. These, and other185,265, 
mechanistic disparities should be accounted for in the background model of SCNA 
significance analyses and we are currently in the process of designing new significance 
tests that have the flexibility to do so. 
  Negative selection is another factor that significantly shapes the cancer genome. 
In our data, for example, homozygous deletions was detected in around 0.04% of 
markers, far below what is expected rate (0.2%, excluding the possibility of homozygous 
arm-level loss). The inability to tolerate the deletion of essential genes can directly affect 
significance analysis by highlighting regions unaffected by negative selection (such as 
gene poor regions), as potentially important. For example, proximity to an essential 
gene may alter the observed events leading to tumor suppressor inactivation. Finally, 
events during cancer evolution may increase tolerance for deletion, such as our finding 
that duplications of large regions of the genome (through WGD or polysomy) tend to 
lead to subsequent increases in numbers of SCNAs (especially deletions) in the 
duplicated regions. Moving forward, whole-genome sequencing data can indicate the 
specific rearrangements that contributed to each SCNA266,267, and assessment of 
genetic heterogeneity within tumors can also distinguish early from late events147,268. 
56Both of these are approaches are likely to inform the mechanisms by which SCNAs are 
generated and the selective pressures that shape them. 
  Chromothripsis is a relatively new mechanism for somatic copy number change, 
and its mechanism is still not fully understood. The large-scale structural 
rearrangements present in this event make whole genome sequencing the ideal 
technique for their identification. However, we currently have many thousands more 
primary tumors analyzed by microarray technology than by WGS, so an algorithm that 
can identify patterns of chromothripsis without the aid of sequencing technology would 
be useful. We found rates of chromothripsis did not track with rates of other SCNAs, 
with rates specifically higher in GBM. Further refinement of this technique in WGD 
samples may allow us to determine whether rates of chromothripsis change after WGD. 
  
57Chapter 3: Significance of recurrent, focal SCNAs across 
disease 
Section Goals 
 
A primary challenge in understanding SCNAs is to distinguish the driver events 
that contribute to oncogenesis and cancer progression from the passenger SCNAs that 
are acquired during cancer evolution but do not contribute towards it
50,190,269,270.  
Positively selected SCNAs will tend to recur across cancers at elevated rates
191,254,271. 
However, SCNAs may also recur in the absence of positive selection due to increased 
rates of generation or decreased negative selection
272,273.  For this reason, it is 
important to understand how mechanisms of SCNA generation, their temporal ordering, 
and negative selection shape the distribution of SCNAs genome-wide
268,272,273. 
A second challenge is to identify the oncogene and tumor suppressor gene 
targets of the driver SCNAs (which often encompass many genes) and elucidate the 
SCNA’s functional roles. The context of the SCNA can be informative. Positive 
correlations with other genetic events may indicate functional synergies, while 
anticorrelations may indicate functional redundancies because redundant events would 
not be required by the same cancer.  Several approaches have been developed to 
determine functional effects of genetic events based on anticorrelation patterns
200,202,274. 
Here, we address these challenges through analyses of the 4934 cancer copy-
number profiles described in Chapter 2.  These profiles, spanning 11 cancer types and 
assembled through The Cancer Genome Atlas Project Pan-Cancer effort, enable 
sensitive determination of significant regions of copy-number change both within and 
58across cancer types.  We have also developed new approaches to identify functionally 
relevant correlations between SCNAs. Among these are correlates with WGD, including 
TP53 mutations, CCNE1 amplifications, and alterations of the PPP2R complex. Finally, 
we used SCNA timing relative to WGD to identify regions of LOH that occur early in 
tumor evolution, allowing us to separate potential initiating regions of significant deletion 
from those that may be the result of increased rate of generation.  
Methods 
1. Impurity-corrected GISTIC 
The less pure a sample, the less signal is derived from the somatic alterations 
present in the tumor, which will decrease its contribution in recurrence analyses. In 
cases where we were able to estimate purity and ploidy from ABSOLUTE, we 
“corrected” total copy-ratios for signal dampening due to cancer cell impurity (i.e. 
contamination with normal DNA).  We called this In-Silico Admixture Removal (ISAR).  
The observed copy-ratio R(x) at locus x is a function of the purity α, cancer cell ploidy 
τ (representing the average copy-number genome-wide), and integer copy-number (in 
the cancer cells) q(x)
147  
 
  R(x) = (α q(x) + 2 (1- α)) / D , 
 
where D represents the average ploidy across all cells in the cancer: 
 
D = α τ + 2 (1 - α). 
 
59From this, we can determine q(x): 
 
  q(x) = D R(x) / α – 2 (1 - α) / α . 
 
We assume that the functionally relevant number is the copy-ratio within cancer cells, 
representing the integer number of copies q(x) divided by the overall ploidy of the cell τ: 
 
  R’(x) = q(x) / τ = R(x) / α – 2 (1 - α) / (α τ) . 
 
Use of R’(x) has the effect of amplifying the signal from low purity samples to be 
equivalent to higher purity samples.  For samples for which ABSOLUTE calls were not 
available, we used R(x).  
To determine significantly recurrent regions of SCNA, we used GISTIC 2.0
75 
applied to the transformed copy-number data. We used a noise threshold of 0.3, a 
broad length cutoff of 0.5 chromosome arms, a confidence level of 95%, and a copy-
ratio cap of 1.5. 
For some lineage-specific analyses, dozens of regions on a single chromosome 
arm were identified as significant peaks due to the presence in many samples of 
discontinuous SCNAs (such as chromothripsis) on those chromosome arms.  This 
phenomenon has been observed previously
271.  We narrowed these regions by applying 
in all lineage-specific analyses an “arm-level peel-off” correction that considers all 
SCNAs on a chromosome arm in a single sample to be part of a single event when 
60determining whether multiple significantly recurrent events exist on that chromosome 
arm.  This approach has also been used in prior analyses
275. 
The genes listed in each peak region include all protein-coding genes and 
microRNAs and additional non-coding RNAs as listed in the files refGene.txt, refLink.txt, 
refSeqStatus.txt, and wgRna.txt from the UCSC Golden Path database 
(ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/) as of 27 February 2012. 
 
2. Significance of chromatin modifying genes among peak regions of 
amplification without known driver genes  
To determine whether epigenetic regulators were enriched in peak regions, we 
compared the number of regions with epigenetic regulators (using a published list
276) to 
permuted datasets in which each gene in each region was replaced by a gene randomly 
selected from elsewhere in the genome. 
 
3. Correlation analysis 
To determine the significance of correlations and anticorrelations between pairs 
of SCNAs, we compared the observed rate of co-occurrences to the rate of co-
occurrences in 5000 permuted copy-number profiles for which we had randomized the 
sample assignment for each chromosome, while maintaining genomic position and 
lineage and sub-lineage assignments.  We only considered SCNAs in different 
chromosomes to avoid confounding due to geographic proximity.  
To control for variable rates of genomic disruption across samples, we modified 
the permutations so that they maintained both the numbers of amplified and deleted 
61markers A
0
j and D
0
j in each sample j.  After randomizing sample assignments for each 
chromosome as described above, we applied simulated annealing
277,278 in which we 
picked a chromosome at random and swapped it between two randomly chosen 
samples within the same lineage at each step, and accepted the step with a probability 
1- Etot, where: 
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and A
t
j and D
t
j represent the numbers of amplified and deleted markers in sample j and 
step t.  Tamp and Tdel are temperature factors that were slowly increased during the 
annealing, and the 1 in the denominator of each value is to avoid dividing by 0 in 
samples without any events. This procedure was applied in two separate analyses: one 
in which we looked at all SCNAs that passed the noise thresholds we used for our 
GISTIC significance analyses (above), and one in which we only considered loci with 
copy-number <-1 or >4.4. The second analysis we termed our “high-level” analysis. 
 
4. Intersection between mutual exclusivity network and Dapple network 
To validate the functionality of our network, we looked at the overlap between our 
network and DAPPLE, a curated dataset of protein-protein interactions
279 (PPIs). Of the 
>400,000 PPI pairs, we took only pairs with a score equal to 1 (indicating highest 
confidence). Two peak regions had an edge between them in the PPI network under 
two conditions; 
621.  A protein within the first peak was a direct interactor with a protein in the second 
peak. 
2.  A protein in the first peak had at least three distinct paths of length 2 in the PPI 
network to a protein in the second peak. 
To improve specificity, we only tested regions containing fewer than 25 genes. 
We determined whether the similarity between the PPI network and the anticorrelation 
network was significant by comparing the extent of overlap to permutations in which the 
edges in the anticorrelation network were randomly reassigned while maintaining the 
overall connectivity of the graph (see Results). By comparing both observed and 
anticorrelation networks to the same PPI network, we controlled for the propensity of 
regions with many genes to map to more PPIs. 
 
5. Somatic genetic correlates with WGD 
To determine which of the 200 most significant somatic mutations correlate with 
WGD, we used the permmatswap function in the R
280 package “vegan”
281 with the 
“quasifit” handle
34 to produce a series of independent assignments for mutations on 
each gene within each sample. This function maintained the number of mutations per 
gene per lineage, as well as the number of the number of mutations per sample.  
To determine which of the peak regions had SCNAs that correlate with WGD, we 
compared the number of times each SCNA was observed in WGD samples in our 
observed data to the number of times the SCNA was observed in WGD samples in the 
permutations created by our simulated annealing approach above.  
 
636. Overlap of peak regions of SCNA 
Two regions were considered to overlap if their 95% confidence intervals 
intersected. To determine significance of overlap, we compared the number of peak 
regions that overlapped across at least two lineages in the observed data to 100,000 
permutations in which the locations of each peak region were randomly shuffled within 
its chromosome arm (disallowing extension past the telomere or centromere). 
 
7. GRAIL analysis 
We used GRAIL
282 (www.broadinstitute.org/mpg/grail/) to find common functional 
terms in the literature for the genes in peak regions of SCNA. We used only PubMed 
abstracts through December 2006. We removed the following non-informative keywords 
from those GRAIL found most significant: "growth", "cancer", "cancers", "tumor", 
"tumors", "proliferation", "suppressor", "factors", "loss", "like", "rich", "cel", "cells", 
"yeast", "system", "family", "repeat", "deletions", "elegans", "national". 
 
Author Contributions 
The author was responsible for event and significance analyses of relative data 
and development of Correlation analysis with support and advice from Steven 
Schumacher, Rameen Beroukhim, Matthew Meyerson, and Gad Getz. 
 
 
Results 
Significant regions of Somatic Copy Number Alteration 
We identified 70 recurrently amplified and 70 recurrently deleted regions in a 
unified “Pan-Cancer” analysis across all lineages (Fig. 5a, Table 2). SCNAs involving 
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65Figure 5- Pancancer significance analysis 
(a) Significance of focal SCNAs.  GISTIC q-values (x-axis) for deletions (left, blue) and 
amplifications (right, red) are plotted across the genome (y-axis).  Candidate gene targets within 
each peak are indicated for the 25 most significant peaks; in cases where no clear candidate was 
identified, the cytoband was indicated.  Values in parentheses indicate the number of genes in 
each peak.  Green lines indicate the significance threshold (q=0.25). (b) Frequencies of 
amplification minus frequencies of deletion (red and blue indicated propensity to amplifications 
and deletions, respectively) across lineages (x-axis; see Supplementary Table 1 for a list of 
lineage abbreviations) for all 84 significant peak regions of SCNA, arranged in order of 
significance (y-axis). The ordering of lineages reflects the results of unsupervised hierarchical 
clustering of these data.  Magnified views of the values for the ten most significant amplification 
and deletion peaks, respectively, are shown to the right, alongside candidate targets for these 
regions. Criteria for selecting the indicated candidates are described in the Methods. (c) 
Associated terms in literature in peak regions containing fewer than 25 genes, according to a 
GRAIL analysis of (top) all peak regions and (bottom) peak regions without known cancer genes 
or large genes. 
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66Table 2: Pan-cancer regions of significant SCNA
A) Amplification
Peak Name Rank
Genomic 
location
Peak region
GISTIC q-
value
Gene 
count
Target(s) Frequently mutated genes
B
CCND1 1 11q13.3 chr11:69464719-69502928 2.05E-278 2 CCND1
K CCND1 = 6.6e-08
EGFR 2 7p11.2 chr7:55075808-55093954 2.30E-240 1 EGFR
K EGFR = 2.2e-15
MYC 3 8q24.21 chr8:128739772-128762863 6.50E-180 1 MYC
K
TERC 4 3q26.2 chr3:169389459-169490555 5.40E-117 2 TERC
 P
ERBB2 5 17q12 chr17:37848534-37877201 1.59E-107 1 ERBB2
K ERBB2 = 1.3e-06
CCNE1 6 19q12 chr19:30306758-30316875 4.77E-90 1 CCNE1
K
MCL1 7 1q21.3 chr1:150496857-150678056 1.25E-80 6 MCL1
K
MDM2 8 12q15 chr12:69183279-69260755 2.59E-62 2 MDM2
K
INTS4 9 11q14.1 chr11:77610143-77641464 1.01E-54 1 INTS4
WHSC1L1 10 8p11.23 chr8:38191804-38260814 3.43E-46 2 WHSC1L1
E, LETM2
M
CDK4 11 12q14.1 chr12:58135797-58156509 5.14E-41 5 CDK4
K CDK4 = 0.0048
KAT6A 12 8p11.21 chr8:41751300-41897859 2.97E-39 2 KAT6A
P,E, IKBKB
**
SOX2 13 3q26.33 chr3:181151312-181928394 1.21E-38 2 SOX2
K
PDGFRA 14 4q12 chr4:54924794-55218386 1.08E-37 3 PDGFRA
K
BDH1 15 3q29 chr3:197212101-197335320 1.21E-31 1 BDH1
M
1q44 16 1q44
T chr1:242979907-249250621 4.48E-31 83
MDM4 17 1q32.1 chr1:204367383-204548517 1.98E-29 3 MDM4
K
TERT 18 5p15.33 chr5:1287704-1300024 9.34E-27 1 TERT
K
KDM5A 19 12p13.33
T chr12:1-980639 1.59E-25 11 KDM5A
E
MYCL1 20 1p34.2 chr1:40317971-40417342 3.99E-25 2 MYCL1
K
IGF1R 21 15q26.3 chr15:98667475-100292401 8.62E-25 9 IGF1R
K
PARP10 22 8q24.3 chr8:144925436-145219779 5.44E-20 15 PARP10
P,E, CYC1
M
G6PD 23 Xq28 chrX:153760870-153767853 3.66E-19 1 G6PD
PHF12 24 17q11.2 chr17:27032828-27327946 1.75E-16 21 PHF12
E, ERAL1
M
20q13.33 25 20q13.33 chr20:62187847-62214354 2.96E-16 2
PAF1 26 19q13.2 chr19:39699366-39945515 1.66E-15 13 PAF1
P,E IL28A=0.021, SUPT5H=0.084
BCL2L1 27 20q11.21 chr20:30179028-30320705 2.85E-15 4 BCL2L1
K
TUBD1 28 17q23.1 chr17:57922443-57946458 7.19E-15 1 TUBD1 TUBD1 = 0.009
[ZNF703] 29 8p11.23 chr8:37492669-37527108 2.44E-14 0
1q23.3 30 1q23.3 chr1:160949115-161115281 7.73E-13 9
8q22.2 31 8q22.2 chr8:101324079-101652657 4.22E-11 3 SNX31 = 0.015
BRD4 32 19p13.12 chr19:15310246-15428182 5.04E-10 3 NOTCH3
P, BRD4
P,E
KRAS 33 12p12.1 chr12:24880663-25722878 9.47E-10 7 KRAS 
K KRAS = 1.5e-14
NKX2-1 34 14q13.2 chr14:35587755-37523513 1.33E-09 14 NKX2-1
K
NFKBIA=0.0098, 
RALGAPA1=0.027
NFE2L2 35 2q31.2 chr2:178072322-178171101 5.48E-09 5 NFE2L2 NFE2L2 = 3.9e-14
ZNF217 36 20q13.2 chr20:52148496-52442225 5.83E-08 1 ZNF217
K ZNF217 = 0.0082
13q34 37 13q34
T chr13:108818892-115169878 6.28E-08 45 ING1 = 0.00026
KAT6B 38 10q22.2 chr10:76497097-77194071 1.41E-07 9 KAT6B
E, VDAC2
M
NSD1 39 5q35.3 chr5:176337344-177040112 1.75E-06 22 NSD1
E, PRELID1
M NSD1 = 4.9e-10
FGFR3 40 4p16.3 chr4:1778797-1817427 2.14E-06 2 FGFR3
P, LETM1
M FGFR3 = 0.00018
9p13.3 41 9p13.3 chr9:35652385-35739486 2.55E-06 8
COX18 42 4q13.3 chr4:73530210-74658151 2.68E-06 7 COX18
M
7q36.3 43 7q36.3
T chr7:153768037-159138663 3.19E-06 30 PTPRN2
 L, DPP6
 L
18q11.2 44 18q11.2 chr18:23857484-24119078 3.83E-06 2
SOX17 45 8q11.23 chr8:55069781-55384342 2.02E-05 1 SOX17 SOX17 = 0.00092
11q22.2 46 11q22.2 chr11:102295593-102512085 0.00015337 3
CBX8 47 17q25.3 chr17:77770110-77795534 0.00023029 1 CBX8
E
AKT1 48 14q32.33 chr14:105182581-105333748 0.00028451 7 AKT1
K AKT1 = 1.1e-14
CDK6 49 7q21.2 chr7:92196092-92530348 0.00069831 3 CDK6
K
6p21.1 50 6p21.1 chr6:41519930-44297771 0.0010459 70
EHF 51 11p13 chr11:34574296-34857324 0.0011002 1 EHF
6q21 52 6q21 chr6:107098934-107359899 0.0011806 4
19q13.42 53 19q13.42
T chr19:55524376-59128983 0.0013319 138 ZNF471 = 5.4e-05
17q21.33 54 17q21.33 chr17:47346425-47509605 0.0025775 2
BPTF 55 17q24.2 chr17:65678858-66288612 0.0028375 11 BPTF
 E
E2F3 56 6p22.3 chr6:19610794-22191922 0.0033658 7 E2F3
K
19p13.2 57 19p13.2 chr19:10260457-10467501 0.0038041 12 MRPL4
M DNMT1 = 0.099
17q25.1 58 17q25.1 chr17:73568926-73594884 0.012337 2
KDM2A 59 11q13.2 chr11:67025375-67059633 0.012445 3 KDM2A
E
8q21.13 60 8q21.13 chr8:80432552-81861219 0.020548 6 MRPS28
M
2p15 61 2p15 chr2:59143237-63355557 0.021056 25 XPO1 = 1.1e-05
14q11.2 62 14q11.2
T chr14:1-21645085 0.027803 57
NEDD9 63 6p24.2 chr6:11180426-11620845 0.082606 2 NEDD9
K
5p13.1 64 5p13.1 chr5:35459650-50133375 0.094657 61
SLC1A3=0.0021, 
IL7R=0.0021
LINC00536 65 8q23.3 chr8:116891361-117360815 0.095294 1 LINC00536
10p15.1 66 10p15.1 chr10:4190059-6130004 0.10391 21
22q11.21 67 22q11.21 chr22:18613558-23816427 0.13213 105
PHF3 68 6q12 chr6:63883156-64483307 0.17851 4 PHF3
E, EYS
L PHF3 = 0.051
PAX8 69 2q13 chr2:113990138-114122826 0.19717 2 PAX8
K
9p24.2 70 9p24.2
T chr9:1-7379570 0.20405 45
67Table 2- B) Deletions Continued
Peak Name Rank
Genomic 
location
Peak region
GISTIC q-
value
Gene 
count
Target(s) Frequently mutated genes
B
CDKN2A 1 9p21.3 chr9:21865498-22448737 0 4 CDKN2A
K CDKN2A = 4.4e-15
STK11 2 19p13.3 chr19:1103715-1272039 1.46E-238 7 STK11
K STK11 = 2.5e-13
PDE4D 3 5q11.2 chr5:58260298-59787985 2.02E-143 3 PDE4D
L
PARK2 4 6q26 chr6:161693099-163153207 5.85E-137 1 PARK2
L,K
LRP1B 5 2q22.1 chr2:139655617-143637838 4.25E-107 1 LRP1B
L
CSMD1 6 8p23.2 chr8:2079140-6262191 2.39E-96 1 CSMD1
L
1p36.23 7 1p36.23 chr1:7829287-8925111 1.23E-93 8
ARID1A 8 1p36.11 chr1:26900639-27155421 5.74E-87 2 ARID1A
K ARID1A = 1.5e-14
PTEN 9 10q23.31 chr10:89615138-90034038 1.12E-79 2 PTEN 
K PTEN = 2.2e-15
WWOX 10 16q23.1 chr16:78129058-79627770 8.14E-76 1 WWOX
L WWOX = 0.092
RB1 11 13q14.2 chr13:48833767-49064807 3.88E-75 2 RB1
K RB1 = 1.7e-13
FAM190A 12 4q22.1 chr4:90844993-93240505 9.26E-75 1 FAM190A
L
2q37.3 13 2q37.3
T  chr2:241544527-243199373 1.77E-70 29 ING5
E
22q13.32 14 22q13.32
T chr22:48026910-51304566 8.20E-65 45 BRD1
E, HDAC10
E
11p15.5 15 11p15.5
T chr11:1-709860 1.02E-62 34 SIRT3
E, PHRF1
E HRAS = 7.8e-13
LINC00290 16 4q34.3 chr4:178911874-183060693 1.21E-55 1 LINC00290
FHIT 17 3p14.2 chr3:59034763-61547330 3.01E-55 1 FHIT
L
RBFOX1 18 16p13.3 chr16:5144019-7771745 1.00E-45 1 RBFOX1
L
PTPRD 19 9p24.1 chr9:8310705-12693402 3.24E-38 1 PTPRD
L
18q23 20 18q23
T chr18:74979706-78077248 1.69E-37 12
FAT1 21 4q35.2 chr4:187475875-188227950 6.81E-36 1 FAT1
K FAT1 = 2.4e-15
MPHOSPH8 22 13q12.11
T chr13:1-20535070 2.57E-31 10 MPHOSPH8
E
15q15.1 23 15q15.1 chr15:41795901-42068054 2.71E-29 4 MGA = 0.0083, RPAP1=0.035
11q25 24 11q25
T chr11:133400280-135006516 4.93E-26 14
1p13.2 25 1p13.2 chr1:110048528-117687124 1.69E-25 100 TRIM33
E NRAS=1.8e-13, CD58=0.079
NF1 26 17q11.2 chr17:29326736-29722618 6.59E-23 5 NF1
K NF1 = 3.3e-13
MACROD2 27 20p12.1 chr20:14302876-16036135 9.00E-19 3 MACROD2
L
7p22.3 28 7p22.3
T chr7:1-1496620 1.04E-17 18
6p25.3 29 6p25.3 chr6:1608837-2252425 3.01E-17 2
21q11.2 30 21q11.2
T chr21:1-15482604 2.34E-14 14
9p13.1 31 9p13.1 chr9:38619152-71152237 9.75E-14 48
ZNF132 32 19q13.43
T chr19:58661582-59128983 3.77E-13 24 TRIM28
E, ZNF132
5q15 33 5q15 chr5:73236070-114508587 8.15E-13 156 APC
K, CHD1
E APC=2.6e-13, RASA1=0.0029
MLL3 34 7q36.1 chr7:151817415-152136074 9.26E-13 1 MLL3
K,E MLL3 = 1.1e-05
19q13.32 35 19q13.32 chr19:47332686-47763284 2.38E-12 10
15q12 36 15q12
T chr15:1-32929863 3.40E-11 155 OTUD7A = 0.027
12q24.33 37 12q24.33
T chr12:131692956-133851895 1.24E-10 27
POLE=3.9e-05, 
PGAM5=0.038
10q26.3 38 10q26.3
T chr10:135190263-135534747 2.09E-10 14
6q21 39 6q21 chr6:86319089-117076132 4.56E-10 141
PRDM1
E, HDAC2
E, 
PRDM13
E PRDM1 = 0.00054
PPP2R2A 40 8p21.2 chr8:25896447-26250295 1.78E-09 1 PPP2R2A
IKZF2 41 2q34 chr2:211542637-214143899 3.24E-09 4 IKZF2
K, ERBB4
L ERBB4 = 0.00058
CNTN4 42 3p26.3
T chr3:1-3100786 6.44E-09 3 CNTN4
L
3p12.2 43 3p12.2 chr3:75363575-86988125 1.22E-07 12 ROBO1
L, CADM2
L
RAD51B 44 14q24.1 chr14:68275375-69288431 1.38E-07 2 RAD51B
L ZFP36L1 = 0.0016
11q23.1 45 11q23.1 chr11:105849158-117024891 5.31E-07 84 ATM
K
ATM=1.4e-06, 
POU2AF1=0.082
IMMP2L 46 7q31.1 chr7:109599468-111366370 5.74E-07 2 IMMP2L
L
NEGR1 47 1p31.1 chr1:71699756-74522473 7.25E-07 2 NEGR1
L
BRCA1 48 17q21.31 chr17:41178765-41336147 7.25E-07 2 BRCA1
K BRCA1 = 3.5e-08
9q34.3 49 9q34.3 chr9:135441810-139646221 8.73E-06 94
NOTCH1
K, BRD3
E, 
GTF3C4
E
NOTCH1=1e-08, RXRA=2.1e-
05, COL5A1=0.0022, 
TSC1=0.012
ANKS1B 50 12q23.1 chr12:99124001-100431272 8.73E-06 2 ANKS1B
L
DMD 51 Xp21.2 chrX:30865118-34644819 5.15E-05 4 DMD
L
ZMYND11 52 10p15.3
T chr10:1-857150 7.12E-05 4 ZMYND11
E
PRKG1 53 10q11.23 chr10:52644085-54061437 9.79E-05 3 PRKG1
L
FOXK2 54 17q25.3 chr17:80443432-80574531 0.00019271 1 FOXK2
AGBL4 55 1p33 chr1:48935280-50514967 0.000219 2 AGBL4
L
CDKN1B 56 12p13.1 chr12:12710990-12966966 0.00035777 5 CDKN1B
K CDKN1B = 2.2e-06
14q32.33 57 14q32.33
T chr14:94381429-107349540 0.00074358 227 SETD3
E, TDRD9
E
AKT1=2.1e-13, TRAF3=9.7e-
05
14q11.2 58 14q11.2
T chr14:1-30047530 0.0010181 162 PRMT5
E, CHD8
E CHD8 = 0.034
2p25.3 59 2p25.3
T chr2:1-20072169 0.0011137 86 MYCN
K MYCN=0.068
5q35.3 60 5q35.3
T chr5:153840473-180915260 0.0028515 212 NSD1
E, ODZ2
L
NPM1=3.5e-13, NSD1=1.9e-
09, ZNF454=0.0019, 
UBLCP1=0.03, 
GABRB2=0.07
PTTG1IP 61 21q22.3 chr21:46230687-46306160 0.012227 1 PTTG1IP
22q11.1 62 22q11.1
T chr22:1-17960585 0.020332 15
SMAD4 63 18q21.2 chr18:48472083-48920689 0.036866 3 SMAD4
K SMAD4 = 6.6e-15
17p13.3 64 17p13.3
T chr17:1-1180022 0.040814 16
4p16.3 65 4p16.3
T chr4:1-1243876 0.056345 27
9p21.2 66 9p21.2 chr9:27572512-28982153 0.091742 3
10q25.1 67 10q25.1 chr10:99340084-113910615 0.11879 137 HPSE2
L, SMNDC1
E
SMC3=0.00031, 
GSTO2=0.086
SMYD3 68 1q44 chr1:245282267-247110824 0.15417 8 SMYD3
E
8p11.21 69 8p11.21 chr8:42883855-47753079 0.17382 4
Xp22.33 70 Xp22.33
T chrX:1-11137490 0.21462 52 MXRA5 = 0.031
68Table 2-Notes Continued
BGENE = p-value from [Lawrence et al. upublished data] corrected to FDR within peak
KKnown frequently amplified oncogene or deleted TSG
PPutative cancer gene
EEpigenetic regulator
MMitochondria-associated gene
**Immediately adjacent to peak region
TAdjacent to telomere or centromere of acrocentric chromosome
69these regions included 21% of all focal amplifications and 23% of all focal deletions. 
Focal SCNAs within peak regions tended to be shorter than focal SCNAs elsewhere on 
the chromosome (median 12.2 Mb in peak regions vs 19.4 Mb genomewide, p<0.0001), 
and were more often high-amplitude events (p<0.0001). The number of focal SCNAs 
involving peak regions per sample tracked the total number of SCNAs (r=0.84, 
p<0.0001), ranging from 0.4 focal SCNAs in the typical acute myeloid leukemia to 12.3 
focal SCNAs in the typical ovarian cancer (mean 5.2).   
Tissue types of similar lineages tended to have similar rates of amplification and 
deletion in peak SCNA regions (Fig. 5a). We observed clusters of squamous cell 
carcinomas (head and neck squamous cell carcinoma, lung squamous cell carcinoma 
and bladder cancer) and reproductive cancers (ovarian and endometrial cancer) with 
breast cancer. 
The 70 peak regions of amplification contain a median of three genes each 
(including microRNAs), with 60 peaks containing fewer than 25 genes.  Twenty-four of 
these peak regions contain an oncogene known to be activated by amplification (Table 
2), including seven of the top ten regions (CCND1, EGFR, MYC, ERBB2, CCNE1, 
MCL1, and MDM2). The ninth and tenth most significant regions (11q14.1 and 8p11.23, 
respectively) do not contain known oncogenes, but the latter contains the histone 
methyltransferase WHSC1L1 and is 18 kb away from the known amplified oncogene 
FGFR1. The fourth most significantly amplified peak region (3q26.2) contained TERC, 
which encodes the RNA substrate for the known oncogene TERT, which is itself in a 
peak region of amplification (5p15.33).  Another peak with eight genes (9p13.3) contain 
RMRP, another TERT-associated RNA14,283. 
70The 70 peak regions of deletion contain a median of four genes (including 
microRNAs), with 52 peaks containing fewer than 25 genes. Twenty-two of these 
regions contain one of the 100 largest genes in the genome and 12 contain known 
tumor suppressors (Table 2; two additional large regions contain the known tumor 
suppressors ATM and NOTCH1). Four others each contain a single gene (PPP2R2A, 
PTTG1IP, FOXK2, and LINC00290). We discuss PPP2R2A and its binding partner 
PPP2R1A (which is significantly mutated in the same set of cancers19,26‐28 284 in greater 
detail below. LINC00290 is a long non-coding RNA, a group whose role in cancer is 
increasingly being appreciated29‐32,285,286. Two other regions contain suspected tumor 
suppressors (ERRFI128,33‐37,287, and FOXC138‐41,288).  
The features most associated with genes in the amplification and deletion peak 
regions are known to be associated with cancer (Fig. 5c). We applied GRAIL50‐52,289, 
which uses literature citations to find common features of genes in selected regions of 
the genome.  We considered amplifications and deletions separately, and only peaks 
with fewer than 25 genes. 
Among the 37 peak regions of amplification with fewer than 25 genes and without 
known targets (Table 2), the most associated features were related to epigenetic and 
mitochondrial regulation: “Histone”, “Cytochrome”, “Mitochondrial”, and 
“Acetyltransferase” (Fig. 5c). Thirteen of these 37 regions contain chromatin-state and 
histone-modifying genes (Table 2), reflecting significant enrichment (p<0.0001)
40. 
Among these, five (BRD4, KAT6A, KAT6B, NSD1, and PHF1) are subject to recurrent 
rearrangements in leukemias, sarcomas, and midline carcinomas26,191,290‐295.  The BRD4 
peak also contains NOTCH3, another potential oncogene3,296. Two others, KDM2A and 
71KDM5A, are reported to regulate the activity of TP53 and RB1, respectively104,105,297,298. 
The finding that multiple peak regions of amplification contain epigenetic regulators is 
consistent with growing evidence suggesting epigenetic alterations and chromatin 
remodeling plays a critical role in many forms of cancer147,299‐301. Ten regions contain 
genes encoding mitochondria-associated proteins (Table 2); none of these are subject 
to recurrent rearrangements in cancer. The 21 peak regions of deletion with fewer than 
25 genes and without known tumor suppressor or large genes were most associated 
with “Pten”, “Phosphatase”, “Leucine”, and “Prostate”. 
Fifty of the 140 peak regions contain a significantly mutated gene, including 23 
regions without known oncogene or tumor suppressor gene targets and 32 regions with 
fewer than 25 genes (Table 2). We calculated the significance of mutations (including 
both point mutations and small insertion-deletion events identified in the paired 
sequencing data) for each gene in each region using the methods of 19,189,284,302 and 
corrected for multiple hypotheses reflecting the number of genes in the region. In three 
cases, there were two significantly mutated genes per peak, for a total of 35 significantly 
mutated genes. These 35 genes included eight of the 23 known amplification-activated 
oncogenes and all of the 12 known tumor suppressor genes in these peak regions 
(Table 2).  An additional two of the 35 genes (both in amplification peaks) are 
oncogenes known to be activated by mutations but not by amplifications. 
Frame-shift and nonsense mutations that are likely to cause loss of function were 
significantly enriched in genes in deleted regions (p=0.0002), accounting for 19% of 
these mutations compared to 12% of mutations found in genes in amplified regions. We 
excluded regions with known oncogenes or tumor suppressor genes or more than 25 
72genes from this analysis.  These findings are consistent with the prediction that deleted 
regions without known tumor suppressors are enriched for novel tumor suppressors or 
genes whose functions are non-essential.  
Most peak regions in lineage-specific analyses intersected peak regions in other 
lineages, and indeed in the Pan-Cancer analysis (Fig. 6).  We obtained a median of 74 
peak regions for each lineage (ranging from 25 in acute myeloid leukemia to 95 in 
endometrial cancer; 42% were amplification peaks and 58% were deletion peaks), 
resulting in a total of 770 peak regions. Of these, 84% intersected peak regions in at 
least one other lineage (p<0.0001), and 65% intersected peak regions in the Pan-
Cancer analysis. Peak regions tended to be larger in the lineage-specific than the Pan-
Cancer analyses (1.4 vs 0.7 Mb), indicating the improved resolution of the Pan-Cancer 
analysis. 
Nevertheless, some significant SCNAs were identified in lineage-specific but not 
the Pan-Cancer analysis.  Across all lineages, we identified 229 peaks not present in 
the Pan-Cancer analysis, including amplifications of the known amplified oncogenes 
MET, CCND2, ERBB3, and MYCN and deletions of the known tumor suppressor genes 
TP53 and CDKN2C. 
 
Correlations reflect overall levels of genomic disruption 
For each pair of peak regions, we looked for positive and negative correlations 
between focal SCNAs involving these regions (Fig. 7a). We compared the number of 
samples with SCNAs involving both regions between observed data and permuted data 
in which SCNAs were randomly assigned to samples while maintaining genomic 
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Figure 7 – Motivation and results for correlations 
analysis SCNAs  
(a) Illustration of question, displaying a heatmap of copy-
number profiles across 4934 cancers (x-axis), arranged in 
order of increasing genomic disruption. (b) Fraction of region 
pairs exhibiting significant positive correlation (left), negative 
correlation (right), or neither (middle), using standard analysis 
techniques (top) and after controlling for variations in genomic 
disruption (bottom). (c) Fraction of genome involved in focal 
SCNAs in samples displayed in panel (a) among observed 
data (red line), permutations generated by standard 
techniques (blue line) and permutations that maintain levels of 
genomic disruption (black dashed line). 
75positions and SCNA structure. We only permuted SCNAs within lineages (and sub-
lineages when available) to avoid lineage-dependent confounders, and evaluated 
correlations between regions on different chromosomes to avoid correlations due to 
chromosomal structure (see Methods).  We focused on peak regions with less than 25 
genes. 
We identified significant positive correlations (q<0.25) between 53% of region 
pairs, but no significant anticorrelations (Fig. 7b). The high rate of positive correlations 
results from widely differing levels of genomic disruption across samples, which are not 
maintained in permuted datasets (Fig. 7c).  Similar results are obtained with other 
standard statistical approaches such as Fisher’s exact tests (data not shown). These 
findings indicate that varying levels of overall genomic disruption confound analyses of 
functionally relevant correlations between SCNAs. 
We therefore re-evaluated correlations between SCNAs after controlling for 
genomic disruption, by maintaining in the permuted data the fractions of the genome 
affected by each of amplifications and deletions in each sample (Fig. 7c, Fig. 8a-d; 
Methods). We performed the analysis in two ways: evaluating all SCNAs, and 
evaluating only high-level amplifications and homozygous deletions (Table 3; see 
Methods).  In many cases, high-level amplification or homozygous deletion may be 
necessary to activate an oncogene or inactivate a tumor suppressor gene50,137,189,303 and 
in such cases, correlated features may be masked by noise in lower level events. 
When evaluating all SCNAs, we identified significant positive correlations 
between <1% of region pairs (40 interactions) and anticorrelations between 7% of 
region pairs (396 interactions, Fig. 7b). Correcting for genomic disruption altered the 
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Figure 8 – Controls for correlation analysis 
(a-d) Comparison of random permutation and controlled 
permutation in recapitulating observed distribution of SCNAs. 
Each plot compares the number of samples (y-axis) against 
fraction of genome amplified. Red dots signify observed 
distribution and blue box plots represent permutations of this 
data. (a) and (b) illustrated random permutations of 
amplifications and deletions, respectively, controlling for 
lineage. (c-d) represent our simulated annealing approach. 
(e) A comparison of p-values obtained from the lineage-
controlled standard analysis of correlations (y-axis) and an 
analysis that controls for varying levels of genomic disruption 
(x-axis). Although the p-values tend to correlate, the ranking 
is not the same, and many interactions that appear 
significant in one test are not significant in the other.  Most 
interactions appear significant in the standard analysis. 
77Table 3: high level correlations
p_value peak1 peak2 q_value peak1 peak2
0.00012 14 11 0.066707 PDGFRA CDK4
0.000122 2 71 0.066707 EGFR CDKN2A
0.000482 57 110 0.175743 19p13.2 PPP2R2A
78Table 3: high level anticorrlations Continued
p peak1 peak2 q peak1 peak2
0.00012 22 6 0.044472 8q24.3 CCNE1
0.000122 11 71 0.044472 CDK4 CDKN2A
0.00012 14 2 0.044472 PDGFRA EGFR
0.000241 1 27 0.052723 CCND1 BCL2L1
0.000241 8 71 0.052723 MDM2 CDKN2A
0.000361 21 5 0.056489 IGF1R ERBB2
0.000361 65 9 0.056489 LINC00536 INTS4
0.000482 1 21 0.058581 CCND1 IGF1R
0.000482 71 81 0.058581 CDKN2A RB1
0.000964 12 28 0.062027 KAT6A TUBD1
0.000723 7 29 0.062027 MCL1 [ZNF703]
0.000843 22 32 0.062027 8q24.3 BRD4
0.000843 3 1 0.062027 MYC CCND1
0.000964 1 6 0.062027 CCND1 CCNE1
0.000964 29 5 0.062027 [ZNF703] ERBB2
0.000723 2 8 0.062027 EGFR MDM2
0.000723 110 79 0.062027 PPP2R2A PTEN
0.001687 29 58 0.090902 [ZNF703] 17q25.1
0.00241 13 58 0.090902 SOX2 17q25.1
0.001566 6 25 0.090902 CCNE1 20q13.33
0.002289 22 1 0.090902 8q24.3 CCND1
0.001928 41 1 0.090902 RMRP CCND1
0.002289 65 1 0.090902 LINC00536 CCND1
0.002289 2 11 0.090902 EGFR CDK4
0.002289 30 71 0.090902 1q23.3 CDKN2A
0.001807 4 71 0.090902 TERC CDKN2A
0.00241 19 5 0.090902 KDM5A ERBB2
0.002169 15 8 0.090902 BDH1 MDM2
0.002169 76 79 0.090902 CSMD1 PTEN
0.002771 1 58 0.101052 CCND1 17q25.1
0.002892 3 118 0.102044 MYC BRCA1
0.003012 21 6 0.102974 IGF1R CCNE1
0.003373 12 54 0.108547 KAT6A 17q21.33
0.003373 30 2 0.108547 1q23.3 EGFR
0.003614 6 36 0.112978 CCNE1 ZNF217
0.003976 22 8 0.117558 8q24.3 MDM2
0.003976 4 8 0.117558 TERC MDM2
0.004096 38 6 0.117933 KAT6B CCNE1
0.004458 63 1 0.118948 NEDD9 CCND1
79Table 3: high level anticorrlations Continued
p peak1 peak2 q peak1 peak2
0.004458 28 6 0.118948 TUBD1 CCNE1
0.004337 55 6 0.118948 BPTF CCNE1
0.004699 10 19 0.119546 WHSC1L1 KDM5A
0.004699 3 88 0.119546 MYC RBFOX1
0.00506 59 6 0.12302 KDM2A CCNE1
0.00506 7 10 0.12302 MCL1 WHSC1L1
0.006506 10 47 0.15473 WHSC1L1 CBX8
0.007229 30 29 0.158169 1q23.3 [ZNF703]
0.007108 10 55 0.158169 WHSC1L1 BPTF
0.006988 9 21 0.158169 INTS4 IGF1R
0.006988 17 89 0.158169 MDM4 PTPRD
0.007831 8 6 0.164759 MDM2 CCNE1
0.007831 63 9 0.164759 NEDD9 INTS4
0.008554 3 136 0.166493 MYC 9p21.2
0.008313 22 9 0.166493 8q24.3 INTS4
0.008072 13 8 0.166493 SOX2 MDM2
0.008675 17 10 0.166493 MDM4 WHSC1L1
0.008434 3 36 0.166493 MYC ZNF217
0.009277 4 11 0.17202 TERC CDK4
0.009157 4 80 0.17202 TERC WWOX
0.009759 29 54 0.175023 [ZNF703] 17q21.33
0.009759 10 28 0.175023 WHSC1L1 TUBD1
0.010241 30 1 0.177835 1q23.3 CCND1
0.010241 65 33 0.177835 LINC00536 KRAS
0.010723 7 1 0.180475 MCL1 CCND1
0.010723 13 3 0.180475 SOX2 MYC
0.011084 11 136 0.183731 CDK4 9p21.2
0.012169 10 58 0.185243 WHSC1L1 17q25.1
0.012169 20 22 0.185243 MYCL1 8q24.3
0.012289 12 55 0.185243 KAT6A BPTF
0.011928 15 71 0.185243 BDH1 CDKN2A
0.011687 35 71 0.185243 NFE2L2 CDKN2A
0.012048 1 91 0.185243 CCND1 FAT1
0.01253 32 23 0.185243 BRD4 G6PD
0.01241 3 9 0.185243 MYC INTS4
0.012892 14 6 0.185571 PDGFRA CCNE1
0.012771 13 36 0.185571 SOX2 ZNF217
0.013253 13 92 0.185882 SOX2 MPHOSPH8
0.013133 34 71 0.185882 NKX2-1 CDKN2A
80Table 3: high level anticorrlations Continued
p peak1 peak2 q peak1 peak2
0.013494 15 9 0.186866 BDH1 INTS4
0.014096 74 71 0.190388 PARK2 CDKN2A
0.014096 9 36 0.190388 INTS4 ZNF217
0.014819 20 15 0.192283 MYCL1 BDH1
0.01494 65 32 0.192283 LINC00536 BRD4
0.014819 20 32 0.192283 MYCL1 BRD4
0.014699 3 124 0.192283 MYC FOXK2
0.016867 71 114 0.21457 CDKN2A RAD51B
0.017711 56 1 0.217704 E2F3 CCND1
0.017711 3 11 0.217704 MYC CDK4
0.017349 49 10 0.217704 CDK6 WHSC1L1
0.018916 71 137 0.22539 CDKN2A 10q25.1
0.020602 22 54 0.22539 8q24.3 17q21.33
0.020361 3 54 0.22539 MYC 17q21.33
0.019518 9 28 0.22539 INTS4 TUBD1
0.018795 15 55 0.22539 BDH1 BPTF
0.02 86 71 0.22539 LINC00290 CDKN2A
0.020482 12 21 0.22539 KAT6A IGF1R
0.019759 10 21 0.22539 WHSC1L1 IGF1R
0.019759 13 19 0.22539 SOX2 KDM5A
0.02012 71 79 0.22539 CDKN2A PTEN
0.019277 4 88 0.22539 TERC RBFOX1
0.021084 69 13 0.22614 PAX8 SOX2
0.021084 30 10 0.22614 1q23.3 WHSC1L1
0.021325 12 36 0.226504 KAT6A ZNF217
0.021687 3 8 0.228128 MYC MDM2
0.023373 3 59 0.24353 MYC KDM2A
0.024217 71 123 0.246528 CDKN2A PRKG1
0.024337 13 71 0.246528 SOX2 CDKN2A
0.024217 4 72 0.246528 TERC STK11
81estimated significance of these interactions and also changed the rank ordering of those 
significance estimates (Fig. 8e). High-level amplifications and homozygous deletions 
are relatively rare, limiting our power to detect anticorrelations in the high-level analysis. 
Among the 1094 interactions we were powered to detect, we observed positive 
correlations between <1% of region pairs (3 interactions, Table 3) and anticorrelations 
between 10% of region pairs (108 interactions, Fig. 9a, Table 3). The three correlations 
included deletions of CDKN2A with amplifications of EGFR, amplifications of PDGFR 
with amplifications of CDK4, and deletions of PPP2RA with amplifications of 19p13.2. 
We predicted that anticorrelated SCNAs would often indicate functional 
redundancies, and therefore genes in the affected regions would often be in similar 
pathways and interact physically.  We tested this hypothesis by comparing networks 
representing significantly anticorrelated SCNAs (“anticorrelation networks”) with 
DAPPLE, a set of curated protein-protein interactions (PPIs)50,191,192,279 (see Methods). 
Networks formed by our anticorrelations analyses and by PPIs significantly 
overlapped (p<0.0001 and p=0.006 for all-SCNA and high-level analyses, respectively, 
Fig. 9b-c).  For example, in the analysis of all SCNAs, we observed 100 overlapping 
edges, a 2-fold increase over the 43.4 overlapping edges expected by chance.  This 
significance was not observed for correlated events (p=1 for both all-SCNA and high–
level analyses). These results suggest that the observed anticorrelations are related to 
biological interactions. 
The anticorrelations networks were enriched for both isolated nodes and highly 
connected “hub” regions (Fig. 9d). To analyze the structure of these networks, we 
generated control anticorrelation networks representing the most significant edges from 
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Figure 9 – Biological redundancies suggested by 
mutual exclusivity 
(a) Genetic interactome map for high-level SCNAs. Nodes 
represent peak regions with fewer than 25 genes and are 
connected by edges if focal high-level SCNAs 
(amplifications to >4.4 copies and deletions to <1 copy) are 
significantly anticorrelated. (b-c) The number of significant 
anticorrelations that overlap known protein-protein 
interactions in the observed genetic interactome network 
(red arrow) and permuted networks (blue bars).  These 
results are from the analysis of all SCNAs, and high-level 
SCNAs, respectively (d) Distribution of connectivity values 
(number of nodes to which each node is connected) for the 
observed genetic interactome network (red dots) and 
permuted networks (box plots) in the all-SCNAs analysis. 
83permuted data in which we had randomized the SCNA sample assignments within 
lineage. In the all-SCNA analysis, 28 regions were anticorrelated with fewer than three 
other regions, relative to three isolated nodes in the average permutation (p<0.01).   
The isolated nodes in the all-SCNA analysis were enriched for regions containing 
large genes (including 10 of 28 such regions; p=0.004). Conversely, they trended 
toward excluding regions with known oncogenes or tumor suppressors (five of 35 such 
regions; p=0.06). Most peak regions exhibit fewer anticorrelations in the high-level 
analysis, possibly due to decreased power.  The most extreme exception was CDKN2A, 
which anticorrelated with 14 regions in the high-level analysis and only nine regions in 
the all-SCNA analysis. Consistent with these findings, CDKN2A is often inactivated by 
homozygous deletions. 
Whole genome doubling: correlates and consequences on cancer evolution   
We applied a similar analysis to identify events associated with WGD.  We 
included both SCNAs and mutations, using the 200 most significantly mutated genes 
across the TCGA Pan-Cancer dataset284,302. Three SCNA peak regions and two 
significantly mutated genes correlated with WGD (Table 4). TP53 mutations and 
CCNE1 amplifications correlated with WGD; both have been functionally associated 
with tolerance of tetraploidy in experimental models304‐306. Our findings indicate these 
associations apply to human tumors across multiple lineages. We also found that 
deletions of PPP2R2A and mutations of its binding partner PPP2R1A were correlated 
with WGD. These two genes belong to phospho-protein phosphatase complex 2 
(PPP2), which regulates mitotic spindle formation and can lead to chromosomal 
missegregation and abnormal mitoses when depleted307,308.      
84Table	 ﾠ4:	 ﾠCorrelates	 ﾠwith	 ﾠWGD
putative	 ﾠgene Rank p_value
Anticorrelations	 ﾠwith	 ﾠWGD
Amplications
MYC 3 0.0065
8q24.3 22 0.0007
Deletions
CDKN2A 1 0
PTEN 9 0
10q25.1 67 0.0016
NF1 26 0.0053
DMD 51 0
Mutations
PIK3CA 2 0.002
CTCF 28 0.004
MAP3K1 45 0.004
ATM 68 0.006
putative	 ﾠgene Rank p_value
Correlations	 ﾠwith	 ﾠWGD
Amplications
CCNE1 6 0.00012
Deletions
CSMD1 6 0.00012
PPP2R2A 40 0.00012
Mutations
TP53 1 <0.001
PPP2R1A 84 0.008
85Eleven genetic events anti-correlated with WGD, including two amplifications, 
five deletions and four mutations (Table 4).  The deletions included CDKN2A, PTEN, 
and NF1, and three of the four mutations also involved genes known as or proposed to 
be tumor suppressors (CTCF309, MAP3K1310, and ATM). The anticorrelations of these 
tumor suppressors may result from a greater difficulty in biallelically inactivating tumor 
suppressors in samples with extra copies subsequent to WGD147. 
We can use the unique signature that WGD places on the cancer genome to 
determine when specific regions were lost during cancer development. A loss of 
heterozygosity (LOH) deletion in WGD samples will appear to be a single event of 
amplitude two (going from two copies to zero copies). We hypothesized that TSGs 
important to tumor initiation are more likely to occur prior to WGD. Conversely, the 
timing of LOH in peaks whose significance may be derived from increased SCNA 
generation would be similar to timing of events observed throughout the rest of the 
genome. We looked at what fraction of focal LOH on each significant peak occurred 
prior to WGD and compared these numbers to overall fraction of LOH observed prior to 
WGD.   
We found that LOH in well-studied TSGs occurred relatively early in cancer 
development, whereas many significant regions thought to be caused by fragile sites or 
lack of negative selection were not significantly different from background (Table 5). 
These groups were evenly distributed across significant region list when sorted by 
GISTIC significance (Kolmogorov-Smirnov test, p=0.27 and 0.86 for TSGs and large 
genes, respectively). However, regions that were more likely to occur prior to WGD 
were significantly enriched for known TSGs (one-sided KS test, p = 0.007), with the top 
86Table 5: LOH timing relative to WGD
Peak Name GISTIC Rank Genomic location GISTIC q-value Gene count Target(s) Frequently mutated genes
B wgd timing q 
value
CDKN2A 1 9p21.3 0 4 CDKN2A
K CDKN2A = 4.4e-15 2.85E-15
CSMD1 6 8p23.2 2.39E-96 1 CSMD1
L 9.23E-14
PPP2R2A 40 8p21.2 1.78E-09 1 PPP2R2A 6.55E-09
FOXK2 54 17q25.3 0.00019271 1 FOXK2 1.08E-05
BRCA1 48 17q21.31 0.000000725 2 BRCA1
K BRCA1 = 3.5e-08 0.0002
15q15.1 23 15q15.1 2.71E-29 4 MGA = 0.0083, RPAP1=0.035 0.0005
9p21.2 66 9p21.2 0.091742 3 0.0014
RB1 11 13q14.2 3.88E-75 2 RB1
K RB1 = 1.7e-13 0.0059
NF1 26 17q11.2 6.59E-23 5 NF1
K NF1 = 3.3e-13 0.0059
PTEN 9 10q23.31 1.12E-79 2 PTEN 
K PTEN = 2.2e-15 0.0174
7p22.3 28 7p22.3
T 1.04E-17 18 0.0196
21q11.2 30 21q11.2
T 2.34E-14 14 0.0196
RAD51B 44 14q24.1 0.000000138 2 RAD51B
L ZFP36L1 = 0.0016 0.0196
19q13.32 35 19q13.32 2.38E-12 10 0.0248
STK11 2 19p13.3 1.46E-238 7 STK11
K STK11 = 2.5e-13 0.0276
PTPRD 19 9p24.1 3.24E-38 1 PTPRD
L 0.032
SMAD4 63 18q21.2 0.036866 3 SMAD4
K SMAD4 = 6.6e-15 0.0462
CDKN1B 56 12p13.1 0.00035777 5 CDKN1B
K CDKN1B = 2.2e-06 0.0468
IMMP2L 46 7q31.1 0.000000574 2 IMMP2L
L 0.1279
MACROD2 27 20p12.1 9E-19 3 MACROD2
L 0.1378
18q23 20 18q23
T 1.69E-37 12 0.1431
MLL3 34 7q36.1 9.26E-13 1 MLL3
K,E MLL3 = 1.1e-05 0.1431
ANKS1B 50 12q23.1 0.00000873 2 ANKS1B
L 0.1431
FHIT 17 3p14.2 3.01E-55 1 FHIT
L 0.1721
10q26.3 38 10q26.3
T 2.09E-10 14 0.1721
3p12.2 43 3p12.2 0.000000122 12 ROBO1
L, CADM2
L 0.1721
11q25 24 11q25
T 4.93E-26 14 0.179
ZNF132 32 19q13.43
T 3.77E-13 24 TRIM28
E, ZNF132 0.179
PTTG1IP 61 21q22.3 0.012227 1 PTTG1IP 0.179
IKZF2 41 2q34 3.24E-09 4 IKZF2
K, ERBB4
L ERBB4 = 0.00058 0.2653
RBFOX1 18 16p13.3 1E-45 1 RBFOX1
L 0.3041
ZMYND11 52 10p15.3
T 0.0000712 4 ZMYND11
E 0.3402
17p13.3 64 17p13.3
T 0.040814 16 0.3431
PARK2 4 6q26 5.85E-137 1 PARK2
L,K 0.4359
PDE4D 3 5q11.2 2.02E-143 3 PDE4D
L 0.4561
22q11.1 62 22q11.1
T 0.020332 15 0.7488
WWOX 10 16q23.1 8.14E-76 1 WWOX
L WWOX = 0.092 0.8334
SMYD3 68 1q44 0.15417 8 SMYD3
E 0.8334
1p36.23 7 1p36.23 1.23E-93 8 0.8611
FAT1 21 4q35.2 6.81E-36 1 FAT1
K FAT1 = 2.4e-15 0.8869
CNTN4 42 3p26.3
T 6.44E-09 3 CNTN4
L 0.8869
8p11.21 69 8p11.21 0.17382 4 0.8869
NEGR1 47 1p31.1 0.000000725 2 NEGR1
L 0.9142
6p25.3 29 6p25.3 3.01E-17 2 0.9275
ARID1A 8 1p36.11 5.74E-87 2 ARID1A
K ARID1A = 1.5e-14 0.9326
FAM190A 12 4q22.1 9.26E-75 1 FAM190A
L 0.9326
MPHOSPH8 22 13q12.11
T 2.57E-31 10 MPHOSPH8
E 0.9326
LRP1B 5 2q22.1 4.25E-107 1 LRP1B
L 0.9604
LINC00290 16 4q34.3 1.21E-55 1 LINC00290 0.9604
PRKG1 53 10q11.23 0.0000979 3 PRKG1
L 0.9604
AGBL4 55 1p33 0.000219 2 AGBL4
L 0.9604
8710 most significant regions including RB1, CDKN2A, NF1, PTEN, and BRCA1 (Table 
5). This enrichment was not observed for significant regions containing large genes 
(p=0.94). PPP2R2A, whose deletion was found to correlate with WGD above, was the 
second most significant region with respect to early LOH (FDR p-value 9x10
-14). The 
sixth most significant peak in this analysis (FDR p-value = 5x10
-4) contains 4 genes, 
including Max-gene associated protein (MGA), which is also significantly mutated 
across the same dataset.  
 
Discussion 
Significant regions of SCNA in the Pancancer dataset 
Using current significance techniques, correcting for sample purity and ploidy, we 
found 140 significant regions in the Pan-Cancer analysis, only 35 of which contained 
known amplified oncogenes or tumor suppressor genes.  As mentioned above, some of 
the remaining regions may be false positive SCNAs and some of the remaining regions 
may recur because these regions are subject to relatively small amounts of negative 
selection or due to mechanistic biases favoring the generation of SCNAs in these 
regions.  Indeed, we found that SCNAs involving large genes (potentially less negative 
selection) or significant regions near telomeres (mechanistic bias) often did not 
anticorrelate with any other genetic events, suggesting the genes in these regions may 
have limited functional roles in oncogenesis.  However, it remains likely that many 
additional oncogenes and tumor suppressor genes are within these regions. Moreover, 
these 140 regions and the additional 229 peak regions identified in the lineage-specific 
analyses are likely to compose a subset of the regions that are significantly altered in 
88cancer.  Analyses of other cancer types have identified additional peak regions, and the 
limited resolution of the array platform may have obscured detection of some SCNAs. 
Varying levels of genomic disruption across cancers are likely to engender 
biases in analyses of correlations not only between SCNAs, but also between SCNAs 
and other features of these cancers.  For example, increased genomic disruption has 
been associated with poor prognosis in multiple cancer types253.  Poor prognosis is 
therefore likely to be associated with increased rates of SCNA across much of the 
genome.  Controlling for this tendency is required to correctly identify SCNAs that are 
functionally associated with progression.  It will also be important to account for other 
possible confounders, such as mechanistically linked events (e.g. chromothripsis or 
SCNAs that encompass multiple peak regions). Unlike other analysis, our method 
controls for the background rate of SCNAs in each sample and does not depend on 
previous determination of significant regions or genes, which should increase the 
stability of our results202,261.  
WGD frequency and timing.  
Besides TP53, we found four genetic events that correlated with WGD. The exact 
role of WGD in cancer progression, as either a driver event or a frequent consequence 
of an unstable genome, is still poorly understood, but these correlates may provide 
clues as to potential causes of WGD. The PPP complex role in tumor suppression has 
been suggested previously, and having two components in the 5 genes the correlate 
with WGD suggests its role in guiding and stabilizing mitosis may explain how loss of 
function can lead to tumor formation. 
89 While SCNAs on many tumor suppressors tended to anti-correlate with WGD, 
using the timing of SCNAs in relation to the WGD event could be a useful tool in 
identifying significant regions likely involved early in tumor development. Using the 
WGD to temporally sequence events in this manner could be incorporated in specific 
significance analyses, with earlier events providing more evidence of a “tumor initiator” 
role for a given alteration. We found that events on well-studied TSG genes frequently 
occurred early in cancer development compared to other genes, whereas many regions 
whose significance may be due to mechanism where not temporally biased. This 
analysis identified a couple peaks that exhibited patterns more closely associated with 
known tumor suppressors, suggesting a potential role in tumor formation.  
   
90Chapter 4: The discovery of non-driver cancer dependencies 
using high-throughput shRNA pooled screens. 
Section goals 
 
 While finding specific vulnerabilities of primary tumors through identifying the 
drivers of cancer evolution has been remarkably successful, comprehensive, 
personalized medicine may require a more inclusive approach to identifying therapeutic 
targets. Most cancer malignancies are thought to be the result of a small handful of 
driver alterations that together overcome the many barriers to unrestrained growth. 
Focusing therapies only on driver alterations may mean that, for each patient, we will 
have a small handful of opportunities to find specific vulnerabilities that are a direct 
response of these driver alterations. Many driver alterations, such as amplifications of 
transcription factor or inactivation of tumor suppressor genes, have proven refractory to 
current techniques of small molecule inhibition, raising the possibility that some cancers 
will not have driver alterations that expose tractable therapeutic targets.  Expanding the 
universe of potential therapeutic targets is therefore a worthwhile endeavor. The goal of 
this section was to discover vulnerabilities predicted by passenger alterations by 
integrating an RNAi pooled screen across many cell lines with genome-wide SNP6.0 
array SCNA data to determine if partial copy-number loss of specific genes renders 
cells highly dependent on the remaining copy. We identified a class of genes that render 
cells that harbor copy-number loss highly dependent on the expression of the remaining 
copy. These were enriched for cell essential genes, most predominantly components of 
the proteasome, spliceosome, and ribosome. 
91Methods 
 
Copy-number and High Methylation analysis of Tumor Samples 
Copy-numbers were determined for 3,131 cancer samples using Affymetrix 250K 
SNP array data as previously described311. Marker and gene locations were based on 
the hg18 genome build. We considered markers with relative log2 copy number ratios 
less than -0.1 to be affected by partial copy number loss, and markers less than -1.28 
as homozygous deletions26. Copy-number profiles, and the locations, lengths, and 
amplitudes of the amplification and deletion events underlying these profiles, were 
determined as previously described
311. We determined the significance of depletion of 
homozygous deletions among candidate CYCLOPS genes by comparing observed 
rates of homozygous deletion to the distribution of rates after permutation of gene 
names. DNA methylation state Beta-values were collected for 601 ovarian tumors from 
the TCGA web portal. Gene level Beta values > 0.7 were considered high DNA 
methylation.  
 
Copy number analysis of cancer cell lines from CCLE 
For each sample, we created a 100 bin histogram of copy number values for all 
markers, and then used a 5-bin moving average to smooth this distribution. This 
procedure typically yielded 2-5 well-separated peaks (local maxima with height as 
measured from local max to surrounding local minima >2% of genome), presumably 
corresponding to integer level copy loss and gains. Based on these peaks, samples 
were separated into one of two categories for classification. If a sample contained one 
peak between log2 copy number -0.05 and 0.05, with a second peak between -0.05 and 
92-0.4, the first peak was defined as copy neutral, and the second peak as partial copy 
loss. In this case, the cutoff for copy loss was set at 95% upper bound of the second 
peak, and the cutoff for copy neutral was set at 95% lower bound of the first peak. If 
there were no peak that met our height criteria within these regions in a given sample, 
markers <-0.4 were considered copy loss while markers >-0.2 were considered copy 
neutral. In either case, markers that lay between our two cutoffs were left uncalled and 
genes with these copy numbers were excluded from further analysis. Markers with log2 
copy number ratios ≤ -1.28 were considered homozygous loss and genes with these 
copy numbers were also removed from further analyses.  We used the Kolmogorov-
Smirnov test to determine enrichment of the CYCLOPs genes identified in our original 
analysis among the most significant genes in our analysis of the Validation dataset. 
 
Analysis of copy number and expression correlations 
Quantized normalized expression data was obtained from the CCLE 
(www.broadinstitute.org/ccle) and TCGA (https://tcga-data.nci.nih.gov/tcga/ ) portals. 
Enrichment of Pearson correlation coefficients among CYCLOPS candidates and 
pathways was determined by permuting gene names. A similar analysis was used to 
determine significance of correlation between Bortezomib logIC50 data for 133 cancer 
cell lines collected from Sanger center Cancer Genome Project 
(http://www.sanger.ac.uk/genetics/CGP/) portal and the expression patterns for these 
lines from the CCLE (www.broadinstitute.org/ccle).   
 
CYCLOPS analysis 
93For each cell line, we classified each gene as intact (no copy-number loss), 
partial loss, or to be excluded (for genes undergoing homozygous loss or with 
ambiguous data) based on thresholds determined using the distribution of relative copy-
numbers generated from analysis of SNP array data for that cell line. Gene dependency 
scores were determined using the ATARiS algorithm253. The statistical significance of 
the difference in mean gene dependency scores between “intact” and “partial loss” cell 
lines was determined by comparing the observed data to data representing 50,000 
random permutations of class labels, each maintaining the number of cell lines and 
lineage distribution in each class. Multiple hypotheses were corrected using the FDR 
framework. 
 
Author contributions:  
The author was responsible for the data curation, quality control, and analysis, 
with advice from Deepak Nijhawan, William Hahn and Rameen Beroukhim.  
 
Results 
By analyzing copy-number profiles from 3,131 cancers across a wide diversity of 
cancer types
26, we found that most cancers exhibit relative copy-number loss affecting 
at least 11% of the genome and that many cancers exhibit much more extensive loss of 
genetic material (Fig. 10a). Here we note that the phenotypic effects of SCNA may be 
dosage dependent, such that a single gain or loss may represent a larger deviation from 
“balance” in a diploid cell (2n) than cells with higher ploidy. With this in mind, we used 
data with DNA intensity normalized to the total DNA content of the sample. Much of this 
widespread genomic disruption is due to copy-number alterations involving whole 
chromosomes or chromosome arms, presumably due to mechanisms that favor the 
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Figure 10- Characteristics of genomic loss in cancer: 
(a) The percentage of the cancer genome involved in 
copy-number loss. (b) The fraction of deleted regions 
associated with deletion events of varying lengths. (c) 
Frequency of copy number loss across the genome 
among 3,131 cancers. The total frequency (purple, left 
panel) and frequencies due to focal (blue) and arm-level 
(teal) events (right panel) are shown. (d) Biallelic 
inactivation of a tumor suppressor is often associated with 
a focal alteration of one copy (red bar) and hemizygous 
loss of all genes on the chromosome arm containing the 
other copy. (e) Number of genes affected by copy loss 
events that include prominent tumor suppressor genes. 
For each sample where the indicated tumor suppressor 
gene underwent copy number loss, we calculated the 
number of genes affected by the largest copy loss event 
affecting that gene. The results are plotted as a 
histogram. 
95generation of such large events (Fig. 10b). As a consequence, most genes undergo 
copy-number loss in a substantial fraction of cancers (average 16.2, range 3.7-40.2%; 
Fig. 10c). A subset of the genes affected by recurrent copy-number alterations 
contribute to cancer development as tumor suppressor genes; however, a substantial 
fraction of these genes are recurrently lost due to passenger events or because of their 
proximity to a frequently deleted tumor suppressor gene (Fig. 10d-e). We hypothesized 
that for a subset of non-driver genes, hemizygous loss may be tolerated and frequent 
but complete loss would lead to cell death. In some of these cases, hemizygous loss 
might lead to sensitivity to further inhibition of the gene relative to cells that harbor two 
copies of these genes. 
To identify genes whose loss correlated with a greater sensitivity to further gene 
suppression, we integrated gene dependencies and copy-number data from 86 cancer 
cell lines (Table 6) in Project Achilles, described above. Out of the 111 lines available in 
the Achilles dataset, 101 of the barcode arrays passed internal quality control, and 86 of 
those also contained Affymetrix SNP 6.0 array data from the Cancer Cell Line 
Encyclopedia (CCLE) 
233,312. For 7,250 of these genes, the Ataris algorithm
253 
determined there were multiple shRNAs that had comparable effects across cell lines, 
suggesting their effects were due to suppression of the intended target and used these 
shRNAs to construct composite “gene dependency scores”. For each gene, we first 
classified each cell line by whether or not it had copy-number loss in that gene and then 
calculated the mean gene dependency score among cell lines in each class. We then 
determined the difference in mean scores between the copy-loss and copy-neutral 
classes and rated the significance of this difference by permuting class labels (Fig. 11). 
96Table 6-Cell Lines used in Achilles CYCLOPS analysis
Cell line Tissue of Origin Cell line Tissue of Origin
786O kidney HEC1A endometrium
A2780 ovary COLO741 skin
OVCAR4 ovary KYSE510 esophagus
L33 pancreas LS411N large intestine
HS944T skin KYSE150 esophagus
CAOV3 ovary KYSE450 esophagus
HT29 large intestine LOVO large intestine
NCIH1975 lung KYSE30 esophagus
A549 lung AGS stomach
NCIH196 lung U251MG cns
PANC0327 pancreas MIAPACA2 pancreas
IGROV1 ovary NCIH2122 lung
OVCAR8 ovary KMS12BM leukemia
TOV21G ovary OV90 ovary
KM12 large intestine NCIH2171 lung
OE33 esophagus DLD1 large intestine
MDAMB453 breast HL60 leukemia
HLF liver HEYA8 ovary
SJSA1 bone TYKNU ovary
LS513 large intestine EFO21 ovary
HCC827 lung RMGI ovary
COV362 ovary BXPC3 pancreas
NCIH661 lung EFO27 ovary
CFPAC1 pancreas ASPC1 pancreas
HPAC pancreas RT112 urinary tract
SKCO1 large intestine A2058 skin
NCIH82 lung KURAMOCHI ovary
OVISE ovary SW480 large intestine
OVMANA ovary IGR39 skin
NCIH1650 lung CAOV4 ovary
NIHOVCAR3 ovary COLO205 large intestine
KP4 pancreas C2BBE1 large intestine
HUG1N stomach SNUC1 large intestine
TE9 esophagus SNUC2A large intestine
COV504 ovary PANC0813 pancreas
HCC70 breast RKO large intestine
NCIH508 large intestine SU8686 pancreas
TE15 esophagus GP2D large intestine
A204 soft tissue SW48 large intestine
QGP1 pancreas COV434 ovary
TT esophagus HUTU80 small intestine
JHOC5 ovary LN229 cns
SNU840 ovary RKN ovary
CAOV4 ovary
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Figure 11- Analysis to find cancer 
vulnerabilities predicted by partial loss: 
Schematic describing the approach to identifying 
CYCLOPS genes. For each gene, we separated 
cell lines with and without loss of the gene and 
compared their dependency on that gene by 
permuting class labels. 
Table 7 - Top Genes from CYCLOPS analysis
CYCLOPS Analysis of 5312 genes (6085 Gene Dependence Solutions)
Gene cyto band # of loss lines # of neutral lines p value
PSMC2 7q22.1 11 73 0.00002
EIF2B2 14q24.3 17 68 0.00002
EEF2 19p13.3 35 48 0.00002
PHF5A 22q13.2 24 62 0.00002
HPGD 4q34.1 34 48 0.00004
RPS15 19p13.3 33 50 0.00004
SNRPB 20p13 10 74 0.00004
POLR2F 22q13.1 22 63 0.00004
USPL1 13q12.3 27 58 0.00008
SMC2 9q31.1 19 67 0.00012
SMU1 9p13.3 27 57 0.00014
PUF60 8q24.3 10 75 0.00016
RPS11 19q13.33 16 70 0.0002
POLG 15q26.1 18 67 0.00022
ZNF583 19q13.43 12 74 0.00022
CPT1B 22q13.31 23 61 0.00022
BMP8A 1p34.2 9 77 0.00024
TIE1 1p34.2 7 78 0.00028
SF3A2 19p13.3 34 49 0.00028
SNRNP70 19q13.33 17 69 0.0003
RBM17 10p15.1 21 60 0.00032
PCNA 20p12.3 10 73 0.00032
PSMA4 15q25.1 20 64 0.00036
LSM4 19p13.11 21 62 0.00036
EEF1A1 6q13 20 66 0.00048
FBXO6 1p36.22 13 73 0.00052
ASCL3 11p15.4 30 53 0.00056
PGF 14q24.3 17 68 0.00056
ETV2 19q13.12 12 74 0.00056
PAFAH1B1 17p13.3 31 55 0.00068
UBA52 19p13.11 20 63 0.00068
OBP2A 9q34.3 11 74 0.00074
PABPN1 14q11.2 18 67 0.00076
NUPL1 13q12.13 29 55 0.00078
CEBPG 19q13.11 14 72 0.00082
PSMC4 19q13.2 10 75 0.0009
PARK7 1p36.23 15 71 0.00096
98To minimize the confounding effect of lineage, all permutations maintained the initial 
lineage distribution within each class. We also restricted these analyses to the 5,312 
genes for which each class contained at least seven cell lines. We identified 56 
candidate genes with False Discovery Rate (FDR)192 p-values less than 0.25 (Table 7) 
and named them “CYCLOPS” genes (Copy-number alterations Yielding Cancer 
Liabilities Owing to Partial losS).  
Recently, RNAi pooled screens have come under fire for the discordance 
between individual experiments, as well as potential domination of signal from off-target 
effects relating to miRNA313. To assess how much of our CYCLOPS signal could be 
attributed to on-target activity, we looked to see how the correlation between a gene’s 
dependency score and copy number compared to correlations with copy number of 
other genes. We found significantly more genes with positive correlation between copy 
number and dependency score than when we performed the same test with scrambled 
gene labels (Pearson’s correlation, 71 observed genes with FDR p<0.25, scrambled set 
mean = 1.42, sd = 1.91, p<0.0001) This suggests the correlation between copy number 
and gene dependency we observe is unlikely to be observed by chance, if, for example, 
our data was driven solely by off-target effects. In addition, we validated the CYCLOPS 
vulnerabilities using an alternative RNAi dataset (shRNA Activity Rank Profile, or 
shARP)312 representing consequences of expressing 78,432 shRNAs targeting 16,056 
genes on the proliferation of 72 breast, ovarian, or pancreatic cancer cell lines. We 
applied the same analysis pipeline, constrained to the “Validation Set” of 47 cell lines for 
which we had copy-number data and the 6,574 genes for which at least seven cell lines 
were in each class (copy-loss and copy-neutral). These genes included 3,282 of the 
99genes that underwent full analysis in the Achilles dataset and 40 of the CYCLOPS 
candidates identified in that analysis. Although the lineage distribution was markedly 
different between the Validation and Achilles datasets (breast and pancreatic cancers 
made up 90% of the cell lines in the Validation set but only 15% in Project Achilles), the 
40 CYCLOPS candidates identified in the Achilles analysis tended also to be highly 
enriched for relative sensitivity after partial loss in the shARP analysis (KS statistic, 
p=2x10
-9).  
    
Features of CYCLOPS genes 
In copy-number analyses collected from 3,131 tumor samples and cancer cell 
lines314, each CYCLOPS candidate was found to undergo hemizygous loss in an 
average of 18.5% of samples (range 8%-33%), which was as common as for the other 
5,256 genes in the analysis (average 17.7%, range 4%-34%; two tail p=0.17). In 
contrast, CYCLOPS genes exhibited much lower rates of homozygous deletion (p=0.02) 
and DNA methylation (p=0.0045) (Fig. 12a). This observation suggested that CYCLOPS 
genes are enriched for genes required for cell proliferation or survival. Indeed, we used 
the set of genes found to be essential in S. cerevisiae
315 to identify 1,336 homologous 
human genes and found that CYCLOPS genes are not only highly enriched (p<0.0001) 
in this group of essential genes but show comparable rates of genetic and epigenetic 
alterations (Table 8).  
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Figure 12- Characteristics of CYCLOPS genes: 
(a) Frequency of hemizygous deletion, homozygous 
deletion, or DNA methylation of CYCLOPS and other 
genes. Data are presented as averages ± S.E.M. (b) 
Strength of correlation between copy number and 
mRNA expression level across genes profiled in the 
CCLE and TCGA ovarian cancer datasets. Results 
represent Pearson correlation coefficients between 
log2 copy number levels and quantile normalized 
mRNA levels for 16,767 genes across 806 cell lines 
in the CCLE (Barretina et al., 2012) and 11,119 
genes across 429 ovarian tumors from the TCGA 
(Bell et al., 2011). (c) Strength correlation between 
copy number and expression in genes categorized 
by their expression across multiple tissues. Genes 
were separated into two categories based on 
expression patterns in 6 immortalized cell lines, as 
determined by RNA-seq. Genes with RPKM vales 
were greater than 0.1 for all samples were 
considered “ubiquitously expressed” (blue) versus all 
other genes assayed were (red).   
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Table 8 - rates of loss in essential genes   
Copy Number and Methylation Frequencies for Essential Genes 
Essential Genes Analyzed (n=1277)   
Control set (n=20,597)     
  Essential  Control 
Homozygous Deletion 
Frequency 
0.0077% +/- 
.00168%  0.015798% +/- 0.00122% 
Partial Genomic Loss 
Frequency  15.63% +/- 0.19%  15.74% +/- 0.04765% 
    
     
Essential Genes Analyzed (n=963)   
Control set (n=18800)     
Hypermethylation  5.59% +/- 0.64%  11.96% +/- 0.2% 
 
A pathway enrichment analysis of CYCLOPS candidates showed the 
spliceosome, proteasome, and ribosome were the most highly enriched pathways (KS 
statistic FDR p = 1.4x10
-8, 2.7x10
-5, and 1.8x10
-4 respectively, Table 9, Methods). 
These pathways were 
also the most 
significantly enriched 
in our analysis of the 
Validation set (spliceosome FDR=3.1x10
-15; proteasome FDR=1.5x10
-12; ribosome 
FDR=2.3x10
-17). Taken together, these observations indicate that CYCLOPS genes are 
a unique subset of cell essential genes for which partial but not complete suppression is 
compatible with cancer cell viability. 
These observations lead us to hypothesize that copy-number loss might unveil 
vulnerabilities in CYCLOPS genes through decreased gene expression. We therefore 
evaluated the relation between copy-number loss and expression using integrated SNP 
Table 9 - KEGG pathway enrichment among CYCLOPS 
candidates 
KEGG pathway  FDR value  # of CYCLOPS genes 
Spliceosome 1.40E-08  9 
Proteasome  2.70E-05  3 
Ribosome 1.80E-04  4 
102and expression data for 16,767 and 11,118 genes respectively in two panels of 
samples: the Cancer Cell Line Encyclopedia (CCLE) of 805 cell lines across 24 cancer 
types
316, and 429 ovarian cancers profiled by The Cancer Genome Atlas Project
317. In 
consonance with prior reports from other datasets
318, the correlation between copy-
number and expression revealed that genes fall into one of two classes: a class in 
which mRNA levels are relatively independent of copy-number (CCLE: modal r = 0.05; 
TCGA: modal r = 0.07), and a second class in which copy-number and gene expression 
are more closely correlated (CCLE: modal r = 0.49; TCGA: modal r = 0.61; Fig. 12b). 
We found that CYCLOPS candidates were enriched in the latter class (CCLE p = 
0.0004; TCGA p = 0.04), and indeed the average strength of correlation between copy 
loss and mRNA expression was significantly higher for CYCLOPS candidates than for 
the other genes in our analysis (CCLE r = 0.39 vs 0.26, p
 < 0.0001; TCGA, r = 0.44 vs 
0.34, p = 0.0017). Notably, amongst all 158 KEGG pathways, the three pathways most 
enriched in CYCLOPS candidates also have significant correlations between copy-
number and expression: spliceosome (CCLE r = 0.46, FDR=2.2x10
-5; TCGA r = 0.56, 
FDR = 3.9 x 10
-5), proteasome (CCLE r= 0.52, FDR= 2.2x10
-5; TCGA r= 0.60, FDR= 3.9 
x 10
-5) and ribosome (CCLE r=0.44, FDR=2.2x10
-5; TCGA r=0.47, FDR=1.1x10
-4).  
This bimodal distribution of associations between copy-number and expression 
appears to reflect two classes of genes: those that are ubiquitously expressed, and 
those that are selectively expressed.  We used RNA-seq data from 7 cell lines across 
multiple lineages (GM12878 Lymphoblasts, K562 AML,H1HESC human embryonic 
stem cells, HSMM_human skeletal muscle, HUVEC human vascular epithelium, HMEC 
breast normal, HCC1954 breast cancer) and classified genes as either being 
103ubiquitously expressed (RPKM >0.1 for all cell lines) our selectively expressed (RPKM 
for at least one cell line). We favored RNA sequencing over array based expression 
platforms because the former are more reliable for comparisons across genes
319. The 
ubiquitous vs. selective expression classification is strongly associated with the bimodal 
distribution we observe in correlation between copy number and expression in the 
CCLE (t-test p=0; Fig. 12c).  These observations indicate that mRNA expression of 
essential and ubiquitously expressed genes, and CYCLOPS genes in particular, is 
reduced as a result of copy loss. 
 
Discussion 
Discovery of new vulnerabilities due to genomic disruption in cancer 
Advances in cancer therapeutics benefit from our ability to identify vulnerabilities 
predicted by genomic features that are unique to cancer cells. Indeed, the inhibition of 
recurrent activating mutations in proto-oncogenes has led to several new cancer 
treatments. The cancer-specific vulnerabilities we have identified herein are the 
consequence of alterations in genes affected by genomic disruption that may have no 
consequences to the process by which the cell transformed or continues to proliferate. 
These genomic alterations are more frequent than most known driver alterations, occur 
across lineages, and could theoretically be targeted in a large number of patients. 
CYCLOPS genes as synthetic lethal targets 
CYCLOPS genes represent a specific form of synthetic lethality. Several studies 
have investigated synthetic lethality with activation of pathways that drive cancer but 
that cannot themselves be easily targeted. For example, synthetic lethality is one 
approach to targeting inactivated tumor suppressor genes, whose functions cannot 
104easily be reconstituted. This approach has had success in breast and ovarian cancers 
that have BRCA1 or BRCA2 loss, and as a result lack the homologous recombination 
DNA repair pathway, making them exclusively depend on the nucleotide excision DNA 
repair pathway (Bryant, 2005; Farmer, 2005). Targeting CYCLOPS genes represents a 
different approach to synthetic lethality, in which the intervention is synthetic lethal with 
a genetic event independent of the effects that event has on the pathways that drive 
cancer. 
Cancer heterogeneity, evolution, and passenger alterations. 
One concern raised with targeting passenger alterations is the emergence of 
resistant clones and their implications on long-term therapeutic efficacy. Unlike driver 
alterations, cancers are not dependent on the specific alteration for tumor maintenance, 
but instead are vulnerable based on their specific evolutionary trajectory. One may 
imagine that overcoming this vulnerability would be easier than finding new ways to 
replicate the function of targeted driver alterations. While this assumption is reasonable, 
it is still worthwhile to pursue expansion of therapies to non-driver targets. 
 
   
105Chapter 5: The proteasome and PSMC2 as a Cyclops target 
Section goals 
Having isolated a set of potential cancer vulnerabilities predicted by partial loss in 
a panel of cancer cell lines, the goal of this section was to determine the mechanism of 
vulnerability for one of these candidates.  We chose PSMC2 for two reasons. First, it 
was the highest-ranked CYCLOPS candidate in our original analysis, and was also 
significant in the validation RNAi screen320.  Second, it is a member of the proteasome, 
whose components were more generally enriched among CYCLOPS genes, and which 
already serves as a therapeutic target in cancer.  
The proteasome is the primary complex responsible for protein degradation. 
Proteins are constantly being produced and degraded in living cells321, and much of the 
early work on protein degradation elucidated energy independent enzymes such as 
trypsin and other proteases. However, experiments using labeled amino acids in the 
1950s discovered that the majority of amino acids released from organ-derived samples 
was inhibited under anaerobic conditions and cyanide addition, suggesting that this was 
an energy dependent process322. While it was understood that protein turnover is a 
constant process, Goldberg discovered that puromycin-induced early termination of 
polypeptides led to their being more rapidly degradation323, suggesting that protein 
folding can affect in vivo stability324.  The proteasome was the primary organelle 
involved in this process, and was found to be an ATP-dependent protease325 
responsible for both mis-folded protein degradation326 and regulation of active protein 
levels through programmed degradation. This is directed by covalently linking targeted 
106proteins with a small, repeat peptide named ubiquitin, a process whose elucidation was 
awarded the Nobel prize327,328.    
The term “proteasome” applies to a set of similar, large (over 2.5 megadaltons) 
complexes all involved in protein degradation. The 28 proteins in common to all 
proteasome assemblies are collectively referred to as the 20S proteasome, to which 
multiple independent regulatory complexes may be attached, each imparting different 
functionality329. Production of this large and intricate machine takes place in a highly 
coordinated and reproducible procedure, with the construction and attachment of each 
subcomplex occurring in a precise order330‐333. Additionally, because individual proteins 
non-functional in isolation, and are required in specific stoichiometric amounts during 
complex formation, most of the subunits are under tight transcriptional control through a 
negative feedback loop involving a single transcription factor334‐337. While this 
coordination is presumably efficient in regulating levels of proteasome in response to 
cellular requirement, it may make it more challenging for the cell to respond to 
deficiency in a single subunit of the complex, such as that generated by genetic loss in 
cancer. 
The 19S proteasome is the most abundant subassembly to co-complex with the 
20S proteasome, forming the 26S proteasome, which is the fundamental complex 
responsible for ubiquitin mediated protein degradation
338.  PSMC2 is a ATPase subunit 
of the 19S complex that catalyzes the unfolding and translocation of substrates into the 
20S proteasome330.   
Direct inhibition of the proteasome is a vulnerability in multiple myeloma due to 
the specific cellular requirements of these cells. Multiple myeloma is a malignancy 
107derived from plasma cells and their aberrant production of a large amount of 
immunoglobulin may lead to heavy reliance on the unfolded protein response (UPR) 
system339‐341.  Even though proteasome function is necessary for eukaryotic cellular 
survival, proteasome inhibitors, which block the UPR pathway and lead to apoptosis, 
were found to be well-tolerated in clinical trials342 and bortezomib is now considered a 
first-line therapy for multiple myeloma343. The clinical success of bortezomib, which 
targets an essential cellular component, opens the doors for other therapies that look for 
a therapeutic window between cancer and normal cells, even in pan-essential 
pathways.  
Methods 
Cell Culture 
Cancer cell lines were obtained from the Cancer Cell Line Encyclopedia. The 
generation of immortalized ovarian surface epithelial cells was previously described344. 
TYKNU and HEYA8 were cultured in DMEM supplemented with 10% Fetal bovine 
serum and 2mM L-Glutamine and all the remaining cell lines were cultured in RPMI 
1640 supplemented with 10% Fetal bovine serum.  
Lentiviral production  
Lentiviruses were produced for expression constructs or shRNA constructs in 
293T cells cultured in DMEM with 10% FBS supplemented with 4 mM L-Glutamine 
using the three-vector system as described
344. The virus was diluted (1:10) and added 
to 2 x 10
5 cells in a 6 well plate containing 8 µg/ml of polybrene (Sigma). Plates were 
centrifuged for 15 min, 1126 X g at room temperature. For selection of virally infected 
cells 24 h post infection 2 µg/ml of Puromycin (LKO.1) or 10 µg/ml of Blasticidin 
108(LEX303) was added.  Where applicable, lysate was collected and protein levels were 
analyzed 5 d after infection.    
Competition Assays using shRNA constructs 
We found that a single lentiviral integrant expressing either shRNA-1 or shRNA-3 
was sufficient to suppress PSMC2 levels in PSMC2
Neutral cells relative to cells that 
express shLacZ (Fig. 13c); competition assays were therefore performed at a 
multiplicity of infection of 1. To perform competition assays, PSMC2 shRNA-3, PSMC2 
shRNA-4, and PSMC2 shLacZ in pLKO.1 were modified by inserting GFP into the 
puromycin cassette (BamHI/Kpn1) to yield pLKO GFP constructs that expressed these 
shRNAs. Cells were infected with lentivirus that contained the indicated shRNA in 
pLKO.1 GFP and treated for 24 h with three fold dilutions of virus according to protocols 
for lentiviral infection. At 48 h, the cells were analyzed using a BD LSR II flow cytometry 
system (BD Biosciences) for GFP+ cells. The well in which the viral titer resulted in 
approximately 50% of GFP+ cells was then cultured for 21 d. Using FACS, we analyzed 
these cell populations for GFP+ cells on days 7, 14, and 21 and recorded the 
percentage of GFP+ cells normalized to the day 0 time point. 
PSMC2 shRNA inducible system 
The following sense-antisense oligonucleotides (IDT) were annealed and then 
cloned into Tet-pLKO-neo (Addgene #21916) (AgeI/EcoRI).  
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Plasmid sequences were confirmed by sequencing. Lentivirus generated using 
these constructs was used to infect either OVCAR8 or A2780 cells. Stably infected cells 
were selected with Geneticin (500 ug/ml) (Sigma). Cells were treated with 100 ng/ml of 
doxycycline unless otherwise indicated (Sigma).  Beginning 4 d after the addition of 
doxycycline, OVCAR8 cells begin to die.  Therefore, to assess the level of PSMC2 
suppression in OVCAR8 cells, we collected cells 3 d after the addition of doxycycline.  
Since the proliferation and viability of A2780 cells, in contrast, are not affected by the 
addition of doxycycline, we collected cells 4 d after the addition of doxycycline at which 
point PSMC2 levels had achieved a new steady state.  All proliferation or viability 
studies on both cell lines were conducted 7 d after the addition of doxycycline.  Lysates 
from cells using this system were made in Buffer A for all immunoblots except for 
Ubiquitin immunoblots, which were made in Buffer B.  
Ectopic V5-PSMC2 expression 
PSMC2 was engineered with a V5 sequence at the N terminus and cloned into 
pLEX303. To minimize a second translation initiation site that used the endogenous 
ATG, we amplified PSMC2 using a 5’ primer that contained a sequence that would code 
for the V5 epitope and also mutated the endogenous methionine to a threonine. The 
sequence of the exogenous construct added the following amino acids to the N-
shRNA Sense  Antisense 
PSMC2 
shRNA-2 
5’CCGGGCCAGGGAGATTGGATAGAAACTC
GAGTTTCTATCCAATCTCCCTGGCTTTTTG 
5’AATTCAAAAAGCCAGGGAGATTGGATAGAAA
CTCGAGTTTCTATCCAATCTCCCTGGC 
PSMC2 
shRNA-3 
5’CCGGGCCTGCCTTATCTTCTTTGATCTCG
AGATCAAAGAAGATAAGGCAGGCTTTTTG 
5’AATTCAAAAAGCCTGCCTTATCTTCTTTGATCT
CGAGATCAAAGAAGATAAGGCAGGC 
PSMC2 
shLacZ 
5’CCGGTGTTCGCATTATCCGAACCATCTC
GAGATGGTTCGGATAATGCGAACATTTTTG 
5’AATTCAAAAATGTTCGCATTATCCGAACCATC
TCGAGATGGTTCGGATAATGCGAACA 
110terminus (MGKPIPNPLLGLDST) where the final T (Threonine) is in place of the 
endogenous methionine. No modifications were made to the C-terminus. OVCAR8 or 
IOSE cells were serially infected with lentivirus containing either pLEX303 GFP 
(obtained from the TRC) or pLEX303 V5-PSMC2.  Repeat infections were performed 
with respective constructs until the expression of ectopic V5-PSMC2 (as measured by 
western blot) was comparable to the endogenous protein. OVCAR8 cells that expressed 
either V5-PSMC2 or GFP were infected with lentivirus that express PSMC2 shRNA-1 or 
PSMC2 shLacZ in pLKO.1. 5 d after infection, the cells were analyzed by immunoblot 
and 7 d after infection, in triplicate the cells were analyzed for total ATP content 
(Promega). Relative ATP content was normalized to the cells infected with shLacZ.   
Finally, cell lines used for orthotopic xenograft tumors were engineered to express firefly 
luciferase. Lentivirus made from vectors containing the luciferase gene (LEX301) and 
obtained from the TRC was used to infect the indicated cell lines.    
Cellular Protein Lysate 
All cells were first harvested and pelleted in cold PBS. All subsequent procedures 
were performed at 4°C.  For lysate generated in “Buffer A”, the cell pellet was 
resuspended in 10% Glycerol, 25mM Hepes pH 7.4, 10mM MgCl2, 1mM ATP, 1mM 
DTT, and phosphatase and protease inhibitors without EDTA (Roche). Sonication was 
performed at low intensity using a micro-tip on ice for 1 min (50% cycle). The resulting 
cell mixture was centrifuged at 13000 X g for 15 min at 4°C. The supernatant was 
collected and centrifuged at 100,000 X g for 60 min. The subsequent supernatant was 
collected and used in future studies as lysate. Protein amount was normalized using the 
Bradford reagent (Bio-Rad). For lysate generated in “Buffer B”, the cell pellet was 
111resuspended in 20 mM Tris-HCL pH 7.5, 150mM NaCl, 10% Glycerol, 1% Triton-X, 0.2 
mM DTT, 250 ug/ml NEM supplemented with protease inhibitors (Roche) and 
Phosphatase Inhibitors (PhosStop -Roche).  Samples were incubated for 15 min and 
supernatants were collected after centrifugation at 15,000 X g. Finally, for lysate 
generated in “RIPA”, the cell pellet was resuspended in 1X RIPA buffer (Boston 
Bioproducts) that was supplemented with protease inhibitors with EDTA (Roche) for 15 
min.  The supernatant was collected after centrifugation at 15,000 X g for 15 min. 
Protein lysates made in RIPA or Buffer B were normalized with THERMO BCA 
normalization kit (Bio-Rad), using a BSA standard curve.   Lysate analysis of 26S 
proteasome components across ovarian cancer cell lines and PSMC2 levels following 
shRNA expression were generated in RIPA buffer.  For all experiments that involved 
native analysis of the proteasome, lysate was made in Buffer A and then analyzed 
either in non-denaturing or denaturating (SDS loading buffer) conditions.  
Purification of Complex
PSMC2 and the 26S proteasome 
Continuous glycerol gradients (from 10%-40%) were made in 25mM Hepes pH 
7.4, 10mM MgCl2, 1mM ATP, 1mM DTT. 18 mg of lysate (Buffer A) was loaded at the 
top of a 14 ml gradient and centrifuged for 20 hours at 195,000 x g. Fractions were 
removed from top of each gradient in 1 ml increments. Native PAGE described above 
was used to determine which fractions contained Band A or 26S proteasome and the 
indicated pooled fractions were then pooled and incubated with Anti-V5 agarose 
conjugates. Immunoprecipitates were eluted and analyzed by immunoblot.  
26S proteasome activity  
112In vitro, we measured excitation-emission spectra (360 nm to 430 nm) during 
incubation at 37°C every 30 sec for 1 h for a 100 μl solution containing 5 μl of lysate 
(Buffer A) in 50mM Tris-HCl pH 8.0, 40mM KCl, 5mM MgCl2, 1mM ATP, 1mM DTT, and 
100μM Sucrose-LLVY-AMC (Bachem). We converted these measurements to amount 
of peptide cleavage using a standard curve generated from the excitation-emission 
spectra of AMC (Bachem). Samples were tested in triplicate with and without the 
addition of 1 μM bortezomib. The average value of peptide cleavage in the bortezomib 
sample was subtracted to determine 26S proteasome activity. 
Native gel analysis for proteasome content or proteasome activity 
10 μg of lysate (Buffer A) was loaded onto 3-8% Tris-Acetate PAGE (Invitrogen) 
and run in Tris-Glycine at 4°C and 60V for 17 h. Gels were transferred to nitrocellulose 
membranes in Tris-Glycine at 70V for 4 h for immunoblotting or in gel peptidase activity. 
The latter was performed by incubating with gentle agitation in 50mM Tris-HCl pH 8.0, 
5mM MgCl2, 1mM ATP, 1mM DTT, and 50μM Suc-LLVY-AMC (Bachem) at 37°C for 30 
min. Gels were visualized under UV transillumination. Following photography of 26S 
proteasome activity, gels were incubated for another 45 minutes at 37°C in the same 
buffer with the addition of 0.2% SDS and re-analyzed by UV transillumination to assess 
20S peptidase activity. 
Immunoprecipitation of Complex
PSMC1/PSMC2 and the 26S proteasome 
Immunoprecipitation was performed by incubating fractions with 50 μl of Anti-V5 
agarose conjugated beads (Sigma) and rotating for 16 h at 4°C. Each wash step began 
with centrifugation at 1000 X g for 3 min, removal of the supernatant, and resuspension 
in 1 ml of buffer A. Three washes were completed and the samples were then incubated 
113in 100 μl of 20 μM V5 peptide (Sigma) in buffer A. Equal volumes were then denatured 
in SDS loading buffer and analyzed by immunoblot.  
PSMC2 mRNA levels determination 
Cells were harvested and pelleted in PBS. RNA was extracted from cell pellets 
and resuspended in Trizol Reagent (Invitrogen) according to manufacturer’s protocol. 
The precipitated total RNA was then resuspended in 0.1 ml of a 1x TurboDNase buffer 
with 2U of DNase (Ambion) and incubated at 37°C for 15 min. RNA was then purified 
using the Qiagen RNEasy kit according to manufacturer’s instructions for “RNA Clean 
Up”. 1 μg of RNA was used to generate cDNA using the M-MLV Reverse Transcriptase 
kit (Invitrogen) according to the recommended protocol. PCR reactions were performed 
in replicates of five using SybR PCR master mix (Applied Biosystems) and Ct values 
were automatically determined using Applied Biosystems 7300 System software. The 
resulting data were normalized to housekeeping genes and analyzed using the delta-
delta Ct method for fold difference between control and test samples. Unless otherwise 
indicated PGK1 was used as an internal control.   Primers used in quantitative RT-PCR 
are as follows:  PGK1 (5’AGAGGGAGCCAAGATTGTCA, 
5’GGTATGCCAGAAGCCACAGT), Tubulin (5’TCTGTTCGCTCAGGTCCTTT, 
5’TGTGTCCTTGCACCCAAATA), and PSMC2 
(5’TCCACCCGGTACAGGCAAGACACT, 5’CGAGCCCCCTCACCGACGTA) 
PSMC2 siRNA experiments in A2780 cells 
5 x 10
5 cells were plated in 10 cm plates on Day 0. Each plate was transfected 
with a total of 500 pmol of siRNA and 20μL lipofectomine RNAi Max (Invitrogen) using 
the manufacturer’s recommended procedure. Three pre-annealed PSMC2 siRNAs were 
114obtained from IDT DNA and pooled in equimolar ratios:  siRNA-1 (5’-
GCUGUAAAUAAGGUCAUUAAGUCTT, 5’-AAGACUUAAUGACCUUAUUUACAGCUU), siRNA-2 (5’-
AGAUAAUCAAUGCUGAUUCGGAGGA, 5’-UCCUCCGAAUCAGCAUUGAUUAUCUUU), siRNA-3 (5’-
CCCACAUAUUUAAGAUUCACGCUCG, 5’-CGAGCGUGAAUCUUAAAUAUGUGGGUC). The 
concentration of the pool was varied and the difference was made up with control siRNA 
(Ambion). 24 hours after transfection, 2.5 x 10
5 viable cells (determined by trypan blue) 
were plated in duplicate for a six-day proliferation assay. The remaining cells were 
plated and harvested for lysate (RIPA) 3 d after transfection.  
PSMC2 siRNA experiments in A2780-Dox cells 
1.5 x 10
6 of A2780-Dox-shLacZ and A2780-Dox-shRNA-2 cells were plated in 10 
cm plates on Day 0, two for each cell line. On Day 1, the media from one plate of each 
cell line was replaced with media containing 100 ng/ml of doxycycline. On day 2, these 
cells were passaged into 96 well plates at 2,500 cells/well, as well as a single 10 cm 
plate (to be used for RNA) for each condition and cell line. On Day 3, these cells were 
transfected with 0.2 mM lipofectomine RNAi Max (Invitrogen) along with siRNA at a total 
concentration of 20 nM, with varying levels of siRNA specific for either PSMC2 or 
PSMC5 using the manufacturer’s recommended procedure. PSMC2 siRNA are listed 
above, with additional PSMC5 siRNAs obtained from IDT DNA predesigned siRNA 
(Catalog # HSC.RNAI.N002803.12.1,  HSC.RNAI.N002803.12.2, 
HSC.RNAI.N002803.12.3) and pooled in equimolar ratios. The concentration of the pool 
was varied and the difference was made up with control siRNA (Ambion). Proliferation 
was measured by cell titer glo, and qRT-PCR data was used to determine 
concentrations where siPSMC2 (2.5 nM) and siPSMC5 (5 nM) led to similar levels of 
suppression of their respective targets. 
115PSMC2 and Control siRNA nanoparticle siRNA sequences 
Gene  Sense Strand  Antisense Strand 
siRNA-1  5’- GCUGUAAAUAAGGUCAUUAUU 5’- UAAUGACCUUAUUUACAGCUU 
siRNA-2  5’- GCCAGGUGUACAAAGAUAAUU 5’- UUAUCUUUGUACACCUGGCUU
siRNA-3  5’- GGACCCACAUAUUUAAGAUUU 5’- AUCUUAAAUAUGUGGGUCCUU
GFP  5’-GGCUACGUCCAGGAGCGCA	 5’-UGCGCUCCUGGACGUAGCC 
Bortezomib sensitivity experiments 
Throughout the experiment, A2780 cells engineered in the PSMC2 shRNA 
inducible system were either treated with vehicle or 30 ng/ml of doxycycline.  
Doxycycline treatment was started on Day 0.  On day 4, cells were plated at 2000 cells/ 
well in a 96 well plate.  The following day, the cells were treated with varying 
concentrations of bortezomib or vehicle.  Total ATP levels were measured by Cell Titer 
Glo (Promega) 72 h after adding bortezomib.  The data was normalized to the vehicle 
treated sample.  Graphpad was used to determine the IC50 by constructing a non-linear 
regression with a four-parameter variable slope.   
Cell Cycle and Apoptosis Assays using the PSMC2 shRNA inducible system 
We cultured either A2780 or OVCAR8 cells engineered with our PSMC2 shRNA 
inducible system in the presence or absence of doxycycline (100 ng/ml) and collected 
them for analysis after 3 d. We used the BrdU Flow Kit (BD Pharmigen) according to 
manufacturer’s protocol to determine the percentage of cells in each phase of the cell 
cycle 72 h after the addition of doxycycline. At the same time point, we independently 
determined the number of cells undergoing apoptosis by FACS analysis of Annexin-5 
according to the manufacturers recommended procedure (Invitrogen).  
Generation of PSMC2 and Control siRNA nanoparticles 
The generation of tumor-penetrating nanocomplexes carrying PSMC2-siRNA 
(Dharmacon) and measurement of their uptake and effects on cellular proliferation was 
116performed as described
345. The p32-receptor specificity of cellular uptake was probed 
by applying a monoclonal antibody directed against p32 (100 ug/mL) to cells 1 h prior to 
the addition of TPN. More information about the reagents, chemicals and siRNA 
sequences can be found in the Extended Experimental Procedures. 
Generation of orthotopic xenografts and nanoparticle administration 
10
6 OVCAR8 cells, 0.510
6 OVCAR8 cells expressing V5-PSMC2, or 0.210
6 
A2780 cells expressing doxycycline-inducible shRNA against PSMC2 were implanted 
intraperitoneally in 4-6-week-old NCr/nude mice (Charles River). Once tumors were 
established and confirmed by bioluminescence imaging, animals were treated 
intraperitoneally with nanoparticles carrying GFP-specific siRNA (TPN/siGFP), or TPN 
containing  PSMC2-specific siRNA (1 mg siRNA/kg/injection) every 3 d for 21 d as 
described
345. Mice bearing A2780 tumors expressing the doxycycline-inducible 
shPSMC2 were continuously fed with doxycycline-containing diet (2000 mg/kg) 
beginning two days after tumor cell injection. Mice were sacrificed and tumors harvested 
at the end of the experiment or when the tumor burden resulted in a failure to thrive 
according to institutional recommendations. Tumor lysates were made by homogenizing 
tumors using an eppendorf micropestle in RIPA buffer supplemented with protease 
inhibitors. We restricted analyses of PSMC2 expression to tumors that were relatively 
devoid of mouse tissue. 
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Results 
To test the possibility that our observations were the result of a confounding 
genetic alteration, we determined whether expression and copy-number levels of every 
other gene for which we had expression or copy-number data significantly correlated 
with PSMC2 sensitivity. Low PSMC2 expression (FDR < 0.017) and PSMC2 copy loss 
(FDR < 0.008) were the features most significantly correlated with PSMC2 sensitivity 
genome-wide. Conversely, among the 7,250 genes in our Achilles analysis, only 
sensitivity to PSMC2 correlated with PSMC2 copy loss (FDR < 0.25). In particular, 
amongst all 47 other proteasome components surveyed, neither expression levels nor 
copy-number status significantly correlated with PSMC2 sensitivity. Suppression of the 
29 proteasome components in the Achilles data also did not specifically inhibit 
proliferation of cell lines with PSMC2 copy loss. The association between PSMC2 copy 
loss and PSMC2 sensitivity also remained significant when cells with PSMC2 copy-
number gains were excluded from the analysis (p=0.0006). 
Since partial copy loss of cell essential genes, like PSMC2, might afford only 
small differences in sensitivity to suppression between different cells, we also compared 
118the effects of PSMC2 suppression to that observed when we suppressed the 
oncogenes KRAS, PIK3CA, and BRAF. These oncogenes are associated with some of 
the most specific known cancer dependencies through “oncogene addiction”346. In 
consonance with prior studies, suppression of these oncogenes inhibited proliferation of 
cells harboring mutated and constitutively active oncogenes compared to cells 
expressing wild type proto-oncogenes (p<2x10
-5 in each case) (Fig. 13a). However, the 
difference in PSMC2 dependency scores between cell lines with and without PSMC2 
copy loss (PSMC2
Loss and PSMC2
Neutral, respectively) was greater than for any of these 
three models of oncogene addiction (Fig. 13a).  
We confirmed the vulnerability of PSMC2
Loss lines to PSMC2 suppression in a 
direct competition assay by comparing the proliferation rate of uninfected cells to cells 
that co-express GFP and either shLacZ or a PSMC2 shRNA in six ovarian cell lines 
over 21 days. The expression of shLacZ or PSMC2 shRNAs failed to induce significant 
changes in the proliferation of PSMC2
Neutral cells, including two ovarian cancers and one 
non-transformed Immortalized Ovarian Surface Epithelial cell (IOSE) cell line344. In 
contrast, expression of PSMC2 shRNAs reduced the proliferation rate by at least 50% in 
all three PSMC2
Loss ovarian cancer cell lines within 7 days (Fig. 13b-d). 
To confirm that these observed effects were due to the suppression of PSMC2, 
we expressed an N-terminal V5-epitope tagged form of PSMC2 (hereafter referred to as 
V5-PSMC2) in OVCAR8, a PSMC2
Loss cell line. V5-PSMC2 expression was unaffected 
by an shRNA that targets the 3’ UTR of endogenous PSMC2, and rescued the 
proliferation of OVCAR8 cells that express this shRNA (Fig. 13d). 
PSMC2 levels and survival in PSMC2
Loss cell lines 
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120Figure 13- PSMC2 as a CYCLOPS gene: (a) Comparison of gene dependence 
between three models of oncogene addiction and PSMC2. Cell lines were classified by 
mutation status for PIK3CA, BRAF, or KRAS (n=102 in each case) or PSMC2 copynumber 
(n=84). For each class, gene dependency scores reflect the sensitivity to the 
gene on which the categorization was based. Solid bars represent average scores. (b) 
The effect of PSMC2 suppression on the proliferation of six ovarian cell lines. (c-d) PSMC2 
suppression in ovarian cell lines. We individually expressed all four PSMC2 shRNAs 
and a control shRNA, shLacZ. Among the four PSMC2 shRNAs, PSMC2 shRNA-2, 3, 
and 4 were used by ATARiS to calculate the PSMC2 dependency score and exhibited 
consistent suppression of PSMC2. (e) PSMC2 levels (top) and relative proliferation rates 
(bottom) among cells expressing different combinations of PSMC2 shRNA targeting the 3’ 
UTR and ectopic V5-PSMC2 expression. Data are presented as averages ± S.D. 
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121The increased vulnerability of PSMC2
Loss lines correlated with both PSMC2 copy 
loss and lower PSMC2 mRNA expression (FDR p-value<0.05 for both). Expression and 
copy-number of PSMC2 are also correlated in both the CCLE (r = 0.64) and TCGA 
Ovarian (r = 0.49) sample sets (Fig. 14a), indicating that cancer cells that have PSMC2 
copy loss tolerate reduced PSMC2 expression. 
To explore the effects of PSMC2 loss on PSMC2 protein levels, we evaluated 
PSMC2 levels in IOSE cells and ten ovarian cancer cell lines, including five 
PSMC2
Neutral and five PSMC2
Loss lines. To minimize potential confounding of other 
genetic events affecting the 19S complex, we selected PSMC2
Neutral lines that had no 
copy-number gains of PSMC2 and PSMC2
Loss lines that had copy loss of no more than 
one other 19S regulatory complex subunit (Table 10). All five PSMC2
Loss cell lines 
expressed lower levels of PSMC2 than any of the other cell lines (Fig. 14b). In contrast, 
the levels of eight 19S subunits including PSMC1 (Rpt2), PSMC4 (Rpt3), PSMC6 
(Rpt4), PSMC3 (Rpt5), PSMC5 (Rpt6), PSMD2 (Rpn1), PSMD1 (Rpn2), PSMD4 
(Rpn10), or the 20S subunits PSMB5 (β5) and PSMA1-6 (α subunits) failed to correlate 
with PSMC2 copy-number (Fig. 14b). Since PSMC2 is essential for cell proliferation, we 
concluded that PSMC2
Neutral cells either require more PSMC2 or produce more than is 
necessary for cell survival. We therefore investigated how PSMC2
Neutral cells can 
tolerate greater suppression of PSMC2. 
Specifically, we expressed a PSMC2-specific shRNA under the control of a 
doxycycline-regulated promoter in OVCAR8 (PSMC2
Loss) and A2780 (PSMC2
Neutral) 
cells. The addition of doxycycline led to the suppression of PMSC2 in both OVCAR8 
and A2780 cells (Fig. 14c). Under these conditions, A2780 cells continue to proliferate 
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123Figure 14- Effects of PSMC2 on expression of proteasome components: (a) Scatterplots of 
PSMC2 copy number versus mRNA expression derived from cell lines in CCLE (Barretina et al., 
2012) and primary ovarian tumors in TCGA. A linear regression line and the Pearson correlation 
coefficient (r) are also displayed. (b) Comparison between PSMC2 copy number and protein 
expression of 10 other 26S proteasome components. (c) Immunoblot for PSMC2 in PSMC2
Loss 
and PSMC2
Neutral lines containing a Dox-inducible promotor for either shLacZ or shPSMC2. Cells 
were harvested 48 hours after addition of Dox, prior to qualitative observation of any phenotype. 
(d). Effects of Doxycycline-induced PSMC2 suppression on proliferation. (e) Relationship 
between PSMC2 mRNA expression and proliferation in PSMC2
Neutral (left) and PSMC2
Loss (right) 
cells. Data represents averages ± S.D.  
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124Table10-ﾭ‐Copy	 ﾠNumber	 ﾠStatus	 ﾠof	 ﾠ19S	 ﾠProteasome	 ﾠComponents	 ﾠAcross	 ﾠCell	 ﾠLines
"1"	 ﾠIndicates	 ﾠHemizygous	 ﾠDeletion;	 ﾠ"0"	 ﾠindicates	 ﾠCopy	 ﾠNeutrality
gene HEYA8 OVCAR8 OVISE RMGI SKOV3 A2780 IGROV1 OV90 TYKNU RKN
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD4 0 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD14 1 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD1 1 1 0 0 0 0 0 0 0 1
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD6 0 0 1 0 0 0 0 1 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD2 0 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC2 1 1 1 1 1 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD5 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD13 1 1 0 0 0 0 0 1 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC3 1 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD9 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC6 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC1 0 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD7 1 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD11 1 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD3 0 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC3IP 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC5 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD12 0 0 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMD8 0 1 0 0 0 0 0 0 0 0
	 ﾠ	 ﾠ	 ﾠ	 ﾠPSMC4 0 1 0 0 0 0 0 0 0 0
125whereas OVCAR8 cells arrest at G2/M and die by apoptosis, characteristic hallmarks of 
pharmacologic inhibition of the proteasome347,348 (Fig. 15). To verify that A2780 cells 
tolerate a higher percentage of PSMC2 suppression, we varied the degree of PSMC2 
mRNA suppression by changing the concentration of doxycycline from 0.01 ng/ml to 30 
ng/ml, and found that a 50% decrease in PSMC2 expression reduced the proliferation of 
OVCAR8 cells but had no effect on A2780 proliferation (Fig. 14d-e). 
To determine the amount of PSMC2 required to maintain A2780 cell proliferation, 
we suppressed PSMC2 expression further by transfecting a pool of three PSMC2 
specific siRNAs at varying concentrations. Using quantitative RT-PCR and 
immunoblotting, we estimated that untreated OVCAR8 cells express approximately 50% 
of the PSMC2 mRNA and protein found in A2780 cells (Fig. 16a) Furthermore, the 
proliferation of A2780 cells decreased only when PSMC2 expression was suppressed 
by more than 60% (Fig 16b) and that both A2780 and OVCAR8 lose proliferative 
capacity at similar total levels of PSMC2 expression (Fig. 16c), suggesting that they 
have a comparable threshold requirement for PSMC2.  
 
PSMC2
Loss cells exhibit only slight alterations in proteasome content and function 
The tolerance of cells for loss of PSMC2 copy-number and expression indicates 
that cells contain a reservoir of excess PSMC2 that is not required for proliferation. This 
reservoir may be maintained in an excess of fully assembled 26S proteasome or 
elsewhere in the cell. We analyzed proteasome assembly and content by performing 
Polyacrylamide Gel Electrophoresis (PAGE) on crude lysates under native (non-
denaturing) conditions. Under these conditions, the 26S proteasome complex is stable 
126Figure 15- Effects of PSMC2 on cell cycle progression and apoptosis:    Flow 
cytometry measurements of cell cycle progression (left) and apoptosis (right) in 
PSMC2
Neutral and PSMC2
Loss cells with and without suppression of PSMC2. No 
differences in cell cycle progression were observed, but PSMC2
Loss cells undergo 
increased Annexin V staining, indicating increased apoptosis, after PSMC2 suppress  . n o i
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Figure 16- Effects of PSMC2 on cell cycle progression and apoptosis: 
(a) Quantification of relative levels of PSMC2 protein.  The immunoblot (left) indicates PSMC2 
levels in OVCAR8 cell lysates relative to a dilution series using A2780 cell lysates. The graph on 
the right indicates fraction of PSMC2 mRNA in OVCAR8 cells when compared to A2780, using 
two different genes to normalize qPCR product.  (b) PSMC2 expression and relative proliferation 
in A2780 cells subjected to increasing levels of siRNA targeting PSMC2. (c) Schematic combining 
26 data from Fig. 14d-e and Fig. 16b indicates that A2780 and OVCAR8 cells share a similar 
absolute threshold requirement for PSMC2 (dashed line). 
128and active and migrates in two distinct bands, distinguished by having either one or two 
19S subunits incorporated in the formation of the 26S349. Using lysates collected from 
IOSE, two PSMC2
Neutral, and three PSMC2
Loss cancer cell lines (all with comparable 
proliferation rates), we detected 26S
1, 26S
2, and 20S proteasome complexes by 
immunoblotting for the core 20S subunits, PSMA1-6 (Fig. 17a). 
We found that PSMC2
Loss lines express only slightly less 26S proteasome (most 
evident in 26S
2), which is not comparable to the decrease in PSMC2 in these cells (Fig. 
17a), and increased 20S proteasome. Similarly, comparable changes in PSMC2 
expression in isogenic systems failed to substantially affect 26S proteasome content. 
Suppression of PSMC2 levels by 50% in the Dox-shRNA-2 A2780 system led to an 
increase in the 20S complex but little to no change in 26S
1 or 26S
2 proteasome content 
relative to controls (Fig. 17b). Conversely, ectopic expression of PSMC2 in OVCAR8 
cells led to a slight reduction in 20S levels and slight increases in 26S
1 and 26S
2 
proteasome content (Fig. 17b). The levels of other 19S proteasome units remained 
unchanged (Fig. 17c). 
Similarly, peptidase cleavage activity varied only slightly between PSMC2
Neutral 
and PSMC2
Loss lines. We observed the greatest differences in in-gel analyses of 
peptidase activity, which revealed less 26S
2 proteasome peptidase cleavage and 
increased 20S peptidase activity in PSMC2
Loss cells (Fig. 18a). These changes were 
recapitulated by PSMC2 suppression in A2780 cells and reversed by ectopic PSMC2 
expression in OVCAR8 cells (Fig 18b). The decrease in 26S
2 activity in PSMC2
Loss 
relative to PSMC2
Neutral cells, however, was not associated with significant differences in 
peptidase cleavage when quantitatively assayed in whole cell lysates under conditions 
129I
O
S
E
A
2
7
8
0
T
Y
K
N
U
S
K
O
V
3
O
V
C
A
R
8
R
M
G
I
Native
PAGE
20S-
20S
26S
PSMC2Neutral PSMC2Loss
PSMC2
-actin
PSMC2
Actin
Native
PAGE
20S-α
20S
26S
26S
OVCAR8
G
F
P
V
5
-
P
S
M
C
2
Dox
A2780
s
h
L
a
c
Z
s
h
L
a
c
Z
s
h
R
N
A
-
2
s
h
R
N
A
-
2
– – + +
b
Native
PAGE
20S-α
20S
26S1
26S2
OVCAR8
G
F
P
V
5
-
P
S
M
C
2
Dox
A2780
s
h
L
a
c
Z
s
h
L
a
c
Z
s
h
R
N
A
-
2
s
h
R
N
A
-
2
– – + +
a
Low exposure
High exposure
c
GFP
V5
PSMC2
Exogenous gene
PSMC1
PSMC3
PSMC5
Figure 17: PSMC2
Loss cells lack a 
PSMC2 reservoir. (a) Total PSMC2 levels 
(top) and Native PAGE immunoblot for 
PSMA1-6 (middle) in PSMC2
Neutral and 
PSMC2
Loss cells. (b) Native PAGE 
immunoblot for PSMA1-6 in A2780 (left) 
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130I
O
S
E
A
2
7
8
0
T
Y
K
N
U
S
K
O
V
3
O
V
C
A
R
8
R
M
G
I
PSMC2Neutral PSMC2Loss
20S
26S
26S
S
u
c
–
A
M
C
–
L
L
V
Y
c
l
e
a
v
a
g
e
S
u
c
–
A
M
C
–
L
L
V
Y
c
l
e
a
v
a
g
e
20S
26S1
26S2
OVCAR8
G
F
P
V
5
-
P
S
M
C
2
Dox
A2780
s
h
L
a
c
Z
s
h
L
a
c
Z
s
h
R
N
A
-
2
s
h
R
N
A
-
2
– – + +
a
In vitro 26S peptidase activity
S
u
c
–
A
M
C
–
L
L
V
Y
c
l
e
a
v
a
g
e
 
(
f
m
o
l
/
s
e
c
/
µ
g
)
0
20
40
PSMC2Neutral PSMC2Loss
c
e
0
1.0
1.5
0.5
S
u
c
–
A
M
C
–
L
L
V
Y
c
l
e
a
v
a
g
e
 
(
D
o
x
+
/
D
o
x
–
)
S
u
c
–
A
M
C
–
L
L
V
Y
c
l
e
a
v
a
g
e
 
(
f
m
o
l
/
s
e
c
/
µ
g
)
0
20
10
OVCAR8 A2780
G
F
P
V
5
-
P
S
M
C
2
s
h
L
a
c
Z
s
h
R
N
A
-
2
Anti-P4D1
(poly-ubiquitin)
GAPDH
I
O
S
E
A
2
7
8
0
T
Y
K
N
U
O
V
I
S
E
S
K
O
V
3
H
E
Y
A
8
PSMC2Neutral PSMC2Loss
I
G
R
O
V
O
V
C
A
R
8
R
K
N
C
O
V
4
3
4
R
M
G
I
d
f OVCAR8
G
F
P
P
S
M
C
2
Dox
A2780
s
h
L
a
c
Z
s
h
L
a
c
Z
s
h
R
N
A
-
2
s
h
R
N
A
-
2
+ + – –
Ubiquitin
(P4D1)
– –
Exogenous
gene
     .  
131
b
 
Figure 18: PSMC2
Loss cells lack a PSMC2 reservoir .  Native PAGE 26S and 20S peptidase 
cleavage in PSMC2
Neutral and PSMC2
Loss cells (corresponding to 17a). Native PAGE 26S and 20S 
peptidase cleavage in isogenic systems (17b). (c) In vitro 26S proteasome activities in 
PSMC2
Neutral and PSMC2
Loss cells. Each point represents a cell line; dashed lines represent 
averages. We found no significant difference between the activity in these two populations. (d) 
Poly-ubiquitinated protein levels in PSMC2
Neutral and PSMC2
Loss cells. (e) In vitro 26S proteasome 
activities and (f) Poly-ubiquitinated protein levels for the isogenic systems used in (b).  (in the absence of SDS) in which free 20S proteasome does not contribute activity350 
(p=0.39) (Fig. 18c). In this assay, proteasome-specific peptidase activity is determined 
by bortezomib-inhibited cleavage. We found that 97% of activity was ablated by 
bortezomib, suggesting that other proteases did not contribute substantially to the 
measured activity. Lysates from PSMC2
Neutral and PSMC2
Loss lines grown under 
conventional non-stressed conditions also exhibited qualitatively similar total levels of 
poly-ubiquitin (Fig. 18d). 
To test the acute effect of manipulating PSMC2 expression on peptidase activity, 
we measured peptidase activity in lysates of A2780 cells in which we suppressed 
PSMC2 and of OVCAR8 cells engineered to recover PSMC2 expression. Suppression 
of PSMC2 by 50% in A2780 cells led to a 17% reduction in total 26S specific peptidase 
activity, associated with reduced 26S
2 activity (Fig. 18e), neither of which corresponded 
to changes in total levels of poly ubiquitin (Fig. 18f). Conversely, ectopic PSMC2 
expression in OVCAR8 led to a 15% increase in peptidase activity, associated with 
increased 26S
2 activity. The finding in both systems that modulating PSMC2 levels by 
up to 50% resulted in only a 17% alteration in 26S activity suggested that PSMC2 
content was not the limiting component to 26S formation in PSMC2
Neutral cells. 
We found no increased sensitivity to bortezomib in PSMC2
Loss cells and no 
significant correlation between the concentration of bortezomib that inhibits proliferation 
by 50% (IC50) and decreased expression of any of the 47 26S proteasome components, 
across 133 cell lines previously tested351 (Table 11). Suppression of PSMC2 in Dox-
shRNA-2 A2780 cells or ectopic PSMC2 expression in OVCAR8 cells also did not 
substantially affect the bortezomib IC50 (Fig. 19a-b). These observations are consistent 
132Table	 ﾠ11-ﾭ‐Analysis	 ﾠto	 ﾠcorrelate	 ﾠBortezomib	 ﾠIC50	 ﾠwith	 ﾠexpression	 ﾠof	 ﾠproteasome	 ﾠcomponents
Left	 ﾠtail	 ﾠ=	 ﾠgenes	 ﾠwhere	 ﾠhigh	 ﾠexpression	 ﾠcorrelates	 ﾠwith	 ﾠlow	 ﾠbortezomib	 ﾠIC50;	 ﾠ
Right	 ﾠtail	 ﾠ=	 ﾠgenes	 ﾠwhere	 ﾠlow	 ﾠexpression	 ﾠcorrelates	 ﾠwith	 ﾠlow	 ﾠbortezomib	 ﾠ	 ﾠIC50
Proteasome	 ﾠComponent R	 ﾠsided	 ﾠp	 ﾠvalue Left	 ﾠsided	 ﾠp	 ﾠvalue Right	 ﾠsided	 ﾠFDR Left	 ﾠsided	 ﾠFDR
PSMG4 0.9983 0.0017 0.9983 0.0799
PSMD5 0.9788 0.0212 0.9983 0.488
PSMC2 0.9595 0.0405 0.9983 0.488
PSMB2 0.9521 0.0479 0.9983 0.488
PSMD2 0.9481 0.0519 0.9983 0.488
PSMB7 0.9371 0.0629 0.9983 0.488
PSMD12 0.9243 0.0757 0.9983 0.488
PSMD14 0.9042 0.0958 0.9983 0.488
PSMG1 0.904 0.096 0.9983 0.488
PSMD1 0.8962 0.1038 0.9983 0.488
PSME2 0.8712 0.1288 0.9983 0.5497
PSMA7 0.8248 0.1752 0.9983 0.5497
PSMC4 0.8241 0.1759 0.9983 0.5497
PSMB6 0.8225 0.1775 0.9983 0.5497
PSMB8 0.8134 0.1866 0.9983 0.5497
PSMD6 0.8129 0.1871 0.9983 0.5497
PSMA2 0.7981 0.2019 0.9983 0.5581
PSMD10 0.7537 0.2463 0.9983 0.634
PSMB9 0.7437 0.2563 0.9983 0.634
PSMC5 0.7105 0.2895 0.9983 0.6636
PSMB5 0.6971 0.3029 0.9983 0.6636
PSMA3 0.6719 0.3281 0.9983 0.6636
PSMA5 0.6567 0.3433 0.9983 0.6636
PSME1 0.6414 0.3586 0.9983 0.6636
PSMG2 0.6158 0.3842 0.9983 0.6636
PSMD11 0.6133 0.3867 0.9983 0.6636
PSME3 0.6115 0.3885 0.9983 0.6636
PSMC6 0.6022 0.3978 0.9983 0.6636
PSMB3 0.5803 0.4197 0.9983 0.6636
PSMG3 0.5671 0.4329 0.9983 0.6636
PSMA1 0.5496 0.4504 0.9983 0.6636
PSMC3IP 0.5482 0.4518 0.9983 0.6636
PSMD9 0.5338 0.4662 0.9983 0.6639
PSMA8 0.5054 0.4946 0.9983 0.6838
PSMB1 0.4777 0.5223 0.9983 0.7014
PSMB10 0.4346 0.5654 0.9983 0.7303
PSMA4 0.4171 0.5829 0.9983 0.7303
PSMD7 0.3949 0.6051 0.9983 0.7303
PSMD8 0.394 0.606 0.9983 0.7303
PSMB4 0.297 0.703 0.9983 0.826
PSMD3 0.2699 0.7301 0.9983 0.837
PSMD13 0.1462 0.8538 0.9983 0.9526
PSMD4 0.1232 0.8768 0.9983 0.9526
PSMF1 0.1082 0.8918 0.9983 0.9526
PSME4 0.0686 0.9314 0.9983 0.9646
PSMC3 0.0451 0.9549 0.9983 0.9646
PSMA6 0.0354 0.9646 0.9983 0.9646
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Figure 19- PSMC2
Loss cells and sensitivity to bortezomib: (a-b) Dose response curve 
for bortezomib in (a) A2780 cells with and without PSMC2 suppression and (b) OVCAR8 
with and without ectopic V5-PSMC2 expression. 
134with our prior observation that 26S proteasome function is not substantially 
compromised in PSMC2
Loss cells. 
  
PSMC2
Neutral cells have a reservoir of PSMC2 that buffers 26S proteasome levels 
against PSMC2 loss 
The finding that PSMC2
Neutral cells have near equal 26S proteasome content to 
PSMC2
Loss cells even though they express higher levels of PSMC2 suggests that 
PSMC2
Neutral cells contain a separate reservoir of PSMC2 that is preferentially lost when 
levels are reduced. To identify this reservoir, we combined native PAGE with 
immunoblotting for PSMC2 across a panel of cell lines (Fig. 20a). Of the multiple 
reactive bands identified, even after a long exposure, only one band (“Complex
PSMC2”) 
was present in all of the PSMC2
Neutral but none of the PSMC2
Loss lines. Using isogenic 
systems, we also found that PSMC2 suppression in Dox-shRNA-2 A2780 cells led to 
reduced levels of Complex
PSMC2, whereas ectopic PSMC2 expression in OVCAR8 cells 
led to its reappearance (Fig. 20b). These results suggest that Complex
PSMC2 is a 
specific PSMC2 reservoir. 
  We hypothesized that Complex
PSMC2 serves as a “buffer” in PSMC2
Neutral cells, 
enabling such cells to maintain 26S proteasome levels and function in the face of 
reduced PSMC2 expression. In this case, PSMC2 suppression should deplete 
Complex
PSMC2 before reducing 26S proteasome levels. To quantify the consequences of 
reducing PSMC2 on Complex
PSMC2 and 26S proteasome levels, we compared dilutions 
of lysates from Dox shRNA-2 A2780 cells propagated in the absence of doxycycline to 
lysate collected from these cells cultured in doxycycline (Fig. 20c). In cells in which 
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136Figure 20. Complex
PSMC2 buffers PSMC2
Neutral cells against PSMC2 suppression: (a) Native 
PAGE immunoblot for PSMC2 across a panel of PSMC2
Neutral and PSMC2
Loss cells. (b) Native 
PAGE immunoblot for PSMC2 in A2780 after inducible expression (left), and in OVCAR8 cells 
after inducible suppression or ectopic expression, of PSMC2. (c) Quantification of 26S 
proteasome and Complex
PSMC2 levels after PSMC2 suppression in Dox-shRNA-2 A2780 cells by 
Native PAGE (top) and total PSMC2 levels (bottom). (d-f) OVCAR8 cells with and without PSMC2 
suppression analyzed by Native PAGE immunoblots for (d) PSMA1-6 and (e) peptidase cleavage 
measured either in whole-cell and native gel formats (see Fig. 18a-c), and (f) total poly-ubiquitin 
levels 
137PSMC2 was suppressed, the relative loss of Complex
PSMC2 exceeded the decrease in 
26S proteasome content. These observations indicate that Complex
PSMC2 was 
preferentially lost in A2780 cells after PSMC2 suppression. In contrast, PSMC2 
suppression in OVCAR8 cells, which lack Complex
PSMC2, led to near-complete ablation 
of 26S proteasome levels (Fig. 20b) and peptidase activity (Fig. 20e) and to a 
qualitative increase in the amount of poly-ubiquitin (Fig. 20f). 
To analyze the components of Complex
PSMC2, we fractionated lysates from IOSE 
cells expressing either V5-GFP or V5-PSMC2 (Fig. 21a) using a glycerol gradient (Fig. 
21b), and isolated V5-immune complexes containing either Complex
PSMC2 or 26S 
proteasome. Complex
PSMC2 immune complexes (collected in fractions 2-4) contained 
PSMC2, PSMC1 (Rpt2), PSMD2 (Rpn1), and PSMD5 (S5B) (Fig. 21c), subunits of one 
of three complexes known to compose the base of the 19S proteasome 
330‐332,352,353. Complex
PSMC2 did not contain subunits of the other two complexes, PSMC3 
(Rpt5), PSMC4 (Rpt3), PSMC5 (Rpt6), PSMC6 (Rpt6), or members of the 20S 
proteasome, PSMB5 (β5), or PSMA1-6 (α subunits) (Fig. 21c). All of these proteins 
except PSMD5 were detected in immune complexes containing the 26S complex (from 
fractions 7-9). These observations indicate that the PSMC2 reservoir is a subcomplex of 
the 26S proteasome. 
 
The reduction of PSMC2 levels in PSMC2
Loss cells inhibits orthotopic tumor 
growth 
  To explore the therapeutic potential of PSMC2 suppression in vivo, we tested the 
consequences of suppressing PSMC2 in ovarian xenografts. Specifically, we used a 
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Figure 21- Cytosolic fractionation and 
immunopercipitation of PSMC2: (a) 
Native PAGE immunoblots with anti-
PSMC2 (left) and anti-V5 (right) of IOSE 
cells that express either GFP or V5-
PSMC2. (b) Glycerol gradient (10-40%) 
fractionation of IOSE-V5-GFP (left) and 
IOSE-V5-PSMC2 (right) lysate. Fractions 
were analyzed using Native PAGE and 
immunoblotted for PSMC2. (c) 
Immunoblots for 19S complex components 
in V5 immune complexes isolated from 
fractions shown in (b) 
139tumor-targeted nanoparticle delivery system that delivers siRNA into the cytosol of cells 
within the tumor parenchyma345. We generated tumor-penetrating nanocomplexes 
(TPNs) consisting of PSMC2-specific siRNA non-covalently bound to tandem peptides 
bearing an N-terminal cell-penetrating domain, Transportan (TP), and a C-terminal 
tumor-specific domain, LyP-1 (CGNKRTRGC), which binds to its cognate receptor p32 
(Fig. 22a). 
  We first assessed the compatibility of cell lines with TPN-targeted siRNA 
delivery. OVCAR8 and A2780 cells exhibited high cell surface levels of expression of 
p32, whereas IOSE cells exhibited low expression (Fig 22b). In consonance with these 
observations, flow cytometry to quantify cytosolic delivery of fluorescently labeled 
siRNAs indicated substantial accumulation of siRNA in both OVCAR8 and A2780 cells 
(Fig. 22c). A monoclonal antibody directed against p32 (mAb 60.11) substantially 
reduced nanocomplex uptake, whereas a control antibody had no effect on uptake. 
These results indicate that surface p32 expression correlates with enhanced uptake of 
TPNs and that TPN-mediated siRNA delivery is p32 receptor-specific. 
  We next used these TPNs to confirm the vulnerability of PSMC2
Loss cells to 
PSMC2 suppression both in vitro and in vivo. We treated OVCAR8 and A2780 cells in 
vitro with TPNs carrying siRNAs targeting non-overlapping exons of PSMC2. In both cell 
types, we observed a reduction of PSMC2 protein relative to cells treated with TPNs 
carrying GFP siRNA (Fig. 22d). This reduction was associated with a corresponding 
decrease in proliferation only in the OVCAR8 cells (Fig. 22e). We then used these 
TPNs to treat mice harboring orthotopic OVCAR8 or A2780 tumors expressing firefly 
luciferase. We injected TPNs carrying PSMC2-siRNA (1 mg siRNA/kg body weight for 
140a
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Figure 22- Tumor-penetrating nanocomplex-mediated 
delivery of PSMC2-specific siRNA suppresses ovarian 
tumor growth: (a) Schematic depicting the mechanism of 
tumor-penetrating nanocomplex (TPN)-mediated delivery of 
siRNA. (b) FACS analysis of p32 surface expression on A2780 
and OVCAR8 cells. (c) Comparison of cellular uptake of 
fluorescently labeled siRNA in untreated cells (solid grey) and 
cells treated with TPN alone (black line) and in combination with 
IgG (grey line) or an antibody to p32 (solid pink). (d) 
Immunoblots of PSMC2 in A2780 and OVCAR8 cells with and 
without in vitro TPN-mediated delivery of PSMC2-siRNA. (e) C. 
Proliferation of A2780 and OVCAR8 cells after treatment in vitro 
with siGFP or siPSMC2 using either the TPN or a nanoparticle 
containing the scrambled peptide (ARA), relative to mock 
controls 
14114 days) intraperitoneally every three days and monitored tumor burden non-invasively 
by imaging bioluminescence. We observed a reduction in tumor burden (by >75% 
relative to tumors treated with siGFP) only in OVCAR8 tumors (Fig. 23a). A2780 and 
any remaining OVCAR8 tumors treated with TPN/siPSMC2 exhibited lower levels of 
PSMC2 but not two other members of Complex
PSMC2, PSMC1 and PSMD5 (Fig 23b).  
 However,  TPN/siPSMC2 nanoparticles failed to decrease tumor burden of 
PSMC2
Loss cells in which we reconstituted PSMC2 expression in vivo using orthotopic 
tumor xenografts derived from OVCAR8 cells expressing V5-PSMC2 (Fig. 23c). This 
finding confirmed that the effects of TPN/siPSMC2 on tumor growth were the 
consequence of reduced PSMC2 expression. 
Conversely, TPN/siPSMC2 nanoparticles reduced tumor growth and significantly 
improved survival in PSMC2
Neutral cells expressing PSMC2-specific shRNAs (Fig . 23e). 
We measured the effects of TPN/siPSMC2 nanoparticles relative to TPN/siGFP or PBS 
in mice with xenografts of A2780 cells engineered to express inducible PSMC2 shRNA. 
Among mice treated with doxycycline and TPN/siPSMC2, overall survival was 40 days 
and 40% survived more than 42 days, whereas all animals in the TPN/siGFP and PBS 
cohorts succumbed to tumors within 19 days (p=0.0013) (Fig. 23e). These findings 
demonstrated the therapeutic efficacy of PSMC2 suppression in vivo, and support the 
notion that PSMC2
Loss cells are sensitive to suppression of PSMC2 due to decreased 
basal levels of PSMC2 mRNA. 
Discussion 
From a therapeutic standpoint, increasing the number of targetable cancer 
dependencies has the potential to increase the number of treatable patients, and 
focusing on driver alterations limits us to targeted therapies involving these events. 
142b
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Figure 23- Effects of PSMC2 suppression on cellular viability 
in-vivo: (a) Tumor burden of mice bearing disseminated OVCAR8 
(top) or A2780 (bottom) orthotopic xenografts treated with TPN 
carrying either GFP-siRNA or PSMC2-siRNA. n=5 animals per 
group. (b) PSMC2 levels (top) and levels of two other proteasome 
components (bottom) in orthotopic tumors of A2780 or OVCAR8 
after treatment with nanoparticles carrying siGFP or siPSMC2. (c) 
Tumor burden of mice bearing orthotopic tumors of OVCAR8 cells 
expressing V5-PSMC2. n =5 animals per group. (d) Tumor burden 
(top) and overall survival (bottom) of mice bearing orthotopic 
tumors of A2780 cells expressing doxycycline-inducible shRNA 
against PSMC2. n = 5-13 animals per group. Data in all panels 
presented as average ± S.E.M. Significance was determined by 
one-way ANOVA or Log-rank (Mantel-Cox) tests as appropriate. 
n.s. = not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
143Additionally, many driver alterations belong to categories historically refractory to 
reversal with small molecule modulators220,354‐356, which may leave many patients with 
no targetable driver alterations. In such cases, having other targets of opportunity will be 
vital.  
Even when targeting driver alterations, treatment refractory recurrence has been 
almost inevitable357‐359. Rather than evidence against chasing passenger vulnerabilities, 
the repeated failure to find persistent dependence, even in the most likely targets, 
should further motivate us to expand our search for effective therapies to non-traditional 
targets. It is increasingly obvious that targeted therapies, acting in isolation, are unlikely 
to lead to sustained remission, and only by targeting multiple pathways simultaneously 
can we avoid recurrence caused by emergence of resistant subclones. Non-driver 
dependencies, if not effective in isolation can be tool in such combination therapy 
approaches.   
PSMC2 as a CYCLOPS gene 
By integrating data derived from the genomic characterization of human tumors 
with systematic interrogation of essential genes in cancer cell lines, we have identified a 
distinct class of cancer specific vulnerabilities associated with partial copy-number loss 
of essential genes. Hemizygous loss of PSMC2 in particular, and of CYCLOPS genes in 
general, renders cells highly dependent on the remaining allele. Although PSMC2 is 
frequently involved in partial copy-number loss, we did not observe homozygous 
deletion, consistent with the notion that PSMC2 is an essential gene. Partial copy-
number loss, in contrast, resulted in no measurable impact on either proteasome 
function or cell proliferation. Specifically, ectopic expression of PSMC2 failed to 
144enhance cell proliferation, and copy-number loss of PSMC2 was not associated with 
decreased proteasome activity. Taken together these observations define an approach 
to identify a new class of context specific cancer dependencies. 
26S proteasome components are not in stoichiometric equilibrium within cells, 
and the limiting components may differ between cancer and normal cells. For example, 
cells often express free 20S complex, but not 19S, suggesting that 26S proteasome 
levels are limited by the levels of 19S regulatory complex (Fig. 17a). There may be a 
similar imbalance between the modules that make up the base of the 19S complex. We 
found that the module containing PSMC2 (Rpt1), PSMC1 (Rpt2), PSMD2 (Rpn1), and 
PSMD5 (S5B) was in excess in many cancer cell lines, yet became limiting to 19S 
formation in PSMC2
Loss cells, unveiling a new sensitivity. PSMC2 levels are influenced 
by its sub-complex partners360, so interfering with the formation of Complex
PSMC2 or of 
its incorporation into the 19S proteasome may be a specific approach to reduce PSMC2 
levels and proliferation in PSMC2
Loss cells. Indeed, when we suppressed PSMC2 in vivo 
using tumor penetrating nanoparticles, we were able to obtain >75% reductions in tumor 
burden and a doubling of overall survival. 
Since the proteasome is essential in all cells, one concern in targeting CYCLOPS 
gene targets is whether this strategy would induce substantial toxicity to non-cancer 
cells. However, proteasome inhibition has been well tolerated in humans, with 
bortezomib treatment resulting in 70% reduction of proteasome activity as measured by 
LLVY peptide cleavage, with acceptable side effect profiles361. In comparison, 
proliferation of PSMC2
Loss cells is reduced at levels of PSMC2 suppression that result in 
only a 15% reduction of peptide cleavage in PSMC2
Neutral cells. 
145Our findings suggest that one consequence of genomic instability is an alteration 
in the stoichiometry of components of macromolecular machines including the 
proteasome, ribosome, and spliceosome. These observations suggest that many of 
these imbalances may present potential therapeutic targets in individual components or 
precursor complexes, and that these components, rather than the fully assembled 
machines, will require specific inhibition or disruption.  
 
   
146Perspectives and Future Directions 
 
 
SCNA Determination and future significance analyses 
Discrete, allelic SCNA data provides a much richer source of information for 
future significance analyses. In the short term, copy neutral loss of heterozygosity 
(cnLOH) events can be paired with exomic sequencing across many of the TCGA 
samples to better identify potential recessive tumor suppressor genes.  
We are also developing significance analyses specifically designed to take 
advantage of the data from this platform and model both positive and negative selection 
of SCNAs acquired through cancer development. In current analyses, the basic 
assumption is that positive selection through strong driver genes is the primary force 
shaping the somatic alterations we observe. With this assumption, we can assume a 
uniform background of expected somatic alterations, and deviations from this are seen 
as likely driver events in cancer development.  However, many recent studies have 
implied that much of what we observe is shaped by either strong negative selection, 
such as inactivation of essential genes, or from accumulation of modest selective 
pressures362.  
In addition, our group and others have shown that the location of a gene within 
the chromosome may significantly affect the background rate of alterations at that 
locus19,21.  With this in mind, one can imagine that the types of genes neighboring driver 
gene may have just as much influence on the SCNA profile at that locus as the driver 
gene itself. We are developing analyses to incorporate our understanding of event 
generation and attempts to model the selective pressures on each genetic element 
within regions of interest. This model should incorporate, the likelihood of a given set of 
147events based on the location of driver genes as well as other, more common genetic 
elements, such as essential genes, toxic genes, spacing of genetic elements within a 
particular region.  We are also trying to better account for variations in levels of genomic 
disruption between samples and diseases.  
Incorporation of whole genome sequencing data to improve models of SCNA 
determination 
While SNP6.0 arrays are constantly being analyzed in more significant ways to 
produce richer data, there will always be fundamental limitations to the technology. 
Unlike sequencing approaches, arrays do not provide any direct information about 
somatic genomic structural changes, such as translocations. This necessitates a rather 
simplistic view of SCNAs, where each event affects contiguous regions of DNA (with 
minor extensions such as those described in in chapter 2). We know this model to be 
inaccurate. Fortunately, whole genome sequencing is being applied to more and more 
tumors. By comparing our event determination from SNP arrays to event decomposition 
techniques utilizing WGS, we hope to improve our methods of event deconstruction in 
non-WGD samples, and thus extend the information gained through WGS to the 
thousands of samples that have been genomically characterized without WGS.  
 
Extracting functional information from correlative structure in the cancer genome 
We are currently working on extending our SCNA correlation analysis to 
incorporate discrete, allelic information, as well as exomic sequencing data. In these 
analyses, we are controlling for sample specific rates of mutations in a similar way to 
our controls for SCNA rates in each sample.  Activation or inactivation of driver genes 
may be accomplished in many ways during cancer development, so correlation 
148analyses integrating all types of alterations will improve on these results and have the 
potential to be very informative.  By combining whole exome sequencing with a precise 
determination of the amount of DNA at each locus in each sample, we can generate a 
model of expected mutation distribution and develop a permutation test that maintains 
this distribution, in a way similar to our SCNA method.  
In addition, we are controlling for the ploidy at each locus, as we expect that will 
affect the probability of a mutation at that locus. Finally, it has been observed that some 
specific alterations, such as TP53 or PIK3CA, actually correlate or anticorrelate with 
overall levels of disruption above and beyond the expected rate of correlation261. We are 
attempting to control for these locus-specific patterns of alteration as well. This will lead 
to an ability to determine how mutations and SCNAs interact with each other in a locus 
and sample specific manner.  
Varying levels of genomic disruption across cancers are likely to engender 
biases in analyses of correlations not only between SCNAs, but also between SCNAs 
and other features of these cancers.  For example, increased genomic disruption has 
been associated with poor prognosis in multiple cancer types
8,363.  Poor prognosis is 
therefore likely to be associated with increased rates of SCNA across much of the 
genome.  Controlling for this tendency will be required to identify SCNAs that are 
functionally associated with progression.  It will also be important to account for other 
possible confounders, such as mechanistically linked events (e.g. chromothripsis or 
SCNAs that encompass multiple peak regions). 
The future of CYCLOPS  
Identification of novel non-driver targets of cancer dependency 
149It is important to note that the initial pooled RNAi screen is a hypothesis-
generating experiment, and that, for a number of experimental reasons, there is likely a 
high false negative rate in our initial analysis that suggests our 56 initial candidate 
genes we identified may be an underestimate of the true number of potential targets. 
Indeed, more recent analyses using around 200 Achilles-screened cell lines (as 
opposed to the original 86) have identified over significant 300 genes in total, with extra 
genes mostly derived from an increase in power. Our initial analysis of Project Achilles 
only included 5,312 genes and many of these genes may represent false negative 
results due to insufficiently effective shRNAs. The set of 86 cell lines was also too small 
to enable detection of lineage-specific CYCLOPS genes. Indeed, a second RNAi 
dataset enriched in breast and pancreatic lineages revealed new CYCLOPS targets in 
addition to validating the targets described in our more lineage diverse dataset. 
Systematic evaluation of the complete annotated genome using more shRNAs for each 
gene and a larger group of cell lines representing many lineages is likely to uncover 
many more potential targets.  
Resistance to Cyclops. Experiments with clonal expansion after transfection.  
To determine the mechanisms of potential resistance to CYCLOPS 
vulnerabilities, selecting and characterizing single cell clones of PSMC2
Loss lines that 
survive PSMC2 inhibition seems the most natural first step. To find resistances that are 
biologically relevant, we can rule out failures in our perturbation system, such as loss of 
Dox promoter or deletions that remove the effectiveness of the shRNA, by confirming 
Dox addition still leads to PSMC2 inhibition. Assuming resistance is not developed by 
circumventing mRNA suppression, PSMC2 qPCR, rtPCR, SDS-PAGE and native gel 
150western blots may provide insights into resistance mechanisms. One likely mechanism 
is increased expression, either through copy number amplification or increased 
transcription of the remaining allele, either of which could be validated by qPCR and or 
FISH.   
Challenges of interpreting RNAi pooled screens 
shRNAs are an imperfect tool for the discovery of haplo-sufficient bystander 
dependencies. Even in a best case scenario, in order for a gene to be correctly 
identified as a CYCLOPS gene in our screen, the following criteria had to have been 
met: 
1.  It is a CYCLOPS gene 
2.  It has two shRNA in the screen that work 
3.  Those two shRNA have to both have to have incomplete suppression, yet 
sufficient suppression to induce the phenotype in partial loss cells.  
4.  We have enough cell lines within and across lineages with partial loss at the 
locus to adequately assess the significance in gene dependency differences 
between loss and neutral lines.  
Given these restrictions, it is perhaps surprising that our initial analysis identified as 
many genes as it did, and as these pooled screens add more shRNA per gene, more 
gene targets, more cell lines, and better analytics, we may be able to decrease the 
number of false negatives caused by these experimental limitations.  
   Regardless, the correlations we found between dependency on CYCLOPS 
candidates and partial loss in the context of a pooled screen are only hypotheses until 
they are further validated. Each would each need to be experimentally studied to 
151confirm our genome-scale results as interpretation of shRNA data is challenging given 
the preponderance of variable efficacy and off-target effects. In our initial validation, we 
used a targeted, low throughput approach towards validation, but more “medium-
throughput” approaches, including using pooled cell culture technologies, may improve 
our ability to validate CYCLOPS sensitivities.   
Other forms of non-driver dependency 
Our studies using the Achilles cell line screen discovered a set of gene 
dependencies based on partial copy loss of that gene. Besides copy-number loss, other 
types of genomic alteration may also unveil CYCLOPS-related vulnerabilities. In most 
cases, vulnerability to suppression of CYCLOPS genes was associated with decreased 
expression, so other somatic genetic events, such as sequence variants, epigenetic 
modification or chromosome translocations, may similarly predict dependency. While 
many CYCLOPS genes exhibited high correlation between copy number and 
expression, many others did not, and in general, it may be perilous to assume a 
correlation between low expression and increased vulnerability across a panel of cell 
lines will extrapolate to in vivo dependency.  For example, cell lines derived from a 
specific cell lineage may have slightly lower expression of a gene, yet still be dependent 
on it, so expression alone may be dangerous to use as a criteria for bystander 
vulnerability.  
There is also potential for utilizing trans-effects in bystander gene loss. Cancers 
often rely on redundant pathways to make up for acquired deficiencies. For example, 
cancers with BRCA1 loss are more dependent on PARP, a second DNA repair 
pathway364. Similarly, Muller et al. showed that homozygous deletion of the glycolytic 
152gene enolase ENO1, a bystander gene in GBM, will leave cells more dependent on 
ENO2, which may prove to be a therapeutic target365. Although further work will be 
necessary to explore these other classes, CYCLOPS genes alone or in combination 
with oncogenic targets may provide a new approach to cancer therapy. 
Pharmacologic targeting of CYCLOPS genes 
One of the primary motivations for searching for vulnerabilities in bystander 
alterations is to increase our library of targetable dependencies. Unfortunately, many of 
our CYCLOPS candidates do not come from traditionally targetable gene classes. 
Pairing genetics with small molecule screens could highlight passenger vulnerabilities 
that are responsive to currently available small molecules. Unlike shRNA screens, it 
may be more challenging to determine whether a drug dependency predicted by 
bystander loss is caused by direct inhibition of the gene or through a trans effect. For 
example, lenalidomide, used to treat multiple myeloma, has recently been shown to 
decrease abundance of two transcription factors by increasing effectiveness of their 
ubiquitin-mediated degradation. One could imagine finding similar mechanisms to either 
target CYCLOPS genes with current drugs or discover new bystander targets through 
small molecule screens.  
Mechanism of dependency on CYCLOPS genes 
While the biochemistry of proteasome assembly has been recently elucidated, 
the regulation and limiting factors of 19S assembly is less well understood. We found 
that there is relatively little compensation for moderate suppression of one component 
of the proteasome, either transcriptionally or translationally. In the case of partial 
suppression of PSMC2, this leads to decreased levels of the immediate PSMC2-
153containing subcomplex, but relatively stable amounts 19S and 20S proteasome.  
However, suppression of other genes within the complex may lead to very different bio-
chemical results, including significant loss in proteasome function, or even inhibition of 
the negative feedback loop that regulates transcription of 26S proteasome components. 
Determining the transcriptional, translational, and biochemical responses to loss of 
these other genes may improve our understanding of how the proteasome is regulated 
and what triggers changes in complex formation.  
The next step: Expanding our understanding of the CYCLOPS phenomenon 
While our studies on PSMC2 showed how partial loss may lead to increased 
sensitivity, it is unlikely to be the only mechanism for CYCLOPS dependence. In fact, 
some of our CYCLOPS genes showed little correlation between copy number and 
expression, while others undoubtedly have other mechanisms of dosage compensation. 
To that end, researching the mechanism of sensitivity in other CYCLOPS genes may 
lead to improved understanding of this class of genes, in addition to new therapeutic 
targets.  
The second-most enriched pathway in our CYCLOPS gene analysis was the 
spliceosome. Like the proteasome, the spliceosome is a cellular essential 
macromolecular complex366. The SF3B subcomplex comprises a part of the 
spliceosome important in splice-site recognition, and this complex alone contained 
multiple significance CYCLOPS genes. SF3B1 is an obligate member of this complex 
and one of the top CYCLOPS genes in an updated analysis using an increased number 
of Achilles lines. Unlike PSMC2 or its immediate subcomplex, there are small molecule 
inhibitors of the SF3B complex, making partial loss of SF3B1 an enticing therapeutic 
154target. Validation and biochemical characterization experiments on SF3B1
Loss lines are 
currently underway, and initial results are promising, though the mechanism of 
sensitivity in loss lines may be more complicated than in the case of PSMC2. Besides 
the immediate potential for CYCLOPS to predict small molecule sensitivity, these 
experiments further validate CYCLOPS as a novel class of cancer vulnerabilities. 
New high-throughput techniques may help identify inaccuracies in our current screen 
   Since our initial validation of PSMC2 as a CYCLOPS gene, a pathway utilized by 
prokaryotes as an immune response to viri, nicknamed CRISPR, has been engineered 
as a new tool for genetic perturbation367. CRISPR works by using a guide RNA strand to 
direct the CAS9 enzyme, a nuclease, to that sequence in the genome, where it then 
induces a double stranded break. Resolution of these double stranded breaks are error 
prone, so this system allows for directed genome modification by insertion/deletion.  It is 
believed that these CRISPR techniques suffer fewer of the specificity/sensitivity issues 
that plague shRNA experiments, and so provide a much cleaner system for studying the 
phenotypic effects of loss-of-function230. Because many CYCLOPS candidates are 
thought to be essential genes, this is an interesting tool for creating an isogenic system 
with inactivation of a single allele in the CYCLOPS gene (as biallelic inactivation is 
unlikely to be tolerated). In fact, for studies of SF3B1, our lab has created just such an 
isogenic system and shown that these newly created SF3B1
Loss created lines are newly 
sensitive to SF3B1 suppression.  
 
Conclusion  
Somatic copy number alterations are fundamental part of cancer evolution, occur 
through a variety of processes, and result in a complex pattern of changes that span the 
155genome. Our work endeavored to improve the understanding of SCNAs and their 
consequence on cancer development and vulnerabilities. Through this work, we have 
developed new ways to analyze the patterns and significance of SCNAs throughout 
cancer, as well as provide a valuable resource for future studies. 
The extended nature of SCNAs allowed us to query whether affected non-driver 
genes may introduce new opportunities for targeted therapy.  Our studies of CYCLOPS 
genes suggest that non-driver dependencies may represent an underexploited source 
of cancer vulnerability. We showed that in the case of PSMC2, partial loss led to 
decreased mRNA and protein, but not a decrease in function, leaving cells with loss 
more vulnerable to further insult. We hope these efforts will expand the thinking about 
potential therapeutic targets in cancer therapy and lead to a more comprehensive 
search for viable treatment options. 
   
156Appendix 1: SNP6.0 array processing 
 
Standard Affymetric SNP6.0 Array preparation and analysis 
 
For a period of about 5 years, The Cancer Genome Atlas (TCGA), the cancer cell 
line encyclopedia, and many other high-throughput genomics platforms made use of 
SNP 6.0 Affymetrix microarrays144. These arrays probe the DNA content of human 
samples using 906,600 single nucleotide polymorphisms (SNPs) and over 946,000 
probes designed to detect copy number variation. 
The SNP probes are derived from previous versions of Affymetrix arrays143 
(482,000 curated from dbSNP database368) in addition to 424,000 SNPs discovered in 
the International HapMap project369. Each of the 2 alleles at each locus are measured in 
triplicate by 25-mers scattered across the array. 
In addition to the SNP probes, there are 946,000 25-mer copy number (CN) 
probes included in SNP6.0 arrays, 744,000 were chosen to provide even coverage of 
the genome, with 202,000 chosen based on known germline copy number variation370.  
An overview of the bench procedure is diagrammed in 143. The DNA sample is digested 
with restriction enzymes Sty 1 and NSP 1, then ligated to adapters designed to match 
the single stranded DNA overhangs that result from that digestion. A primer that 
recognizes the adapter sequence is then used to amplify the DNA through polymerase 
chain reaction (PCR), with settings set to optimize amplification of fragments between 
200 and 1,100 bp. The resulting product is then fragmented using DNAse1 and 
chemically labeled with a fluorescent dye. Finally, each reaction is loaded onto a 
157SNP6.0 array. These arrays are scanned using a GeneChip Scanner 3000 7G and 
controlled by either Affymetrix GeneChip Command Console (AGCC) or GeneChip 
Operating Software (GCOS), either of which output a standard .CEL file that contains 
information about the intensity, standard deviation, and pixel count for each cell in the 
array.  This .CEL file represents the endpoint of standard Affymetrix analyses, to which 
developers at the Broad Institute have developed a number of additional tools to extract 
information about Somatic copy number changes in cancer samples. 
 
Broad institute Copy number inference pipeline for  SNP 5.0 and 6.0 arrays371 
 
Preprocessing 
The first step in this pipeline is to normalize each array to correct for overall 
differences in array intensity, and then convert each probeset representing a SNP allele 
to a single value. 
Median normalization adjusts the median probe-level value of each array to 
1000, followed by quantile normalization. Next we use Model-based expression indices 
(MBEI) to map these normalized intensities to the normal sample with total intensity 
closest to the median total intensity in the plate. MBEI assumes a linear relationship 
between probe intensity and DNA content,such that the coefficient for this relationship 
may be unique to the probe in question.  Finally, replicate probes are summarized using 
median polish across the samples in the plate.  
 
Copy Number Inference 
158The goal of this section is to convert these normalized intensities (which are 
relative values based on co-developed samples) to copy number values, values relative 
to the total amount of DNA at a particular locus. We assume the intensity for the i-th 
probeset in the j-th sample, yij, is derived from a linear transformation of the underlying 
copy number  
 
     	      	        
 
where     denotes the “background” parameter and     denotes the scale parameter. 
Because of extra information inherent in SNP probes, the pipeline handles SNP and CN 
probes slightly differently 
 
CN probes 
CN probe calibration utilizes the intensity measurements of 5 cell lines, each with 
a different number of copies of the X chromosome (1-5). This panel of cell lines was 
used to create a X-chromosome “dosage” experiment, where the normalized intensity 
values for each probe on the X chromosome was measured for each cell line in the 
panel. These values were then used to fit a probe-specific linear calibration curve for 
each of these probes. To extrapolate these curves to the autosomal chromosomes, a 
regression model was used, with probe-specific GC content, fragment length, and 
median intensity used as regression variables over this set of 5 cell lines (presumably 
diploid over the autosomal chromosomes). Finally, this regression model is used to 
159predict the background and scale parameters on each probe in the current dataset 
(Table 1). 
 
SNP probes 
The background and scale parameters for SNP probes rely on the Birdseed, 
which calculates these parameters by analyzing relative intensities of zero and one 
copy SNP varients in diploid “normals” (non-tumor somatic tissue, usually derived from 
patient blood) run in the same batch. Because this relies on representation of the allele 
within the batch of normal, it is optimal to run at least 15 diploid normal samples in each 
batch. However, if a batch lacks adequate representation at a particular locus we can 
use prior information to fill in these values. Otherwise, the probes are discarded for this 
set of samples. 
 
Sample cleanup and noise reduction 
 
Outlier removal 
Noise is a constant factor in analysis of DNA arrays. This noise can be sample 
specific (e.g. a bubble on the array), or systematic (e.g. inefficient DNA cleavage at a 
particular locus). Outlier elimination attempts to remove probes with extreme values not 
corroborated by other nearby probes. Specifically, taking the 5 probes immediately to 
one side of a given probe, if the difference between the given probe and the median of 
the other 5 probes is greater than 0.3, the probe is considered an outlier with respect to 
160these probes. If a probe is an outlier with respect to probes on both its left, and its right, 
it is replaced with the median of the three values centered on itself. 
 
Tangent normalization 
Even after these extensive normalization procedures, there is variation in probe 
set intensity across samples that remain when comparing individual diploid normal 
samples, or even replicates of the same normal sample.  These patterns of variation 
may reflect changes in experimental conditions between different arrays but could 
provide false copy number alterations in not properly accounted for. To remove these 
variations caused by systemic noise present in normal tissue, we project the copy 
number values of each probe in our tumor sample onto a plane created by values 
obtained from a large archive of normal tissue (presumably diploid). The linear 
projection of our sample onto this “plane” of normal DNA values represents the 
hypothetical diploid sample subjected to a similar set of systemic noise as our tumor 
sample. We then subtract this modeled systemic variation from our tumor sample. It is 
important to point out that known regions of germline copy number variation (CNVs) are 
removed prior to this step as this is an attempt to model systematic (i.e. non-biological) 
noise alone. CNV regions are subsequently added back to data. 
 
Circular Binary Segmentation (CBS) 141,372 
This approach takes each chromosome and attempts to find evidence for 
contiguous regions of equal copy number and transforms the data from thousands of 
161probes, each with a unique copy number value, to segments of data, where each 
segment is composed of multiple probes with a single copy number value. 
CBS does this by taking each segment (starting with the whole chromosome) 
and recursively asking if there is likely to be a copy number breakpoint within that 
segment.  
If a segment consists of markers 1 through m, this equates to asking at each 
marker pair i and j (i<j), whether the mean of values i+1:j is significantly different from 
the mean of values outside of this range (Figure 2). This significance is determined by a 
“hybrid” approach. If the number of markers m in a given segment is less than 1000, 
then the maximum value k for which full permutation test is applied is 25, with k 
increasing by 5 for every doubling of m. For segments smaller than this threshold, the p-
value is derived directly from a full permutation test for all values of i and j such that (j – 
i) > than some minimum segment length (based on inter-probe variation within the 
sample). For values of (j – i) greater than the threshold, the test statistic T was assumed 
to originate from a standard normal distribution. If there exists an (i,j) pair that exceeds 
the significance threshold, the (i,j) that generate the best T statistic are considered the 
end points of a new segment. This process is repeated recursively on each segment, 
until no more segments are created by this approach. Finally, the mean value of 
markers in each segment becomes the value of that segment. 
 
 
HAPSEG and ABSOLUTE 
 
162The absolute algorithm is a parallel analysis technique developed by Carter et al147 
utilizing the extra information present in SNP probes to determine integer allelic copy 
number values at each locus. 
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